WO2013138502A1 - Salts of an epidermal growth factor receptor kinase inhibitor - Google Patents

Salts of an epidermal growth factor receptor kinase inhibitor Download PDF

Info

Publication number
WO2013138502A1
WO2013138502A1 PCT/US2013/030996 US2013030996W WO2013138502A1 WO 2013138502 A1 WO2013138502 A1 WO 2013138502A1 US 2013030996 W US2013030996 W US 2013030996W WO 2013138502 A1 WO2013138502 A1 WO 2013138502A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
acid
salt
theta
peaks
Prior art date
Application number
PCT/US2013/030996
Other languages
French (fr)
Inventor
Mei Lai
Steven Richard Witowski
Richland Wayne Tester
Kwangho Lee
Original Assignee
Celgene Avilomics Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2015500567A priority Critical patent/JP6317320B2/en
Priority to CN201380025160.5A priority patent/CN104284584B/en
Priority to PL13761487T priority patent/PL2825042T3/en
Priority to SG11201405692UA priority patent/SG11201405692UA/en
Priority to EP13761487.1A priority patent/EP2825042B1/en
Priority to MX2014010848A priority patent/MX356179B/en
Priority to CA2866857A priority patent/CA2866857C/en
Priority to SI201331233T priority patent/SI2825042T1/en
Priority to BR112014022790-0A priority patent/BR112014022790B1/en
Priority to RU2014136893A priority patent/RU2711077C9/en
Priority to LTEP13761487.1T priority patent/LT2825042T/en
Priority to RS20181300A priority patent/RS57901B1/en
Priority to KR1020147028832A priority patent/KR102090453B1/en
Priority to CN201811096266.5A priority patent/CN109053595B/en
Application filed by Celgene Avilomics Research, Inc. filed Critical Celgene Avilomics Research, Inc.
Priority to MYPI2014002630A priority patent/MY185243A/en
Priority to ES13761487T priority patent/ES2698298T3/en
Priority to DK13761487.1T priority patent/DK2825042T3/en
Publication of WO2013138502A1 publication Critical patent/WO2013138502A1/en
Priority to IL234426A priority patent/IL234426B/en
Priority to PH12014502037A priority patent/PH12014502037A1/en
Priority to HK15106102.5A priority patent/HK1205430A1/en
Priority to HRP20181784TT priority patent/HRP20181784T1/en
Priority to CY20181101143T priority patent/CY1122176T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C07C309/27—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/02—Saturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention provides salt forms of a compound useful as mutant-selective inhibitors of epidermal growth factor receptor (EGFR) kinase, including polymorphic forms of certain salts.
  • EGFR epidermal growth factor receptor
  • the invention also provides pharmaceutically acceptable compositions comprising salt forms of the present invention and methods of using the compositions in the treatment of various disorders.
  • Protein tyrosine kinases are a class of enzymes that catalyze the transfer of a phosphate group from ATP or GTP to a tyrosine residue located on a protein substrate. Receptor tyrosine kinases act to transmit signals from the outside of a cell to the inside by activating secondary messaging effectors via a phosphorylation event. A variety of cellular processes are promoted by these signals, including proliferation, carbohydrate utilization, protein synthesis, angiogenesis, cell growth, and cell survival.
  • Activating mutations in the tyrosine kinase domain of EGFR have been identified in patients with non-small cell lung cancer (Lin, N. U.; Winer, E. P., Breast Cancer Res 6: 204-210, 2004).
  • the reversible inhibitors Tarceva (erlotinib) and Iressa (gefitinib) currently are first-line therapy for non-small cell lung cancer patients with activating mutations.
  • the most common activating mutations are L858R and delE746-A750.
  • T790M may also be pre-existing; there may be an independent, oncogenic role for the T790M mutation.
  • T790M mutations are linked with certain familial lung cancers.
  • Figure 1 depicts the x-ray powder diffraction (XRPD) pattern for a bis-besylate salt of Compound 1.
  • FIG. 1 depicts the thermogravimetric analysis (TGA) pattern for a bis-besylate salt of Compound 1.
  • FIG. 3 depicts the thermogravimetric analysis (TGA) pattern for a further dried sample of a bis-besylate salt of Compound 1.
  • Figure 4 depicts the differential scanning calorimetry (DSC) pattern for a bis- besylate salt of Compound 1.
  • Figure 5 depicts the infrared (IR) spectrum of a bis-besylate salt of Compound 1.
  • Figure 6 depicts the ⁇ - MR spectrum of a bis-besylate salt of Compound 1.
  • Figure 7 depicts the dynamic vapor sorption (DVS) pattern of a bis-besylate salt of Compound 1.
  • Figure 8 depicts the results of a hydration study of a bis-besylate salt of Compound I, as analyzed by the XRPD patterns.
  • Figure 9 depicts the results of a disproportionation study of a bis-besylate salt of Compound 1, as analyzed by the XRPD patterns.
  • Figure 10 depicts the results of a stability study of a bis-besylate salt of Compound 1, as analyzed by the XRPD patterns.
  • Figure 11 depicts the results of a thermodynamic solubility study of a bis-besylate salt of Compound 1, as analyzed by the XRPD patterns.
  • Figure 12 depicts the dissolution at pH 4.5 of a compressed disc of a bis-besylate salt of Compound 1.
  • Figure 13 depicts the dissolution at pH 3.0 of a compressed disc of a bis-besylate salt of Compound 1.
  • Figure 14 depicts the XRPD pattern for a bis-besylate hydrate salt of Compound 1.
  • Figure 15 depicts the TGA pattern for a bis-besylate hydrate salt of Compound 1.
  • Figure 16 depicts the DSC pattern for a bis-besylate hydrate salt of Compound 1.
  • Figure 17 depicts the IR spectrum of a bis-besylate hydrate salt of Compound 1.
  • Figure 18 depicts the ⁇ - MR spectrum of a bis-besylate hydrate salt of Compound 1.
  • Figure 19 depicts the DVS pattern of a bis-besylate hydrate salt of Compound 1.
  • Figure 20 depicts the results of a stability study of a bis-besylate hydrate salt of Compound 1, as analyzed by the XRPD patterns.
  • Figure 21 depicts the results of a thermodynamic solubility study of a bis-besylate salt of Compound 1, as analyzed by the XRPD patterns.
  • Figure 22 depicts the dissolution at pH 4.5 of a compressed disc of a bis-besylate hydrate salt of Compound 1.
  • Figure 23 depicts the dissolution at pH 3.0 of a compressed disc of a bis-besylate hydrate salt of Compound 1.
  • Figure 24 depicts the XRPD pattern for a mono-maleate salt of Compound 1.
  • Figure 25 depicts the TGA pattern for a mono-maleate salt of Compound 1.
  • Figure 26 depicts the DSC pattern for a mono-maleate salt of Compound 1.
  • Figure 27 depicts the ⁇ - MR spectrum of a mono-maleate salt of Compound 1.
  • Figure 28 depicts the XRPD pattern for a bis-hydrochloride salt of Compound 1.
  • Figure 29 depicts the TGA pattern for a bis-hydrochloride salt of Compound 1.
  • Figure 30 depicts the DSC pattern for a bis-hydrochloride salt of Compound 1.
  • Figure 31 depicts the ⁇ - MR spectrum of a bis-hydrochloride salt of Compound 1.
  • Figure 32 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 33 depicts the TGA pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 34 depicts the DSC pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 35 depicts the IR spectrum of a Form I hydrobromide salt of Compound 1.
  • Figure 36 depicts the ⁇ - MR spectrum of a Form I hydrobromide salt of Compound 1.
  • Figure 37 depicts the DVS pattern of a Form I hydrobromide salt of Compound 1.
  • Figure 38 depicts the results of a hydration study of a Form I hydrobromide salt of Compound 1, as analyzed by the XRPD patterns.
  • Figure 39 depicts the results of a disproportionation study of a Form I hydrobromide salt of Compound 1, as analyzed by the XRPD patterns.
  • Figure 40 depicts the results of a stability study of a Form I hydrobromide salt of Compound 1, as analyzed by the XRPD patterns.
  • Figure 41 depicts the results of a thermodynamic solubility study of a Form I hydrobromide salt of Compound 1, as analyzed by the XRPD patterns.
  • Figure 42 depicts the dissolution at pH 4.5 of a compressed disc of a Form I hydrobromide salt of Compound 1.
  • Figure 43 depicts the dissolution at pH 3.0 of a compressed disc of a Form I hydrobromide salt of Compound 1.
  • Figure 44 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 45 depicts the TGA pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 46 depicts the IR spectrum of a Form I hydrobromide salt of Compound 1.
  • Figure 47 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 48 depicts the ⁇ - MR spectrum for a Form I hydrobromide salt of Compound 1.
  • Figure 49 depicts the DSC pattern of a Form I hydrobromide salt of Compound 1.
  • Figure 50 depicts the results of a slurry experiment involving a form of the free base of Compound 1 and a bis-besylate hydrate.
  • Figure 51 depicts the results of a slurry experiment involving a Form I hydrobromide salt of Compound 1 at pH 6.2.
  • Figure 52 depicts the XRPD pattern for a Form I hydrobromide salt of Compoundl.
  • Figure 53 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 54 depicts the IR spectrum of a Form I hydrobromide salt of Compound 1.
  • Figure 55 depicts the ⁇ - MR spectrum of a Form I hydrobromide salt of Compound 1.
  • Figure 56 depicts the TGA pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 57 depicts the DSC pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 58 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1 after heating.
  • Figure 59 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 60 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 61 depicts the IR spectrum of a Form I hydrobromide salt of Compound 1.
  • Figure 62 depicts the ⁇ - MR spectrum of a Form I hydrobromide salt of Compound 1.
  • Figure 63 depicts the TGA pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 64 depicts the DSC pattern for a Form I hydrobromide salt of Compound 1.
  • Figure 65 depicts the results of a thermodynamic solubility study of a Form I hydrobromide salt of Compound 1, as analyzed by the XRPD patterns.
  • Figure 66 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1, after storage for 1.5 months.
  • Figure 67 depicts the XRPD pattern for a Form III hydrobromide salt of Compound 1.
  • Figure 68 depicts theTGA pattern for a Form III hydrobromide salt of Compound 1.
  • Figure 69 depicts the DSC pattern for a Form III hydrobromide salt of Compound 1.
  • Figure 70 depicts the IR spectrum for a Form III hydrobromide salt of Compound 1.
  • Figure 71 depicts the ⁇ - MR spectrum of a Form III hydrobromide salt of Compound 1.
  • Figure 72 depicts the XRPD pattern for a Form IV hydrobromide salt of Compound 1.
  • Figure 73 depicts the XRPD pattern for a Form V hydrobromide salt of Compound 1.
  • Figure 74 depicts the XRPD pattern for a Form VI hydrobromide salt of Compound 1.
  • Figure 75 depicts the XRPD pattern for a Form VII hydrobromide salt of Compound 1.
  • Figure 76 depicts the XRPD pattern for a Form VIII hydrobromide salt of Compound 1.
  • Figure 77 depicts the TGA pattern for a Form VIII hydrobromide salt of Compound 1.
  • Figure 78 depicts the DSC pattern for a Form VIII hydrobromide salt of Compound 1.
  • Figure 79 depicts the XRPD of an amorphous hydrobromide salt of Compound 1.
  • Figure 80 depicts the XRPD of Form V hydrobromide salt of Compound 1 following desolvation conditions.
  • Figure 81 depicts input material Form I hydrobromide salt of Compound 1 compared with a wet sample, and after stages of drying.
  • Figure 82 depicts the XRPD analysis of hydrobromide salt Forms I and III resulting from competitive slurry experiments at ambient temperature (22 °C).
  • Figure 83 depicts the XRPD analysis of hydrobromide salt Forms I and III resulting from competitive slurry experiments at 60 °C.
  • Figure 84 depicts the XRPD analysis of Form I hydrobromide salt of Compound 1 slurried in EtOH:water mixtures.
  • Figure 85 depicts the XRPD analysis of material slurried in IP A/acetone (9: 1): water mixtures.
  • Figure 86 depicts the XRPD analysis following hydration studies at 15 °C and 35 °C.
  • Figure 87 depicts the form diagram for the hydrobromide salt, including 7 different forms and the relationship between such forms.
  • Compound 1 (N-(3-(2-(4-(4-acetylpiperazin-l-yl)-2-methoxyphenylamino)-5- (trifluoromethyl)pyrimidin-4-ylamino)phenyl)acrylamide)) is designated as compound number I- 4 and the synthesis of compound 1 is described in detail at Example 3 of the '061 application.
  • Compound 1 is active in a variety of assays and therapeutic models demonstrating selective covalent, irreversible inhibition of mutant EGFR kinase (in enzymatic and cellular assays). Notably, compound 1 was found to inhibit human non-small cell lung cancer cell proliferation both in vitro and in vivo. Accordingly, compound 1 and its salts are useful for treating one or more disorders associated with activity of mutant EGFR kinase.
  • the present invention provides a salt of compound 1, represented by compound 2:
  • n 1 or 2;
  • X is benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid,
  • hydrobromic acid hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2 -sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6- trihydroxybenzoic acid.
  • compound 2 can exist in a variety of physical forms.
  • compound 2 can be in solution, suspension, or in solid form.
  • compound 2 is in solid form.
  • said compound may be amorphous, crystalline, or a mixture thereof. Exemplary solid forms are described in more detail below.
  • the present invention provides compound 2 substantially free of impurities.
  • the term “substantially free of impurities” means that the compound contains no significant amount of extraneous matter. Such extraneous matter may include excess acid "X", excess compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, compound 2.
  • at least about 90% by weight of compound 2 is present.
  • at least about 95% by weight of compound 2 is present.
  • at least about 99% by weight of compound 2 is present.
  • compound 2 is present in an amount of at least about 95, 97, 97.5, 98.0, 98.5, 99, 99.5, 99.8 weight percent where the percentages are based on the total weight of the composition.
  • compound 2 contains no more than about 5.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram.
  • compound 2 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram.
  • compound 2 can exist in a variety of solid forms. Such forms include polymorphs and amorphous forms.
  • the solid forms can be solvates, hydrates and unsolvated forms of compound 2. All such forms are contemplated by the present invention.
  • the present invention provides compound 2 as a mixture of one or more solid forms of compound 2.
  • polymorph refers to the different crystal structures (of solvated or unsolvated forms) in which a compound can crystallize.
  • solvate refers to a crystal form with either a stoichiometric or non-stoichiometric amount of solvent. For polymorphs, the solvent is incorporated into the crystal structure.
  • hydrate refers to a solid form with either a stoichiometric or non-stoichiometric amount of water. For polymorphs, the water is incorporated into the crystal structure.
  • the term "about”, when used in reference to a degree 2-theta value refers to the stated value ⁇ 0.3 degree 2-theta (° 2 ⁇ ). In certain embodiments, “about” refers to ⁇ 0.2 degree 2-theta or ⁇ 0.1 degree 2-theta.
  • compound 2 is a crystalline solid. In other embodiments, compound 2 is a crystalline solid substantially free of amorphous compound 2. As used herein, the term "substantially free of amorphous compound 2" means that the compound contains no significant amount of amorphous compound 2. In certain embodiments, at least about 90% by weight of crystalline compound 2 is present, or at least about 95% by weight of crystalline compound 2 is present. In still other embodiments of the invention, at least about 99% by weight of crystalline compound 2 is present.
  • compound 2 is a benzenesulfonic acid (besylate) salt.
  • the salt can be a mono-besylate or a bis-besylate.
  • a besylate salt is optionally solvated or hydrated, such as a monohydrate.
  • an unsolvated bis-besylate salt has a powder X-ray diffraction pattern substantially similar to that depicted in Figure 1.
  • an unsolvated bis-besylate salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 5.62, about 17.41, about 18.90, about 19.07 and about 19.52 degrees 2-theta.
  • an unsolvated bis-besylate salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 5.62, about 17.41, about 18.90, about 19.07 and about 19.52 degrees 2-theta.
  • an unsolvated bis-besylate salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 5.62, about 17.41, about 18.90, about 19.07 and about 19.52 degrees 2-theta.
  • an unsolvated bis- besylate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 5.62, 7.89, 11.23, 12.64, 17.41, 18.90, 19.07, 19.52, 22.63, 23.17, 25.28 and 28.92 degrees 2-theta.
  • an unsolvated bis- besylate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • an unsolvated bis-besylate salt has a thermogravimetric analysis pattern substantially similar to that depicted in Figure 2 or 3.
  • an unsolvated bis-besylate salt has a differential scanning calorimetry pattern substantially similar to that depicted in Figure 4.
  • an unsolvated bis- besylate salt has an infrared spectrum substantially similar to that depicted in Figure 5.
  • an unsolvated bis-besylate salt has an ⁇ - MR spectrum substantially similar to that depicted in Figure 6.
  • an unsolvated bis-besylate salt has a dynamic vapour sorption pattern substantially similar to that depicted in Figure 7.
  • An unsolvated bis-besylate salt can be characterized by substantial similarity to two or more of these figures simultaneously.
  • a bis-besylate hydrate has a powder X-ray diffraction pattern substantially similar to that depicted in Figure 14.
  • a bis- besylate hydrate salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 10.68, about 16.10, about 18.44 and about 22.36 degrees 2- theta.
  • a bis-besylate hydrate salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 10.68, about 16.10, about 18.44 and about 22.36 degrees 2-theta.
  • a bis-besylate hydrate salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 10.68, about 16.10, about 18.44 and about 22.36 degrees 2-theta.
  • a bis-besylate hydrate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 9.33, 10.68, 16.10, 16.43, 16.64, 18.44, 20.05, 20.32, 20.74, 22.36 and 22.83 degrees 2-theta.
  • a bis- besylate hydrate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • a bis-besylate hydrate has a thermogravimetric analysis pattern substantially similar to that depicted in Figure 15.
  • a bis- besylate hydrate has a differential scanning calorimetry pattern substantially similar to that depicted in Figure 16.
  • a bis-besylate hydrate has a infrared spectrum substantially similar to that depicted in Figure 17.
  • a bis-besylate hydrate has an ⁇ - MR spectrum substantially similar to that depicted in Figure 18.
  • a bis-besylate hydrate has a dynamic vapour sorption pattern substantially similar to that depicted in Figure 19.
  • a bis-besylate hydrate can be characterized by substantial similarity to two or more of these figures simultaneously.
  • compound 2 is a camphor sulfonic acid salt (e.g., camphor- 10-sulfonic acid).
  • compound 2 is a mono-camphor sulfonic acid salt.
  • compound 2 is a bis-camphor sulfonic acid salt.
  • compound 2 is a 1,2-ethane disulfonic acid salt. In some embodiments, compound 2 is a mono- 1,2-ethane disulfonic acid salt. In some embodiments, compound 2 is a bis- 1,2-ethane disulfonic acid salt.
  • compound 2 is a hydrobromic acid salt. In some embodiments, compound 2 is an anhydrous monohydrobromic acid salt. In some embodiments, compound 2 is an anhydrous bis-hydrobromic acid salt. A hydrobromide salt is optionally solvated or hydrated. In some embodiments, compound 2 is a monohydrate hydrobromic acid salt. In some embodiments, compound 2 is a solvated hydrobromic acid salt. In some such embodiments, the solvate is selected from dimethylsulfoxide (DMSO), dimethylformamide (DMF) and 1,4-dioxane. In some embodiments, compound 2 is a hydrobromide salt selected from Form I, Form III, Form IV, Form V, Form VI, Form VII and Form VIII, each of which is described in further detail, infra.
  • DMSO dimethylsulfoxide
  • DMF dimethylformamide
  • compound 2 is a hydrobromide salt selected from Form I, Form III, Form IV, Form V, Form VI, Form VII and Form VIII, each
  • compound 2 is a Form I hydrobromide salt.
  • compound 2 is an anhydrous Form I hydrobromide salt.
  • a Form I hydrobromide salt is characterized by the powder X-ray diffraction pattern substantially similar to that depicted in Figure 60.
  • a Form I hydrobromide salt is characterized by the powder X-ray diffraction pattern substantially similar to that depicted in Figure 59.
  • a Form I mono-hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta.
  • a Form I mono-hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta.
  • a Form I mono-hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta. In some embodiments, a Form I mono-hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta.
  • a Form I mono- hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 9.84, 15.62, 17.39, 19.45, 20.69, 21.41, 22.38, 23.56, 25.08 and 27.45 degrees 2- theta.
  • a Form I mono-hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • a Form I mono-hydrobromide salt is characterized by a thermogravimetric analysis pattern substantially similar to that depicted in Figure 63.
  • a Form I mono-hydrobromide salt is characterized by a differential scanning calorimetry pattern substantially similar to that depicted in Figure 64.
  • a Form I mono-hydrobromide salt is characterized by an infrared spectrum substantially similar to that depicted in Figure 61.
  • a Form I mono-hydrobromide salt is characterized by a ⁇ - MR spectrum substantially similar to that depicted in Figure 62.
  • a Form I mono- hydrobromide salt is characterized by substantial similarity to two or more of these figures simultaneously.
  • compound 2 is a Form III hydrobromide salt.
  • compound 2 is an anhydrous Form III hydrobromide salt.
  • a Form III hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 67.
  • a Form III hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta.
  • a Form III hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta.
  • a Form III hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta.
  • a Form III hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta.
  • a Form III hydrobromide salt is characterized by five or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta.
  • a Form III hydrobromide salt is characterized by six or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta.
  • a Form III hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta.
  • a Form III hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • a Form III hydrobromide salt is characterized by a thermogravimetric analysis pattern substantially similar to that depicted in Figure 68. In some embodiments, a Form III hydrobromide salt is characterized by a differential scanning calorimetry pattern substantially similar to that depicted in Figure 69. In some embodiments, a Form III hydrobromide salt is characterized by an infrared spectrum substantially similar to that depicted in Figure 70. In some embodiments, a Form III hydrobromide salt is characterized by a ⁇ - MR spectrum substantially similar to that depicted in Figure 71. In some embodiments, a Form III hydrobromide salt is characterized by substantial similarity to two or more of these figures simultaneously.
  • compound 2 is a Form IV hydrobromide salt.
  • a Form IV hydrobromide salt is a 1,4-dioxane solvate.
  • a Form rv hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 72.
  • a Form IV hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta.
  • a Form IV hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta.
  • a Form IV hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta.
  • a Form IV hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta. In some embodiments, a Form IV hydrobromide salt is characterized by five or more peaks in its powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta.
  • a Form IV hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta.
  • a Form IV hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • compound 2 is a Form V hydrobromide salt.
  • a Form V hydrobromide salt is a ⁇ , ⁇ -dimethylformamide (DMF) solvate.
  • a Form V hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 73.
  • a Form V hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta.
  • a Form V hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta.
  • a Form V hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta.
  • a Form V hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta. In some embodiments, a Form V hydrobromide salt is characterized by five or more peaks in its powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta.
  • a Form V hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta.
  • a Form V hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • compound 2 is a Form VI hydrobromide salt.
  • a Form VI hydrobromide salt is a dimethylsulfoxide (DMSO) solvate.
  • DMSO dimethylsulfoxide
  • a Form VI hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 74.
  • a Form VI hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2- theta.
  • a Form VI hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2-theta.
  • a Form VI hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2-theta.
  • a Form VI hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2-theta.
  • a Form VI hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • compound 2 is a Form VII hydrobromide salt.
  • a Form VII hydrobromide salt is a dimethylsulfoxide (DMSO) solvate.
  • DMSO dimethylsulfoxide
  • a Form VII hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 75.
  • a Form VII hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta.
  • a Form VII hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta.
  • a Form VII hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta.
  • a Form VII hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta. In some embodiments, a Form VII hydrobromide salt is characterized by five or more peaks in its powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta.
  • a Form VII hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta.
  • a Form VII hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • compound 2 is a Form VIII hydrobromide salt.
  • a Form VIII hydrobromide salt is a hydrate.
  • a Form VIII hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 76.
  • a Form VIII hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 11.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta.
  • a Form VIII hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 11.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta.
  • a Form VIII hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 1 1.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta.
  • a Form VIII hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 1 1.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta. In some embodiments, a Form VIII hydrobromide salt is characterized by five or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 1 1.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta.
  • a Form VIII hydrobromide salt is characterized by six or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 11.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta.
  • a Form VIII hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 8.79, about 1 1.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta.
  • a Form VIII hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • a Form VIII hydrobromide salt has a thermogravimetric analysis pattern substantially similar to that depicted in Figure 77. In some embodiments, a Form VIII hydrobromide salt has a differential scanning calorimetry pattern substantially similar to that depicted in Figure 78. In some embodiments, a Form VIII hydrobromide salt is characterized by substantial similarity to two or more of these figures simultaneously.
  • compound 2 is a hydrochloric acid salt. In some embodiments, compound 2 is a mono-hydrochloric acid salt. In some embodiments, compound 2 is a bis-hydrochloric acid salt.
  • a bis-hydrochloride salt has a powder X-ray diffraction pattern substantially similar to that depicted in Figure 28.
  • a bis- hydrochloride salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 17.58, about 23.32, about 25.53 and about 28.37 degrees 2-theta.
  • a bis-hydrochloride salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 17.58, about 23.32, about 25.53 and about 28.37 degrees 2-theta.
  • a bis-hydrochloride salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 17.58, about 23.32, about 25.53 and about 28.37 degrees 2-theta.
  • a bis- hydrochloride salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 17.58, 20.13, 22.14, 23.32, 25.53, 26.60, 27.80 and 28.37 degrees 2-theta.
  • a bis-hydrochloride salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • a bis-hydrochloride salt has a thermogravimetric analysis pattern substantially similar to that depicted in Figure 29.
  • a bis- hydrochloride salt has a differential scanning calorimetry pattern substantially similar to that depicted in Figure 30.
  • a bis -hydrochloride salt has an l H- NMR spectrum substantially similar to that depicted in Figure 31.
  • compound 2 is a maleic acid salt. In some embodiments, compound 2 is a mono-maleic acid salt. In some embodiments, compound 2 is a bis-maleic acid salt.
  • a mono-maleate salt has a powder X-ray diffraction pattern substantially similar to that depicted in Figure 24.
  • a mono- maleate salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 23.59 and about 23.80 degrees 2-theta.
  • a mono-maleate salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 23.59 and about 23.80 degrees 2- theta.
  • a mono-maleate salt is characterized by three peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 23.59 and about 23.80 degrees 2-theta.
  • a mono-maleate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 8.38, 13.74, 16.35, 16.54, 20.67, 23.15, 23.59 and 23.80 degrees 2-theta.
  • a mono-maleate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
  • a mono-maleate salt has a thermogravimetric analysis pattern substantially similar to that depicted in Figure 25.
  • a mono- maleate salt has a differential scanning calorimetry pattern substantially similar to that depicted in Figure 26.
  • a mono-maleate salt has an ⁇ - MR spectrum substantially similar to that depicted in Figure 27.
  • any of the above-described polymorph forms can be characterized, for example, by reference to any of the peaks in their respective X-ray diffraction patterns. Accordingly, in some embodiments, a polymorph described herein is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more XRPD peaks (°2 ⁇ ).
  • compound 2 is a methanesulfonic acid salt. In some embodiments, compound 2 is a mono-methansulfonic acid salt. In some embodiments, compound 2 is a bis-methanesulfonic acid salt.
  • compound 2 is a naphthalene-2 -sulfonic acid salt. In some embodiments, compound 2 is a mono-naphthalene-2-sulfonic acid salt. In some embodiments, compound 2 is a bis-naphthalene-2-sulfonic acid salt.
  • compound 2 is a 1,5 -naphthalene disulfonic acid salt. In some embodiments, compound 2 is a mono- 1,5 -naphthalene disulfonic acid salt. In some embodiments, compound 2 is a bis-l,5-naphthalene disulfonic acid salt.
  • compound 2 is an oxalic acid salt. In some embodiments, compound 2 is a mono-oxalic acid salt. In some embodiments, compound 2 is a bis-oxalic acid salt.
  • compound 2 is a p-toluenesulfonic acid (tosylate) salt. In some embodiments, compound 2 is a mono-p-toluenesulfonic acid salt. In some embodiments, compound 2 is a bis-p-toluenesulfonic acid salt.
  • compound 2 is a 2,4,6-trihydroxybenzoic acid salt. In some embodiments, compound 2 is a mono-2,4,6-trihydroxybenzoic acid salt. In some embodiments, compound 2 is a bis-2,4,6-trihydroxybenzoic acid salt.
  • the present invention provides compound 2 as an amorphous solid.
  • Amorphous solids are well known to one of ordinary skill in the art and are typically prepared by such methods as lyophilization, melting, and precipitation from supercritical fluid, among others.
  • Compound 1 is prepared according to the methods described in detail in the '061 application, the entirety of which is hereby incorporated herein by reference.
  • Compound 2 is prepared from Compound 1, according to the Scheme below.
  • Compound 2 is prepared from Compound 1 by combining Compound 1 with either one or two equivalents of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid to form the salt thereof.
  • another aspect of the present inv ntion provides a method for preparing Compound 2:
  • a suitable solvent may solubilize one or more of the reaction components, or, alternatively, the suitable solvent may facilitate the agitation of a suspension of one or more of the reaction components.
  • suitable solvents useful in the present invention are a protic solvent, a polar aprotic solvent, a nonpolar solvent or mixtures thereof.
  • suitable solvents include water, an ether, an ester, an alcohol, a halogenated solvent, a ketone, or a mixture thereof.
  • the suitable solvent is methanol, ethanol, isopropanol, ethyl acetate, isopropyl acetate, methyl ethyl ketone, methyl isobutyl ketone or acetone.
  • the suitable solvent is dichloromethane.
  • suitable solvents include tetrahydrofuran, dimethylformamide, dimethylsulfoxide, glyme, diglyme, methyl t-butyl ether, t-butanol, n-butanol, and acetonitrile.
  • the suitable solvent is cyclohexane.
  • the present invention provides a method for preparing Compound 2:
  • Compound 1 is dissolved or suspended in a suitable solvent, optionally with heating. In certain embodiments Compound 1 is dissolved at about 20 to about 60 °C. In other embodiments, Compound 1 is dissolved at about 20 to about 25 °C, such as about ambient temperature. In still other embodiments, compound 1 is dissolved at the boiling temperature of the solvent. In other embodiments, compound 1 is dissolved without heating.
  • benzenesulfonic acid camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2.
  • benzenesulfonic acid camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2.
  • benzenesulfonic acid camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2 -sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2.
  • benzenesulfonic acid camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2.
  • benzenesulfonic acid camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2 -sulfonic acid, 1,5- naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2.
  • about 1.8 to about 2.2 equivalents such as about 1.98 to 2.02 equivalents, of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2.
  • benzenesulfonic acid camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic
  • the acid may be added to the mixture of Compound 1 and a suitable solvent in any suitable form.
  • the acid may be added in solid form or as a solution or a suspension in a suitable solvent.
  • the suitable solvent may be the same suitable solvent as that which is combined with Compound 1 or may be a different solvent.
  • the acid is added in solid form.
  • the acid is combined with a suitable solvent prior to adding to Compound 1.
  • the acid is added as a solution in a suitable solvent.
  • suitable solvents include water, an ether, an ester, an alcohol, a halogenated solvent, a ketone, or a mixture thereof.
  • the suitable solvent is methanol, ethanol, isopropanol, ethyl acetate, isopropyl acetate, methyl ethyl ketone, methyl isobutyl ketone or acetone.
  • the suitable solvent is dichloromethane.
  • suitable solvents include tetrahydrofuran, dimethylformamide, dimethylsulfoxide, glyme, diglyme, methyl t-butyl ether, t-butanol, n-butanol, and acetonitrile.
  • the suitable solvent is cyclohexane.
  • the suitable solvent is selected from those above and is anhydrous.
  • the resulting mixture containing Compound 2 is cooled. In other embodiments, the mixture containing Compound 2 is cooled below 20 °C, such as below 10 °C.
  • Compound 2 precipitates from the mixture. In another embodiment, Compound 2 crystallizes from the mixture. In other embodiments, Compound 2 crystallizes from solution following seeding of the solution (i.e., adding crystals of Compound 2 to the solution).
  • Crystalline Compound 2 can precipitate out of the reaction mixture, or be generated by removal of part or all of the solvent through methods such as evaporation, distillation, filtration (e.g., nanofiltration, ultrafiltration), reverse osmosis, absorption and reaction, by adding an anti-solvent such as water, MTBE or heptane, by cooling or by different combinations of these methods.
  • Compound 2 is optionally isolated. It will be appreciated that Compound 2 may be isolated by any suitable physical means known to one of ordinary skill in the art.
  • precipitated solid compound 2 is separated from the supernatant by filtration.
  • precipitated solid Compound 2 is separated from the supernatant by decanting the supernatant.
  • precipitated solid Compound 2 is separated from the supernatant by filtration.
  • isolated Compound 2 is dried in air. In other embodiments isolated Compound 2 is dried under reduced pressure, optionally at elevated temperature.
  • the invention provides a composition comprising Compound 2 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • the amount of Compound 2 in compositions of this invention it is such that is effective to measurably inhibit a protein kinase, particularly an EGFR kinase, or a mutant thereof, in a biological sample or in a patient.
  • a composition of this invention is formulated for administration to a patient in need of such composition.
  • a composition of this invention is formulated for oral administration to a patient.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention refers to a nontoxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, Vitamin E polyethylene glycol succinate (d-alpha tocopheryl polyethylene glycol 1000
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be an aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • a nontoxic parenterally acceptable diluent or solvent for example as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous and non-aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents, such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is typically combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of Compound 2 include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
  • the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well- known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents. [00162] In some embodiments, pharmaceutically acceptable compositions of this invention are formulated for oral administration.
  • compositions are formulated so that a dosage of between 0.01 - 100 mg kg body weight/day of Compound 2 can be administered to a patient receiving these compositions.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • Compound 2 and compositions described herein are generally useful for the inhibition of protein kinase activity of one or more enzymes.
  • Examples of kinases that are inhibited by Compound 2 and compositions described herein and against which the methods described herein are useful include EGFR kinase or a mutant thereof. It has been found that Compound 2 is a selective inhibitor of at least one mutation of EGFR, as compared to wild-type ("WT") EGFR.
  • WT wild-type
  • an at least one mutation of EGFR is T790M.
  • the at least one mutation of EGFR is a deletion mutation.
  • the at least one mutation of EGFR is an activating mutation.
  • Compound 2 selectively inhibits at least one resistant mutation and at least one activating mutation as compared to WT EGFR. In some embodiments, Compound 2 selectively inhibits at least one deletion mutation and/or at least one point mutation, and is sparing as to WT EGFR inhibition.
  • a mutation of EGFR can be selected from T790M (resistant or oncogenic), L858R (activating), delE746-A750 (activating), G719S (activating), or a combination thereof.
  • the term “selectively inhibits,” as used in comparison to inhibition of WT EGFR, means that Compound 2 inhibits at least one mutation of EGFR (i.e., at least one deletion mutation, at least one activating mutation, at least one restistant mutation, or a combination of at least one deletion mutation and at least one point mutation) in at least one assay described herein (e.g., biochemical or cellular).
  • the term "selectively inhibits,” as used in comparison to WT EGFR inhibition means that Compound 2 is at least 50 times more potent, at least 45 times, at least 40, at least 35, at least 30, at least 25, or at least 20 times more potent as an inhibitor of at least one mutation of EGFR, as defined and described herein, as compared to WT EGFR.
  • the term "sparing as to WT EGFR” means that a selective inhibitor of at least one mutation of EGFR, as defined and described above and herein, inhibits EGFR at the upper limit of detection of at least one assay, such as those described in the '061 application (e.g., biochemical or cellular as described in detail in Examples 56-58).
  • in vitro assays include assays that determine inhibition of the phosphorylation activity and/or the subsequent functional consequences, or ATPase activity of activated EGFR (WT or mutant). Alternate in vitro assays quantitate the ability of the inhibitor to bind to EGFR (WT or mutant).
  • Inhibitor binding may be measured by radiolabeling the inhibitor prior to binding, isolating the inhibitor/EGFR (WT or mutant) complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with EGFR (WT or mutant) bound to known radioligands.
  • the term "sparing as to WT EGFR" means that Compound 2 inhibits WT EGFR with an IC 50 of at least 10 ⁇ , at least 9 ⁇ , at least 8 ⁇ , at least 7 ⁇ , at least 6 ⁇ , at least 5 ⁇ , at least 3 ⁇ , at least 2 ⁇ , or at least 1 ⁇ .
  • Compound 2 selectively inhibits (a) at least one activating mutation; and (b) T790M; and (c) is sparing as to WT.
  • an at least one activating mutation is a deletion mutation.
  • an at least one activating mutation is a point mutation.
  • an activating mutation is delE746-A750.
  • an activating mutation is L858R.
  • an activating mutation is G719S.
  • the at least one mutation of EGFR is L858R and/or T790M.
  • the present invention provides a method for inhibiting an activating mutation in a patient comprising administering to the patient Compound 2 or composition thereof, as described herein.
  • the present invention provides a method for inhibiting oncogenic T790M in a patient comprising administering to the patient a provided compound or composition thereof, as described herein.
  • the amount of Compound 2 in a composition is effective to measurably inhibit at least one mutant of EGFR selectively as compared to WT EGFR and other protein kinases (e.g., ErbB2, ErbB4, a TEC-kinase, and/or JAK3), in a biological sample or in a patient.
  • WT EGFR protein kinases
  • other protein kinases e.g., ErbB2, ErbB4, a TEC-kinase, and/or JAK3
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment may be administered after one or more symptoms have developed.
  • treatment may be administered in the absence of symptoms.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • Compound 2 is an inhibitor of at least one mutant of EGFR and is therefore useful for treating one or more disorders associated with activity of one of more EGFR mutants (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof).
  • the present invention provides a method for treating a mutant EGFR- mediated disorder comprising the step of administering to a patient in need thereof Compound 2 or pharmaceutically acceptable composition thereof.
  • mutant EGFR-mediated disorders or conditions means any disease or other deleterious condition in which at least one mutant of EGFR is known to play a role.
  • an at least one mutant of EGFR is T790M.
  • the at least one mutant of EGFR is a deletion mutation.
  • the at least one mutant of EGFR is an activating mutation.
  • the at least one mutant of EGFR is L858R and/or T790M.
  • a provided compound selectively inhibits (a) at least one activating mutation, (b) T790M, and (c) is sparing as to WT.
  • an at least one activating mutation is a deletion mutation. In some embodiments, an at least one activating mutation is a point mutation. In some embodiments, an activating mutation is delE746-A750. In some embodiments, an activating mutation is L858R. In some embodiments, an activating mutation is G719S.
  • another embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which at least one mutant of EGFR is known to play a role.
  • the present invention relates to a method of treating or lessening the severity of a disease or condition selected from a proliferative disorder, wherein said method comprises administering to a patient in need thereof a compound or composition according to the present invention.
  • the present invention provides a method for treating or lessening the severity of one or more disorders selected from a cancer.
  • the cancer is associated with a solid tumor.
  • the cancer is breast cancer, glioblastoma, lung cancer, cancer of the head and neck, colorectal cancer, bladder cancer, or non-small cell lung cancer.
  • the present invention provides a method for treating or lessening the severity of one or more disorders selected from squamous cell carcinoma, salivary gland carcinoma, ovarian carcinoma, or pancreatic cancer.
  • the present invention provides a method for treating or lessening the severity of neurofibromatosis type I (NF1), neurofibromatosis type II (NF2) Schwann cell neoplasms (e.g. MPNST's), or Schwannomas.
  • NF1 neurofibromatosis type I
  • NF2 neurofibromatosis type II
  • MPNST's Schwann cell neoplasms
  • Schwannomas e.g. MPNST's
  • Compound 2 and compositions thereof, according to the method of the present invention may be administered using any amount and any route of administration effective for treating or lessening the severity of a cancer.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • Compound 2 is preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • Compound 2 may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 60 mg/kg, or about 0.1 mg/kg to about 50 mg/kg, or about 0.25 mg/kg to about 45 mg/kg and preferably from about 0.5 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, polyethylene glycol (e.g., PEG 200, PEG 400, PEG 1000, PEG 2000), propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, Vitamin E polyethylene glycol succinate (d-alpha tocopheryl
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • the liquid forms above can also be filled into a soft or hard capsule to form a solid dosage form.
  • Suitable capsules can be formed from, for example, gelatin, strach and cellulose derivatives (e.g., hydroxycellulose, hydropropylmethylcellulose).
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing Compound 2 of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • Compound 2 is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate, Avicel, hydroxypropyl cellulose or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, PVP vinyl acetate, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar— agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium croscarmellose and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as sodium citrate, Avicel
  • Solid compositions of a similar type may also be employed as fillers in soft and hard- filled capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • Compound 2 can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as cosmetic coatings, enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as a polymer, sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of Compound 2 include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention.
  • the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • the invention relates to a method of inhibiting protein kinase activity in a biological sample comprising the step of contacting said biological sample with Compound 2 or a composition comprising said compound.
  • the invention relates to a method of inhibiting at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutations, or combination thereof) activity in a biological sample comprising the step of contacting said biological sample with Compound 2, or a composition comprising the compound.
  • the invention relates to a method of irreversibly inhibiting at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) activity in a biological sample comprising the step of contacting the biological sample with Compound 2, or a composition comprising the compound.
  • Compound 2 selectively inhibits in a biological sample (a) at least one activating mutation, (b) T790M, and (c) is sparing as to WT.
  • an at least one activating mutation is a deletion mutation.
  • an at least one activating mutation is a point mutation.
  • an activating mutation is delE746-A750.
  • an activating mutation is L858R.
  • an activating mutation is G719S.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Inhibition of at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ transplantation, biological specimen storage, and biological assays.
  • Another embodiment of the present invention relates to a method of inhibiting at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) activity in a patient comprising the step of administering to the patient Compound 2 or a composition comprising the compound.
  • the present invention provides a method for inhibiting (a) at least one activating mutation, and (b) T790M in a patient, and (c) is sparing as to WT, wherein the method comprises administering to the patient Compound 2 or composition thereof.
  • an at least one activating mutation is a deletion mutation.
  • an at least one activating mutation is a point mutation.
  • the present invention provides a method for inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is delE746-A750. In some embodiments, the present invention provides a method for inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is L858R. In some embodiments, the present invention provides a method for inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is G719S.
  • the invention relates to a method of inhibiting at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) activity in a patient comprising the step of administering to the patient Compound 2 or a composition comprising the compound.
  • the invention relates to a method of irreversibly inhibiting at least one mutant of EGFR activity (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) in a patient comprising the step of administering to said patient Compound 2 or a composition comprising the compound.
  • the present invention provides a method for irreversibly inhibiting (a) at least one activating mutation, and (b) T790M in a patient, and (c) is sparing as to WT, wherein said method comprises administering to the patient Compound 2 or composition thereof.
  • an irreversibly inhibited at least one activating mutation is a deletion mutation.
  • an irreversibly inhibited at least one activating mutation is a point mutation.
  • the present invention provides a method for irreversibly inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is delE746-A750.
  • the present invention provides a method for irreversibly inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is L858R. In some embodiments, the present invention provides a method for irreversibly inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is G719S.
  • the present invention provides a method for treating a disorder mediated by one or more of at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) in a patient in need thereof, comprising the step of administering to said patient Compound 2 or pharmaceutically acceptable composition thereof.
  • a disorder mediated by one or more of at least one mutant of EGFR e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof
  • Such disorders are described in detail herein.
  • additional therapeutic agents which are normally administered to treat that condition, may also be present in the compositions of this invention or as part of a treatment regimen including Compound 2.
  • additional therapeutic agents that are normally administered to treat a particular disease, or condition are known as "appropriate for the disease or condition being treated.”
  • Compound 2 or a pharmaceutically acceptable composition thereof is administered in combination with chemotherapeutic agents to treat proliferative diseases and cancer.
  • chemotherapeutic agents include, but are not limited to, Adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, platinum derivatives, taxane (e.g., paclitaxel), vinca alkaloids (e.g., vinblastine), anthracyclines (e.g., doxorubicin), epipodophyllotoxins (e.g., etoposide), cisplatin, an mTOR inhibitor (e.g., a rapamycin), methotrexate, actinomycin D, dolastatin 10, colchicine, emetine, trimetrexate, metoprine, cyclosporine, daunorubicin, teniposide, amphoterici
  • mTOR inhibitor
  • Compound 2 or a pharmaceutically acceptable composition thereof is administered in combination with an antiproliferative or chemotherapeutic agent selected from any one or more of abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anastrozole, arsenic trioxide, asparaginase, azacitidine, BCG Live, bevacuzimab, fluorouracil, bexarotene, bleomycin, bortezomib, busulfan, calusterone, capecitabine, camptothecin, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cladribine, clofarabine, cyclophosphamide, cytarabine, dactinomycin, darbepoetin alfa, daunorubicin, denileukin,
  • agents the inhibitors of this invention may also be combined with include, without limitation: treatments for Alzheimer's Disease such as donepezil hydrochloride (Aricept ® ) and rivastigmine (Exelon ® ); treatments for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex ® and Rebif ® ), glatiramer acetate (Copaxone ® ), and mitoxantrone; treatments for asthma such as albuterol and montelukast (Singulair ® ); agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF block
  • Compound 2 or a pharmaceutically acceptable composition thereof is administered in combination with a monoclonal antibody or an siRNA therapeutic.
  • the additional agents may be administered separately from a Compound 2- containing composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with Compound 2 in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another (e.g., one hour, two hours, six hours, twelve hours, one day, one week, two weeks, one month).
  • the terms “combination,” “combined,” and related terms refer to the simultaneous or sequential administration of therapeutic agents in accordance with this invention.
  • Compound 2 may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.
  • the present invention provides a single unit dosage form comprising Compound 2, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • compositions of this invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of Compound 2 can be administered.
  • compositions that include an additional therapeutic agent that additional therapeutic agent and Compound 2 may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions may be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions, a dosage of between 0.01 - 1,000 ⁇ g/kg body weight/day of the additional therapeutic agent can be administered.
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • Compound 2 or pharmaceutical compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters.
  • an implantable medical device such as prostheses, artificial valves, vascular grafts, stents and catheters.
  • Vascular stents for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury).
  • patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor.
  • Implantable devices coated with Compound 2 are another embodiment of the present invention.
  • Step 1
  • DIPEA Diisopropylethylamine
  • Step 3
  • the counterions included benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2- sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid and 2,4,6- trihydroxybenzoic acid.
  • One equivalent of each counterion was used and additional experiments with two equivalents of benzenesulfonic acid, hydrochloric acid, sulphuric acid and p-toluenesulfonic acid were performed.
  • the acid solution / slurry was then added to the slurry of Compound 1 in small aliquots in order to minimize the risk of degradation.
  • the pH of the reaction was then checked using universal indicator paper.
  • X-Ray Powder Diffraction X-ray powder diffraction (XRPD) analysis was carried out on a Siemens D5000, scanning the samples between 3 and 30, 35 or 50 °2 ⁇ . For samples ⁇ 100 mg, ca. 5-10 mg of sample was gently compressed onto a glass slide which fitted into the sample holder. For samples >100 mg, ca. 100 mg of sample was gently compressed into a plastic sample holder, so that the sample surface was smooth and just above the level of the sample holder, Measurements were made using the following experimental conditions :
  • Polarized Light Microscopy In polarized light microscopy (PLM), the presence of crystallinity (birefringence) was determined using an Olympus BX50 polarising microscope, equipped with a Motic camera and image capture software (Motic Images Plus 2.0). All images were recorded using the 20x objective, unless otherwise stated.
  • PLM polarized light microscopy
  • thermogravimetric analysis TGA
  • TG/DTA simultaneous thermogravimetric/differential thermal analyser
  • DTA differential thermal events
  • the sample pan was then loaded into a Seiko DSC6200 (equipped with a cooler) cooled and held at 25°C. Once a stable heat-flow response was obtained, the sample and reference were heated to ca. 260 °C-280 °C at scan rate of 10°C/min and the resulting heat flow response monitored.
  • a Sotax AT7 dissolution bath (USP 2, EP 2 apparatus) was used for the dissolution study in which paddles were used to stir the media. All tests were carried out at 37°C and a paddle speed of 100 rpm.
  • the bis-besylate salt was selected to be scaled up, using acetone as the solvent.
  • the hydrobromide salt was selected to be scaled up, using acetonitrile:water (90: 10) as the solvent.
  • the mono-maleate and bis-hydrochloride salts were also selected for scale-up experiments to assess whether these are solvated/hydrated.
  • TGA/DTA was carried after 3 days of drying at ambient under vacuum as well as after further drying for 2 days at 40 °C under vacuum and 2 days at 60 °C under vacuum. After the ambient drying process, the TGA showed a 6.7% weight loss between ca. 50-150 °C ( Figure 2) (for an acetone solvate, 1 mole equivalent of acetone would be ca. 6.3 wt%). After further drying, the TGA showed a 0.47% weight loss from the outset, likely due to unbound moisture or solvent. A further small 0.16% weight loss corresponded with the endotherm at onset ca. 142 °C ( Figure 3).
  • DSC analysis ( Figure 4) indicated a broad endotherm from the outset likely due to unbound solvent. A second endotherm was present at onset ca. 139.4 °C (peak 146.1°C).
  • DVS analysis ( Figure 7) showed a water uptake of ca. 2.2% between 20 and 70% RH.
  • the material also appears to hydrate during DVS analysis as indicated by the change in polymorphic form seen by post DVS XRPD analysis (not shown).
  • the XRPD diffractogram also showed some loss in crystallinity.
  • Karl Fischer Coulometry indicated a ca. 0.77% water content (Note: due to the manual introduction of the solid material into the titration cell, measured values below 1% are generally slightly higher than the actual water content).
  • HPLC purity evaluation indicated a purity of ca. 97.6% for the bis- besylate salt with the main peak eluting at a retention time of ca. 13.05 minutes.
  • the bis-besylate salt was exposed to environments of 40°C/75%RH (relative humidity, open and closed vial) and 80°C (open vial) for 1 week to determine stability. Resulting solids were analysed by XRPD and HPLC to establish if any changes had occurred.
  • the 1 Week stability study results from XRPD ( Figure 10) and HPLC analysis (not shown) at 40°C/ 75% RH using an open and closed vial and 80°C using an open vial are indicated Table 5. Table 5.
  • TGA/DTA indicated a weight loss of ca. 2.1% between ca. 70 - 100 °C ( Figure 15). This corresponds approximately with the 2.03 wt% water required for a monohydrate. A ca. 2.2% weight loss was present from the outset to ca. 70 °C, likely due to unbound water. Although the total ca. 4.2% weight loss corresponds approximately with a dihydrate, the first weight loss occurs from the outset followed by a second clear weight loss corresponding with mono amounts of water. As the first weight loss occurs from ca. 25 °C, this would likely be due to unbound water.
  • DSC analysis indicated a broad endotherm between ca. 40-115 °C. Two further endotherms were then present at onset 119.7 °C (peak 134.3 °C) and onset 153.8 °C (peak 165.1 °C) ( Figure 16).
  • PLM analysis showed some birefringence, however the particle size is very small and no clear morphology could be seen (not shown). Hot-stage microscopy was carried out on a sample of the bis-besylate hydrate. No visual changes could be observed prior to the material melting and degrading (turned brown) at ca. 160 °C.
  • HPLC purity determinations indicated an initial purity of ca. 98.4% and a purity of ca. 98.3% after 1 week storage at 40 °C/75% RH.
  • a larger batch of the bis-besylate hydrate salt was prepared using the following procedure. Approximately 20 mL of acetone was added to ca. 14 g of Compound 1 in a round bottomed flask to form a slurry. In a separate flask, ca. 10 mL of acetone was added to 2 equivalents of benzenesulfonic acid in order to dissolve the acid. The acid solution was then added in small aliquots to the freebase slurry whilst stirring at ca. 0 °C. The resulting slurry was then allowed to stir at ambient for ca. 2 hours. It was then placed at ca. 5 °C for 2 days before stirring for a further 3 hours at ambient temperature.
  • the acetone was then removed and ca. 20 mL of water was added to the material.
  • the slurry was temperature cycled (0 °C - ambient temperature (ca. 22 °C)) in 2 hour cycles for ca. 1 day.
  • the solid was then isolated by filtration and allowed to dry at ambient conditions under vacuum before analysis. The drying was continued for ca. 10 days.
  • TGA/DTA was carried after 2 days of drying at ambient under vacuum.
  • the TGA showed a 0.4% weight loss from the outset, likely due to unbound moisture or solvent.
  • a large 10.9% weight loss is associated with endothermic/exothermic events in the DTA between ca. 145-185 °C, followed by further weight losses due to likely degradation (Figure
  • TGA/DTA was carried after 2 days of drying at ambient under vacuum.
  • the TGA showed a 2.7% gradual weight loss from the outset to ca. 180 °C.
  • a further 4.3% weight loss is seen between ca. 180-210 °C, which corresponds with an endotherm in the DTA trace (Figure 29).
  • DSC analysis indicated a broad endotherm between ca. 30-160 °C. A further endotherm is then present at onset 206.4°C (peak 226.5°C), directly followed by a smaller endotherm at peak 238.2°C ( Figure 30).
  • Karl Fischer analysis showed ca. 3.3% water content (ca. 2.8% water required for a monohydrate).
  • TGA/DTA showed a 1.01% weight loss from the outset, likely due to unbound moisture or solvent. No further weight losses were seen prior to degradation at onset ca. 230°C ( Figure 33).
  • Karl Fischer Coulometry indicated a ca. 1.65% water content.
  • thermodynamic solubility experiments carried out on the bis-besylate salt.
  • the diffractogram appears different from the input hydrobromide material, all known forms of the
  • thermodynamic solubility experiments carried out on the bis-besylate salt.
  • TGA/DTA (Figure 45) showed a 1.2% weight loss from the outset to ca. 100°C, likely due to unbound moisture or solvent. No further weight losses were seen prior to degradation at onset ca. 230°C.
  • the TGA/DTA is similar to the trace obtained for the 1 equivalent scaled-up form of Example 6.
  • thermodynamic solubility experiments carried out on the hydrobromide salt resulted in the formation of an unknown solid form.
  • the following experiments were carried out. Initially, approximately 100 mg of the hydrobromide (1 equiv.) material was slurried in a pH 6.2 aqueous solution at ambient and XRPD analysis was carried out at time points 5 min., 1 hr, 2 hrs, 4 hrs and 8 hrs. Further analysis was then also carried out on the converted material.
  • the reaction was then filtered and the solid dried under vacuum at ambient temperature (ca. 22°C). The drying was continued for ca. 2 days. Due to the partially crystalline nature of the material after drying, the material was then slurried in ca. 50 mL of an acetone:water (90: 10) mixture. The reaction was temperature cycled between ca. 4-22 °C in 1 hour cycles while stirring for ca. 2 days. The reaction was then filtered and dried at ambient for ca. 4 days before being analyzed. The yield after the further slurrying was 16.4 g (63%).
  • PLM (not shown) showed small particles with no defined morphology and little birefringence.
  • TGA/DTA (Figure 56) showed a weight loss from the outset of ca. 0.4%, likely due to unbound moisture or solvent. No further significant weight losses were seen prior to degradation at onset ca. 230 °C.
  • KF analysis determined the water content of the material to be ca. 0.76%.
  • HPLC purity determination indicated a purity of ca. 98.1%.
  • the content of carbon, hydrogen and nitrogen in the material was determined by placing the samples into a tin capsule, placed inside an autosampler drum of an elemental analysis system.
  • the sample environment was purged by a continuous flow of helium and the samples dropped at pre-set intervals into a vertical quartz tube maintained at 900 °C.
  • the mixture of combustion gases was separated and detected by a thermal conductivity detector giving a signal proportional to the concentration of the individual components of the mixture.
  • the content of bromine in the material was determined by oxygen flask combustion of the sample. Once the combustion and absorption into solution had occurred, the samples were titrated using a calibrated Mercuric Nitrate solution. Elemental analysis (CHN and bromide) indicated the following percentages:
  • Ion chromatography was carried out using a Metrohm 761 Compact Ion Chromatograph for the analysis of ions in aqueous solutions. Calibration standards were prepared from certified 1000 ppm stock solutions. Ion chromatography showed the presence of 12.38% bromide.
  • the reactor temperature was raised to 20 °C for 2 hours.
  • the reaction was then again cooled to ca. 4 °C and maintained at this temperature for a further 3 hours.
  • the reaction mixture was then filtered and dried under vacuum at ambient temperature (ca. 22 °C) for 3 days. The solid was stirred periodically during the drying process.
  • the yield after drying was 258.1 g (71%).
  • PLM analysis showed a needle-like, fibrous morphology when wet (not shown). Upon drying and hence polymorph conversion, the needle-like morphology was lost with small particles resulting.
  • TGA/DTA (Figure 63) showed a weight loss from the outset of ca. 0.4%, likely due to unbound moisture or solvent. No further significant weight losses were seen prior to degradation at onset ca. 230 °C. Thus, the material appears to retain ca. 0.5% water at ambient conditions despite extended periods of drying and therefore appears to be slightly hygroscopic.
  • KF analysis determined the water content of the material to be ca. 0.74%.
  • HPLC purity determination indicated a purity of ca. 99.1%.
  • Crash Cooling Experiments. Crash cooling experiments were performed by placing saturated solutions of the material, in each of the 24 selected solvent systems, in environments of 2 °C and -18 °C for a minimum of 48 hours. Any solid material was then recovered for analysis.
  • Rapid Evaporation Experiments. Rapid evaporation experiments were conducted by evaporating the solvents from saturated, filtered solutions of the material, in each of the 24 solvent systems, under vacuum. Any solid material was then recovered and analysed after the solvent had evaporated to dryness.
  • Anti-solvent Addition Experiments. Anti-solvent addition experiments were conducted at ambient temperature by adding the selected anti-solvent to saturated, filtered solutions of the material, in each of the 24 selected solvent systems. The anti-solvent selected was heptane, with tert-butylmethyl ether and water being used for solvents immiscible with heptane. Addition of anti-solvent was continued until there was no further precipitation or until no more anti-solvent could be added. Any solid material was recovered and analysed quickly in order to prevent form changes.
  • Figure 81 shows input material Form I compared with a wet sample, and after stages of drying.
  • Form III an anhydrous form, was obtained from rapid evaporation of DMSO, crash cooling to 2 °C in ethanol, and anti-solvent addition from acetone, acetonitrile, and ethanol.
  • Form III Hydrobromide Salt Preparation. Approximately 500 mg of amorphous Compound 2 HBr salt material was slurried in ca. 6 mL of acetonitrile. The suspension was then temperature cycled between 4 and 25 °C in four hour cycles for ca. 2 days. The secondary screen analysis was carried out on the material when it was damp, due to the instability of Form III.
  • Form III From the characterisation carried out on Form III, this form was determined to be a metastable, likely anhydrous form of the hydrobromide salt. Form III was observed to be very unstable with conversion to Form I occurring upon isolation and drying of the material.
  • Form I was found to be the thermodynamically most stable form in acetone, isopropanol and isopropyl acetate at both ambient and 60 °C. In acetone: water (80:20), conversion to an unidentified form resulted (labelled as Form VIII).
  • Characterization of Form VIII An initial assessment of Form VIII, obtained from competitive slurry experiments of Forms I and III in acetone:water (80:20), was made in order to determine the nature of the form and evaluate whether it is consistent with freebase material or the HBr salt. The material resulting from the competitive slurry experiments appeared light yellow in colour. PLM analysis indicated birefringent material with no clearly defined morphology.
  • the TGA/DTA indicated a weight loss of 5.2% from the outset followed by a second weight loss of 1.2%, with endotherms in the DTA trace at ca. 40 °C and ca. 96 °C.
  • a final endotherm was observed in the DTA trace at onset ca. 184 °C (peak ca. 194 °C).
  • Very little change was observed by hotstage microscopy prior to the melt at ca. 197 °C.
  • DSC analysis indicated a broad endotherm starting from the outset (peak ca. 93 °C ) followed by a second endotherm at peak ca. 140 °C and a third endotherm at onset ca. 178 °C (peak ca. 193 °C).
  • Ion chromatography indicated a bromide content of 12.8% (approximately 1 equivalent).
  • Compound 1 free base and compound 2, as the Form I monohydrobromide (HBr) salt were evaluated in a cross-over dog PK study.
  • Compound 1 free base capsule consisted of compound 1 free base in Vitamin E TPGS and PEG 400 filled into a capsule.
  • the Form I hydrobromide salt capsule consisted of Form I HBr alone filled into a capsule.
  • Compound 1 free base capsule and Form I HBr capsule were dosed orally at 28.5 and 24.5 mg/kg (as active) QD, respectively, to three fasted male non-nai ' ve beagle dogs (body weight range: 10.1 - 10.8 kg) with a 5-day washout period. Approximately 5 mL of tap water was orally administered to encourage swallowing and ensure delivery of capsules into the stomach. Plasma samples were collected at pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose. The plasma concentrations of compound 1 were determined by a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method. The results are provided in Table 20.
  • LC/MS/MS liquid chromatography-tandem mass spectrometry
  • compound 1 When compound 1 is administered orally to fasted dogs at 24.5 - 28.5 mg/kg QD, compound 1 exposure (based on AUC and C max ) is significantly higher when drug is administered as the Form I HBr salt compared to the free base form.
  • Dog #3 had emesis at 30 min post dose. At the 1 h time point, a partial capsule was found under its cage. Thus, data from dog #3 was not included in the calculation of PK parameters.
  • Compound 1 free base and compound 2, as the Form I monohydrobromide (HBr) salt were evaluated in a cross-over dog PK study in which male dogs were pre-treated with either pentagastrin (to decrease gastric pH) or famotidine (to increase gastric pH) prior to oral dosing to control gastric pH.
  • pentagastrin to decrease gastric pH
  • famotidine to increase gastric pH
  • the effect of food on the systemic exposure to compound 1 was also evaluated in dogs receiving Form I HBr with pentagastrin pre- treatment.
  • Compound 1 free base capsule consisted of compound 1 free base in Vitamin E TPGS and PEG 400 filled into a capsule.
  • the Form I hydrobromide salt capsule consisted of Form I HBr alone filled into a capsule.
  • the primary objective of the study is to compare the compound 1 pharmacokinetic (PK) profiles of single doses of Form I monohydrobromide formulations with that of the compound 1 free base in healthy adult males.
  • One group of 12 subjects will be dosed in an effort to obtain the data described above. Each subject will receive the following formulations in a crossover investigation. Dosing will be separated by at least 7 days.
  • Subjects will be provided with a light snack and then fast from all food and drink (except water) for a minimum of 8 h on the day prior to dosing until approximately 4 h post- dose at which time lunch will be provided.
  • An evening meal will be provided at approximately 9 h post-dose and an evening snack at approximately 14 h post-dose. On subsequent days, meals will be provided at appropriate times.
  • Venous blood samples will be withdrawn via an indwelling cannula or by venepuncture at the following times after dosing (hours): 0.5, 1, 1.5, 2, 4, 8, and 12.
  • the primary endpoint of the study is to compare the PK profiles of a formulation of Form I HBr with that of compound 1 as a free base by measuring the following parameters: T lag , C max , T max , AUC (0 -iast), AUC (0 -inf), AUC% ex tra P , F re i, lambda-z, Ti/ 2 el.
  • the secondary endpoint of the study is to collect information about the safety and tolerability of compound 1 (free base) and compound 2 (Form I HBr salt) by assessing: physical examinations, safety laboratory tests, vital signs, electrocardiograms (ECGs), body temperature and AEs.
  • Plasma concentration data will be tabulated and plotted for each subject for whom concentrations are quantifiable.
  • PK analysis of the concentration time data obtained will be performed using appropriate non-compartmental techniques to obtain estimates of the following PK parameters (where relevant).
  • T 1 max the time from dosing at which C max occurs
  • AUC(O-last) the area under the concentration vs time curve from time zero to the last measured time point
  • AUC(O-inf) the area under the concentration vs time curve from time zero extrapolated to infinity
  • AUC% extra p the percentage of AUC ( o-inf ) accounted for by extrapolation
  • AUC(o -tau) the area under the concentration vs time curve within the
  • AUC(0-24) the area under the concentration vs time curve from time zero to 24 hour post morning dose
  • the initial 50 mg HBr dose selected for Regimen B (determined by AUC) is anticipated to be that which is expected to give a similar exposure to the 150 mg free base. This dose is also expected to provide less patient-to-patient variability.
  • the Form I HBr formulation will be dosed again at the revised dose (Regimen C). There will then follow a further period of interim analysis to confirm that the Regimen C dose provides either, 1) a lower active dose as compared to Regimen A that provides an equivalent or higher exposure and/or provide less patient-to- patient variability, or 2) an active dose similar to that of Regimen A with a higher exposure and/or provide less patient-to-patient variability.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.

Description

SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR
CROSS REFERENCE TO RELATED CASES
[0001] The present application claims priority to United States provisional application serial number 61/611,400, filed March 15, 2012, the entirety of which is hereby incorporated by reference.
FIELD OF THE INVENTION
[0002] The present invention provides salt forms of a compound useful as mutant-selective inhibitors of epidermal growth factor receptor (EGFR) kinase, including polymorphic forms of certain salts. The invention also provides pharmaceutically acceptable compositions comprising salt forms of the present invention and methods of using the compositions in the treatment of various disorders.
BACKGROUND OF THE INVENTION
[0003] Protein tyrosine kinases are a class of enzymes that catalyze the transfer of a phosphate group from ATP or GTP to a tyrosine residue located on a protein substrate. Receptor tyrosine kinases act to transmit signals from the outside of a cell to the inside by activating secondary messaging effectors via a phosphorylation event. A variety of cellular processes are promoted by these signals, including proliferation, carbohydrate utilization, protein synthesis, angiogenesis, cell growth, and cell survival.
[0004] There is strong precedent for involvement of the EGFR in human cancer because over 60% of all solid tumors overexpress at least one of these proteins or their ligands. Overexpression of EGFR is commonly found in breast, lung, head and neck, bladder tumors.
[0005] Activating mutations in the tyrosine kinase domain of EGFR have been identified in patients with non-small cell lung cancer (Lin, N. U.; Winer, E. P., Breast Cancer Res 6: 204-210, 2004). The reversible inhibitors Tarceva (erlotinib) and Iressa (gefitinib) currently are first-line therapy for non-small cell lung cancer patients with activating mutations. The most common activating mutations are L858R and delE746-A750.
[0006] Additionally, in the majority of patients that relapse, acquired drug resistance, such as by mutation of gatekeeper residue T790M, has been detected in at least half of such clinically resistant patients. Moreover, T790M may also be pre-existing; there may be an independent, oncogenic role for the T790M mutation. For example, there are patients with the L858R/T790M mutation who never received gefitinib treatment. In addition, germline EGFR T790M mutations are linked with certain familial lung cancers.
[0007] Current drugs in development, including second-generation covalent inhibitors, such as BIBW2992, HKI-272 and PF-0299804, are effective against the T790M resistance mutation but exhibit dose-limiting toxicities due to concurrent inhibition of WT EGFR. Accordingly, there remains a need to find mutant-selective EGFR kinase inhibitors useful as therapeutic agents.
SUMMARY OF THE INVENTION
[0007] It has now been found that the novel benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid salts of the present invention, and compositions thereof, are useful as mutant-selective inhibitors of one or more EGFR kinases and exhibits desirable characteristics for the same. In general, these salts, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of diseases or disorders as described in detail herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1 depicts the x-ray powder diffraction (XRPD) pattern for a bis-besylate salt of Compound 1.
[0009] Figure 2 depicts the thermogravimetric analysis (TGA) pattern for a bis-besylate salt of Compound 1.
[0010] Figure 3 depicts the thermogravimetric analysis (TGA) pattern for a further dried sample of a bis-besylate salt of Compound 1.
[0011] Figure 4 depicts the differential scanning calorimetry (DSC) pattern for a bis- besylate salt of Compound 1.
[0012] Figure 5 depicts the infrared (IR) spectrum of a bis-besylate salt of Compound 1.
[0013] Figure 6 depicts the ^- MR spectrum of a bis-besylate salt of Compound 1.
[0014] Figure 7 depicts the dynamic vapor sorption (DVS) pattern of a bis-besylate salt of Compound 1. [0015] Figure 8 depicts the results of a hydration study of a bis-besylate salt of Compound I, as analyzed by the XRPD patterns.
[0016] Figure 9 depicts the results of a disproportionation study of a bis-besylate salt of Compound 1, as analyzed by the XRPD patterns.
[0017] Figure 10 depicts the results of a stability study of a bis-besylate salt of Compound 1, as analyzed by the XRPD patterns.
[0018] Figure 11 depicts the results of a thermodynamic solubility study of a bis-besylate salt of Compound 1, as analyzed by the XRPD patterns.
[0019] Figure 12 depicts the dissolution at pH 4.5 of a compressed disc of a bis-besylate salt of Compound 1.
[0020] Figure 13 depicts the dissolution at pH 3.0 of a compressed disc of a bis-besylate salt of Compound 1.
[0021] Figure 14 depicts the XRPD pattern for a bis-besylate hydrate salt of Compound 1.
[0022] Figure 15 depicts the TGA pattern for a bis-besylate hydrate salt of Compound 1.
[0023] Figure 16 depicts the DSC pattern for a bis-besylate hydrate salt of Compound 1.
[0024] Figure 17 depicts the IR spectrum of a bis-besylate hydrate salt of Compound 1.
[0025] Figure 18 depicts the ^- MR spectrum of a bis-besylate hydrate salt of Compound 1.
[0026] Figure 19 depicts the DVS pattern of a bis-besylate hydrate salt of Compound 1.
[0027] Figure 20 depicts the results of a stability study of a bis-besylate hydrate salt of Compound 1, as analyzed by the XRPD patterns.
[0028] Figure 21 depicts the results of a thermodynamic solubility study of a bis-besylate salt of Compound 1, as analyzed by the XRPD patterns.
[0029] Figure 22 depicts the dissolution at pH 4.5 of a compressed disc of a bis-besylate hydrate salt of Compound 1.
[0030] Figure 23 depicts the dissolution at pH 3.0 of a compressed disc of a bis-besylate hydrate salt of Compound 1.
[0031] Figure 24 depicts the XRPD pattern for a mono-maleate salt of Compound 1.
[0032] Figure 25 depicts the TGA pattern for a mono-maleate salt of Compound 1.
[0033] Figure 26 depicts the DSC pattern for a mono-maleate salt of Compound 1.
[0034] Figure 27 depicts the ^- MR spectrum of a mono-maleate salt of Compound 1.
[0035] Figure 28 depicts the XRPD pattern for a bis-hydrochloride salt of Compound 1.
[0036] Figure 29 depicts the TGA pattern for a bis-hydrochloride salt of Compound 1. [0037] Figure 30 depicts the DSC pattern for a bis-hydrochloride salt of Compound 1.
[0038] Figure 31 depicts the ^- MR spectrum of a bis-hydrochloride salt of Compound 1.
[0039] Figure 32 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
[0040] Figure 33 depicts the TGA pattern for a Form I hydrobromide salt of Compound 1.
[0041] Figure 34 depicts the DSC pattern for a Form I hydrobromide salt of Compound 1.
[0042] Figure 35 depicts the IR spectrum of a Form I hydrobromide salt of Compound 1.
[0043] Figure 36 depicts the ^- MR spectrum of a Form I hydrobromide salt of Compound 1.
[0044] Figure 37 depicts the DVS pattern of a Form I hydrobromide salt of Compound 1.
[0045] Figure 38 depicts the results of a hydration study of a Form I hydrobromide salt of Compound 1, as analyzed by the XRPD patterns.
[0046] Figure 39 depicts the results of a disproportionation study of a Form I hydrobromide salt of Compound 1, as analyzed by the XRPD patterns.
[0047] Figure 40 depicts the results of a stability study of a Form I hydrobromide salt of Compound 1, as analyzed by the XRPD patterns.
[0048] Figure 41 depicts the results of a thermodynamic solubility study of a Form I hydrobromide salt of Compound 1, as analyzed by the XRPD patterns.
[0049] Figure 42 depicts the dissolution at pH 4.5 of a compressed disc of a Form I hydrobromide salt of Compound 1.
[0050] Figure 43 depicts the dissolution at pH 3.0 of a compressed disc of a Form I hydrobromide salt of Compound 1.
[0051] Figure 44 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
[0052] Figure 45 depicts the TGA pattern for a Form I hydrobromide salt of Compound 1.
[0053] Figure 46 depicts the IR spectrum of a Form I hydrobromide salt of Compound 1.
[0054] Figure 47 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
[0055] Figure 48 depicts the ^- MR spectrum for a Form I hydrobromide salt of Compound 1.
[0056] Figure 49 depicts the DSC pattern of a Form I hydrobromide salt of Compound 1.
[0057] Figure 50 depicts the results of a slurry experiment involving a form of the free base of Compound 1 and a bis-besylate hydrate.
[0058] Figure 51 depicts the results of a slurry experiment involving a Form I hydrobromide salt of Compound 1 at pH 6.2.
[0059] Figure 52 depicts the XRPD pattern for a Form I hydrobromide salt of Compoundl. [0060] Figure 53 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
[0061] Figure 54 depicts the IR spectrum of a Form I hydrobromide salt of Compound 1.
[0062] Figure 55 depicts the ^- MR spectrum of a Form I hydrobromide salt of Compound 1.
[0063] Figure 56 depicts the TGA pattern for a Form I hydrobromide salt of Compound 1.
[0064] Figure 57 depicts the DSC pattern for a Form I hydrobromide salt of Compound 1.
[0065] Figure 58 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1 after heating.
[0066] Figure 59 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
[0067] Figure 60 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1.
[0068] Figure 61 depicts the IR spectrum of a Form I hydrobromide salt of Compound 1.
[0069] Figure 62 depicts the ^- MR spectrum of a Form I hydrobromide salt of Compound 1.
[0070] Figure 63 depicts the TGA pattern for a Form I hydrobromide salt of Compound 1.
[0071] Figure 64 depicts the DSC pattern for a Form I hydrobromide salt of Compound 1.
[0072] Figure 65 depicts the results of a thermodynamic solubility study of a Form I hydrobromide salt of Compound 1, as analyzed by the XRPD patterns.
[0073] Figure 66 depicts the XRPD pattern for a Form I hydrobromide salt of Compound 1, after storage for 1.5 months.
[0074] Figure 67 depicts the XRPD pattern for a Form III hydrobromide salt of Compound 1.
[0075] Figure 68 depicts theTGA pattern for a Form III hydrobromide salt of Compound 1.
[0076] Figure 69 depicts the DSC pattern for a Form III hydrobromide salt of Compound 1.
[0077] Figure 70 depicts the IR spectrum for a Form III hydrobromide salt of Compound 1.
[0078] Figure 71 depicts the ^- MR spectrum of a Form III hydrobromide salt of Compound 1.
[0079] Figure 72 depicts the XRPD pattern for a Form IV hydrobromide salt of Compound 1.
[0080] Figure 73 depicts the XRPD pattern for a Form V hydrobromide salt of Compound 1.
[0081] Figure 74 depicts the XRPD pattern for a Form VI hydrobromide salt of Compound 1.
[0082] Figure 75 depicts the XRPD pattern for a Form VII hydrobromide salt of Compound 1. [0083] Figure 76 depicts the XRPD pattern for a Form VIII hydrobromide salt of Compound 1.
[0084] Figure 77 depicts the TGA pattern for a Form VIII hydrobromide salt of Compound 1.
[0085] Figure 78 depicts the DSC pattern for a Form VIII hydrobromide salt of Compound 1.
[0086] Figure 79 depicts the XRPD of an amorphous hydrobromide salt of Compound 1.
[0087] Figure 80 depicts the XRPD of Form V hydrobromide salt of Compound 1 following desolvation conditions.
[0088] Figure 81 depicts input material Form I hydrobromide salt of Compound 1 compared with a wet sample, and after stages of drying.
[0089] Figure 82 depicts the XRPD analysis of hydrobromide salt Forms I and III resulting from competitive slurry experiments at ambient temperature (22 °C).
[0090] Figure 83 depicts the XRPD analysis of hydrobromide salt Forms I and III resulting from competitive slurry experiments at 60 °C.
[0091] Figure 84 depicts the XRPD analysis of Form I hydrobromide salt of Compound 1 slurried in EtOH:water mixtures.
[0092] Figure 85 depicts the XRPD analysis of material slurried in IP A/acetone (9: 1): water mixtures.
[0093] Figure 86 depicts the XRPD analysis following hydration studies at 15 °C and 35 °C.
[0094] Figure 87 depicts the form diagram for the hydrobromide salt, including 7 different forms and the relationship between such forms.
DETAILED DESCRIPTION OF THE INVENTION
General Description of Certain Aspects of the Invention:
[0095] United States application number 13/286,061, published as US 2012/0149687 on June 14, 2012 ("the '061 application"), filed October 31, 2011, the entirety of which is hereby incorporated herein by reference, describes certain 2,4-disubstituted pyrimidine compounds which covalently and irreversibly inhibit activity of EGFR kinase. Such compounds include compound 1:
Figure imgf000008_0001
1
[0096] Compound 1 (N-(3-(2-(4-(4-acetylpiperazin-l-yl)-2-methoxyphenylamino)-5- (trifluoromethyl)pyrimidin-4-ylamino)phenyl)acrylamide)) is designated as compound number I- 4 and the synthesis of compound 1 is described in detail at Example 3 of the '061 application.
[0097] Compound 1 is active in a variety of assays and therapeutic models demonstrating selective covalent, irreversible inhibition of mutant EGFR kinase (in enzymatic and cellular assays). Notably, compound 1 was found to inhibit human non-small cell lung cancer cell proliferation both in vitro and in vivo. Accordingly, compound 1 and its salts are useful for treating one or more disorders associated with activity of mutant EGFR kinase.
[0098] It would be desirable to provide a form of compound 1 that, as compared to compound 1, imparts characteristics such as improved aqueous solubility, stability and ease of formulation. Accordingly, the present invention provides several salts of compound 1.
[0099] According to one embodiment, the present invention provides a salt of compound 1, represented by compound 2:
Figure imgf000008_0002
2
where:
n is 1 or 2; and
X is benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid,
hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2 -sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6- trihydroxybenzoic acid.
[00100] It will be appreciated by one of ordinary skill in the art that the acid moiety indicated as "X" and compound 1 are ionically bonded to form compound 2. It is contemplated that compound 2 can exist in a variety of physical forms. For example, compound 2 can be in solution, suspension, or in solid form. In certain embodiments, compound 2 is in solid form. When compound 2 is in solid form, said compound may be amorphous, crystalline, or a mixture thereof. Exemplary solid forms are described in more detail below.
[00101] In other embodiments, the present invention provides compound 2 substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound contains no significant amount of extraneous matter. Such extraneous matter may include excess acid "X", excess compound 1, residual solvents, or any other impurities that may result from the preparation of, and/or isolation of, compound 2. In certain embodiments, at least about 90% by weight of compound 2 is present. In certain embodiments, at least about 95% by weight of compound 2 is present. In still other embodiments of the invention, at least about 99% by weight of compound 2 is present.
[00102] According to one embodiment, compound 2 is present in an amount of at least about 95, 97, 97.5, 98.0, 98.5, 99, 99.5, 99.8 weight percent where the percentages are based on the total weight of the composition. According to another embodiment, compound 2 contains no more than about 5.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 3.0 area percent HPLC of total organic impurities and, in certain embodiments, no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram. In other embodiments, compound 2 contains no more than about 1.0 area percent HPLC of any single impurity; no more than about 0.6 area percent HPLC of any single impurity, and, in certain embodiments, no more than about 0.5 area percent HPLC of any single impurity, relative to the total area of the HPLC chromatogram.
[00103] The structure depicted for compound 2 is also meant to include all tautomeric forms of compound 2. Additionally, structures depicted here are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structure except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Solid Forms of Compound 2:
[00104] It has been found that compound 2 can exist in a variety of solid forms. Such forms include polymorphs and amorphous forms. The solid forms can be solvates, hydrates and unsolvated forms of compound 2. All such forms are contemplated by the present invention. In certain embodiments, the present invention provides compound 2 as a mixture of one or more solid forms of compound 2.
[00105] As used herein, the term "polymorph" refers to the different crystal structures (of solvated or unsolvated forms) in which a compound can crystallize.
[00106] As used herein, the term "solvate" refers to a crystal form with either a stoichiometric or non-stoichiometric amount of solvent. For polymorphs, the solvent is incorporated into the crystal structure. Similarly, the term "hydrate" refers to a solid form with either a stoichiometric or non-stoichiometric amount of water. For polymorphs, the water is incorporated into the crystal structure.
[00107] As used herein, the term "about", when used in reference to a degree 2-theta value refers to the stated value ± 0.3 degree 2-theta (° 2Θ). In certain embodiments, "about" refers to ± 0.2 degree 2-theta or ± 0.1 degree 2-theta.
[00108] In certain embodiments, compound 2 is a crystalline solid. In other embodiments, compound 2 is a crystalline solid substantially free of amorphous compound 2. As used herein, the term "substantially free of amorphous compound 2" means that the compound contains no significant amount of amorphous compound 2. In certain embodiments, at least about 90% by weight of crystalline compound 2 is present, or at least about 95% by weight of crystalline compound 2 is present. In still other embodiments of the invention, at least about 99% by weight of crystalline compound 2 is present.
[00109] In certain embodiments, compound 2 is a benzenesulfonic acid (besylate) salt. The salt can be a mono-besylate or a bis-besylate. A besylate salt is optionally solvated or hydrated, such as a monohydrate.
[00110] According to one aspect, an unsolvated bis-besylate salt has a powder X-ray diffraction pattern substantially similar to that depicted in Figure 1. According to one embodiment, an unsolvated bis-besylate salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 5.62, about 17.41, about 18.90, about 19.07 and about 19.52 degrees 2-theta. In some embodiments, an unsolvated bis-besylate salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 5.62, about 17.41, about 18.90, about 19.07 and about 19.52 degrees 2-theta. In certain embodiments, an unsolvated bis-besylate salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 5.62, about 17.41, about 18.90, about 19.07 and about 19.52 degrees 2-theta. In particular embodiments, an unsolvated bis- besylate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 5.62, 7.89, 11.23, 12.64, 17.41, 18.90, 19.07, 19.52, 22.63, 23.17, 25.28 and 28.92 degrees 2-theta. In an exemplary embodiment, an unsolvated bis- besylate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
Figure imgf000011_0001
According to another aspect, an unsolvated bis-besylate salt has a thermogravimetric analysis pattern substantially similar to that depicted in Figure 2 or 3. According to yet another aspect, an unsolvated bis-besylate salt has a differential scanning calorimetry pattern substantially similar to that depicted in Figure 4. According to a further embodiment, an unsolvated bis- besylate salt has an infrared spectrum substantially similar to that depicted in Figure 5. According to another embodiment, an unsolvated bis-besylate salt has an ^- MR spectrum substantially similar to that depicted in Figure 6. According to a further embodiment, an unsolvated bis-besylate salt has a dynamic vapour sorption pattern substantially similar to that depicted in Figure 7. An unsolvated bis-besylate salt can be characterized by substantial similarity to two or more of these figures simultaneously.
[00111] According to one aspect, a bis-besylate hydrate has a powder X-ray diffraction pattern substantially similar to that depicted in Figure 14. According to one embodiment, a bis- besylate hydrate salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 10.68, about 16.10, about 18.44 and about 22.36 degrees 2- theta. In some embodiments, a bis-besylate hydrate salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 10.68, about 16.10, about 18.44 and about 22.36 degrees 2-theta. In certain embodiments, a bis-besylate hydrate salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 10.68, about 16.10, about 18.44 and about 22.36 degrees 2-theta. In particular embodiments, a bis-besylate hydrate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 9.33, 10.68, 16.10, 16.43, 16.64, 18.44, 20.05, 20.32, 20.74, 22.36 and 22.83 degrees 2-theta. In an exemplary embodiment, a bis- besylate hydrate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
Figure imgf000012_0001
According to another aspect, a bis-besylate hydrate has a thermogravimetric analysis pattern substantially similar to that depicted in Figure 15. According to yet another aspect, a bis- besylate hydrate has a differential scanning calorimetry pattern substantially similar to that depicted in Figure 16. According to a further embodiment, a bis-besylate hydrate has a infrared spectrum substantially similar to that depicted in Figure 17. According to another embodiment, a bis-besylate hydrate has an ^- MR spectrum substantially similar to that depicted in Figure 18. According to a further embodiment, a bis-besylate hydrate has a dynamic vapour sorption pattern substantially similar to that depicted in Figure 19. A bis-besylate hydrate can be characterized by substantial similarity to two or more of these figures simultaneously.
[00112] In certain embodiments, compound 2 is a camphor sulfonic acid salt (e.g., camphor- 10-sulfonic acid). In some embodiments, compound 2 is a mono-camphor sulfonic acid salt. In some embodiments, compound 2 is a bis-camphor sulfonic acid salt.
[00113] In certain embodiments, compound 2 is a 1,2-ethane disulfonic acid salt. In some embodiments, compound 2 is a mono- 1,2-ethane disulfonic acid salt. In some embodiments, compound 2 is a bis- 1,2-ethane disulfonic acid salt.
[00114] In certain embodiments, compound 2 is a hydrobromic acid salt. In some embodiments, compound 2 is an anhydrous monohydrobromic acid salt. In some embodiments, compound 2 is an anhydrous bis-hydrobromic acid salt. A hydrobromide salt is optionally solvated or hydrated. In some embodiments, compound 2 is a monohydrate hydrobromic acid salt. In some embodiments, compound 2 is a solvated hydrobromic acid salt. In some such embodiments, the solvate is selected from dimethylsulfoxide (DMSO), dimethylformamide (DMF) and 1,4-dioxane. In some embodiments, compound 2 is a hydrobromide salt selected from Form I, Form III, Form IV, Form V, Form VI, Form VII and Form VIII, each of which is described in further detail, infra.
[00115] In some embodiments, compound 2 is a Form I hydrobromide salt. In some such embodiments, compound 2 is an anhydrous Form I hydrobromide salt. According to one aspect, a Form I hydrobromide salt is characterized by the powder X-ray diffraction pattern substantially similar to that depicted in Figure 60. In some embodiments, a Form I hydrobromide salt is characterized by the powder X-ray diffraction pattern substantially similar to that depicted in Figure 59. According to one embodiment, a Form I mono-hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta. In some embodiments, a Form I mono-hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta. In certain embodiments, a Form I mono-hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta. In some embodiments, a Form I mono-hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta. In particular embodiments, a Form I mono- hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 9.84, 15.62, 17.39, 19.45, 20.69, 21.41, 22.38, 23.56, 25.08 and 27.45 degrees 2- theta. In an exemplary embodiment, a Form I mono-hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
Figure imgf000014_0001
[00116] According to another aspect, a Form I mono-hydrobromide salt is characterized by a thermogravimetric analysis pattern substantially similar to that depicted in Figure 63. According to yet another aspect, a Form I mono-hydrobromide salt is characterized by a differential scanning calorimetry pattern substantially similar to that depicted in Figure 64. According to a further embodiment, a Form I mono-hydrobromide salt is characterized by an infrared spectrum substantially similar to that depicted in Figure 61. According to another embodiment, a Form I mono-hydrobromide salt is characterized by a ^- MR spectrum substantially similar to that depicted in Figure 62. In some embodiments, a Form I mono- hydrobromide salt is characterized by substantial similarity to two or more of these figures simultaneously.
[00117] In some embodiments, compound 2 is a Form III hydrobromide salt. In some such embodiments, compound 2 is an anhydrous Form III hydrobromide salt. In some embodiments, a Form III hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 67. According to one embodiment, a Form III hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta. In some embodiments, a Form III hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta. In certain embodiments, a Form III hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta. In some embodiments, a Form III hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta. In some embodiments, a Form III hydrobromide salt is characterized by five or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta. In some embodiments, a Form III hydrobromide salt is characterized by six or more peaks in its powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta. In particular embodiments, a Form III hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta. In an exemplary embodiment, a Form III hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
°2-Theta °2-Theta °2-Theta °2-Theta
6.79 16.67 22.91 30.76
8.15 17.08 23.93 31.39
8.98 17.84 24.32 31.75
9.58 18.33 25.39 32.39
10.36 18.74 25.74 32.68
11.35 19.07 26.34 33.33
13.36 19.93 27.47 33.77
14.06 20.89 28.32 34.48
14.58 21.90 28.89 34.57
15.99 22.70 30.50
[00118] In some embodiments, a Form III hydrobromide salt is characterized by a thermogravimetric analysis pattern substantially similar to that depicted in Figure 68. In some embodiments, a Form III hydrobromide salt is characterized by a differential scanning calorimetry pattern substantially similar to that depicted in Figure 69. In some embodiments, a Form III hydrobromide salt is characterized by an infrared spectrum substantially similar to that depicted in Figure 70. In some embodiments, a Form III hydrobromide salt is characterized by a ^- MR spectrum substantially similar to that depicted in Figure 71. In some embodiments, a Form III hydrobromide salt is characterized by substantial similarity to two or more of these figures simultaneously.
[00119] In some embodiments, compound 2 is a Form IV hydrobromide salt. In some such embodiments, a Form IV hydrobromide salt is a 1,4-dioxane solvate. In some embodiments, a Form rv hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 72. According to one embodiment, a Form IV hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta. In some embodiments, a Form IV hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta. In certain embodiments, a Form IV hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta. In some embodiments, a Form IV hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta. In some embodiments, a Form IV hydrobromide salt is characterized by five or more peaks in its powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta. In particular embodiments, a Form IV hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta. In an exemplary embodiment, a Form IV hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
°2-Theta °2-Theta °2-Theta °2-Theta
5.99 12.96 19.38 24.82
6.45 13.42 19.79 26.539
7.23 16.34 21.37 27.12
7.84 16.55 21.58 27.89
9.31 17.00 22.65 28.43
9.71 17.93 23.23 28.74
1 1.07 18.99 24.10
[00120] In some embodiments, compound 2 is a Form V hydrobromide salt. In some such embodiments, a Form V hydrobromide salt is a Ν,Ν-dimethylformamide (DMF) solvate. In some embodiments, a Form V hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 73. According to one embodiment, a Form V hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta. In some embodiments, a Form V hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta. In certain embodiments, a Form V hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta. In some embodiments, a Form V hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta. In some embodiments, a Form V hydrobromide salt is characterized by five or more peaks in its powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta. In particular embodiments, a Form V hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta. In an exemplary embodiment, a Form V hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
Figure imgf000018_0001
[00121] In some embodiments, compound 2 is a Form VI hydrobromide salt. In some such embodiments, a Form VI hydrobromide salt is a dimethylsulfoxide (DMSO) solvate. In some embodiments, a Form VI hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 74. According to one embodiment, a Form VI hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2- theta. In some embodiments, a Form VI hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2-theta. In certain embodiments, a Form VI hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2-theta. In particular embodiments, a Form VI hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2-theta. In an exemplary embodiment, a Form VI hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
°2-Theta °2-Theta °2-Theta °2-Theta
8.38 9.38 18.93 21.58
[00122] In some embodiments, compound 2 is a Form VII hydrobromide salt. In some such embodiments, a Form VII hydrobromide salt is a dimethylsulfoxide (DMSO) solvate. In some embodiments, a Form VII hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 75. According to one embodiment, a Form VII hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta. In some embodiments, a Form VII hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta. In certain embodiments, a Form VII hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta. In some embodiments, a Form VII hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta. In some embodiments, a Form VII hydrobromide salt is characterized by five or more peaks in its powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta. In particular embodiments, a Form VII hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta. In an exemplary embodiment, a Form VII hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
°2-Theta °2-Theta °2-Theta °2-Theta
6.35 16.54 19.53 23.93
8.88 16.88 20.24 24.37
9.29 17.56 21.78 25.00
15.18 18.22 22.12 25.58
15.91 19.10 22.64 26.00
[00123] In some embodiments, compound 2 is a Form VIII hydrobromide salt. In some such embodiments, a Form VIII hydrobromide salt is a hydrate. In some embodiments, a Form VIII hydrobromide salt is characterized by a powder X-ray diffraction pattern substantially similar to that depicted in Figure 76. According to one embodiment, a Form VIII hydrobromide salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 11.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta. In some embodiments, a Form VIII hydrobromide salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 11.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta. In certain embodiments, a Form VIII hydrobromide salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 1 1.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta. In some embodiments, a Form VIII hydrobromide salt is characterized by four or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 1 1.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta. In some embodiments, a Form VIII hydrobromide salt is characterized by five or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 1 1.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta. In some embodiments, a Form VIII hydrobromide salt is characterized by six or more peaks in its powder X-ray diffraction pattern selected from those at about 8.79, about 11.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta. In particular embodiments, a Form VIII hydrobromide salt is characterized by an X-ray powder diffraction pattern which includes the peaks at about 8.79, about 1 1.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta. In an exemplary embodiment, a Form VIII hydrobromide salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
Figure imgf000020_0001
[00124] In some embodiments, a Form VIII hydrobromide salt has a thermogravimetric analysis pattern substantially similar to that depicted in Figure 77. In some embodiments, a Form VIII hydrobromide salt has a differential scanning calorimetry pattern substantially similar to that depicted in Figure 78. In some embodiments, a Form VIII hydrobromide salt is characterized by substantial similarity to two or more of these figures simultaneously. [00125] In certain embodiments, compound 2 is a hydrochloric acid salt. In some embodiments, compound 2 is a mono-hydrochloric acid salt. In some embodiments, compound 2 is a bis-hydrochloric acid salt.
[00126] According to one aspect, a bis-hydrochloride salt has a powder X-ray diffraction pattern substantially similar to that depicted in Figure 28. According to one embodiment, a bis- hydrochloride salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 17.58, about 23.32, about 25.53 and about 28.37 degrees 2-theta. In some embodiments, a bis-hydrochloride salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 17.58, about 23.32, about 25.53 and about 28.37 degrees 2-theta. In certain embodiments, a bis-hydrochloride salt is characterized by three or more peaks in its powder X-ray diffraction pattern selected from those at about 17.58, about 23.32, about 25.53 and about 28.37 degrees 2-theta. In particular embodiments, a bis- hydrochloride salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 17.58, 20.13, 22.14, 23.32, 25.53, 26.60, 27.80 and 28.37 degrees 2-theta. In an exemplary embodiment, a bis-hydrochloride salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
°2-Theta °2-Theta °2-Theta °2-Theta
3.04 19.68 29.50 41.01
3.84 20.13 30.21 41.78
5.40 20.86 30.74 42.64
6.34 21.38 31.56 44.43
7.67 21.67 31.79 44.89
9.20 22.14 32.29 45.62
9.37 23.32 33.03 46.46
10.62 23.99 33.46 46.87
14.48 24.63 34.66 47.18
15.34 25.15 35.62 47.88
15.47 25.53 36.07 48.14
15.81 26.60 36.47 48.72
16.34 27.80 37.08 49.63
16.87 28.37 37.91
17.58 28.73 38.71
18.44 29.08 40.02
According to another aspect, a bis-hydrochloride salt has a thermogravimetric analysis pattern substantially similar to that depicted in Figure 29. According to yet another aspect, a bis- hydrochloride salt has a differential scanning calorimetry pattern substantially similar to that depicted in Figure 30. According to another embodiment, a bis -hydrochloride salt has an lH- NMR spectrum substantially similar to that depicted in Figure 31.
[00127] In certain embodiments, compound 2 is a maleic acid salt. In some embodiments, compound 2 is a mono-maleic acid salt. In some embodiments, compound 2 is a bis-maleic acid salt.
[00128] According to one aspect, a mono-maleate salt has a powder X-ray diffraction pattern substantially similar to that depicted in Figure 24. According to one embodiment, a mono- maleate salt is characterized by one or more peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 23.59 and about 23.80 degrees 2-theta. In some embodiments, a mono-maleate salt is characterized by two or more peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 23.59 and about 23.80 degrees 2- theta. In certain embodiments, a mono-maleate salt is characterized by three peaks in its powder X-ray diffraction pattern selected from those at about 8.38, about 23.59 and about 23.80 degrees 2-theta. In particular embodiments, a mono-maleate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 8.38, 13.74, 16.35, 16.54, 20.67, 23.15, 23.59 and 23.80 degrees 2-theta. In an exemplary embodiment, a mono-maleate salt is characterized by substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about
°2-Theta °2-Theta °2-Theta °2-Theta
7.42 13.74 23.59 33.68
8.38 14.65 23.80 35.05
9.06 15.91 24.75 38.51
9.91 16.35 26.52 41.05
10.13 16.54 27.13 43.03
10.45 17.86 27.90 45.85
10.62 19.96 29.53 46.06
11.16 20.67 30.37 46.44
12.40 22.50 31.30 46.69
13.15 23.15 32.04 48.23
According to another aspect, a mono-maleate salt has a thermogravimetric analysis pattern substantially similar to that depicted in Figure 25. According to yet another aspect, a mono- maleate salt has a differential scanning calorimetry pattern substantially similar to that depicted in Figure 26. According to another embodiment, a mono-maleate salt has an ^- MR spectrum substantially similar to that depicted in Figure 27.
[00129] It will be appreciated that any of the above-described polymorph forms can be characterized, for example, by reference to any of the peaks in their respective X-ray diffraction patterns. Accordingly, in some embodiments, a polymorph described herein is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more XRPD peaks (°2Θ).
[00130] In certain embodiments, compound 2 is a methanesulfonic acid salt. In some embodiments, compound 2 is a mono-methansulfonic acid salt. In some embodiments, compound 2 is a bis-methanesulfonic acid salt.
[00131] In certain embodiments, compound 2 is a naphthalene-2 -sulfonic acid salt. In some embodiments, compound 2 is a mono-naphthalene-2-sulfonic acid salt. In some embodiments, compound 2 is a bis-naphthalene-2-sulfonic acid salt.
[00132] In certain embodiments, compound 2 is a 1,5 -naphthalene disulfonic acid salt. In some embodiments, compound 2 is a mono- 1,5 -naphthalene disulfonic acid salt. In some embodiments, compound 2 is a bis-l,5-naphthalene disulfonic acid salt.
[00133] In certain embodiments, compound 2 is an oxalic acid salt. In some embodiments, compound 2 is a mono-oxalic acid salt. In some embodiments, compound 2 is a bis-oxalic acid salt.
[00134] In certain embodiments, compound 2 is a p-toluenesulfonic acid (tosylate) salt. In some embodiments, compound 2 is a mono-p-toluenesulfonic acid salt. In some embodiments, compound 2 is a bis-p-toluenesulfonic acid salt.
[00135] In certain embodiments, compound 2 is a 2,4,6-trihydroxybenzoic acid salt. In some embodiments, compound 2 is a mono-2,4,6-trihydroxybenzoic acid salt. In some embodiments, compound 2 is a bis-2,4,6-trihydroxybenzoic acid salt.
[00136] According to another embodiment, the present invention provides compound 2 as an amorphous solid. Amorphous solids are well known to one of ordinary skill in the art and are typically prepared by such methods as lyophilization, melting, and precipitation from supercritical fluid, among others.
General Methods of Providing Compound 2:
[00137] Compound 1 is prepared according to the methods described in detail in the '061 application, the entirety of which is hereby incorporated herein by reference. Compound 2 is prepared from Compound 1, according to the Scheme below.
Figure imgf000024_0001
Compound 1 Compound 2
[00138] As depicted in the general Scheme above, Compound 2 is prepared from Compound 1 by combining Compound 1 with either one or two equivalents of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid to form the salt thereof. Thus, another aspect of the present inv ntion provides a method for preparing Compound 2:
Figure imgf000024_0002
Compound 2
comprising the steps of:
providing Compound 1:
Figure imgf000024_0003
Compound 1
combining Compound 1 with one or two equivalents of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid in a suitable solvent; and
optionally isolating Compound 2.
[00139] A suitable solvent may solubilize one or more of the reaction components, or, alternatively, the suitable solvent may facilitate the agitation of a suspension of one or more of the reaction components. Examples of suitable solvents useful in the present invention are a protic solvent, a polar aprotic solvent, a nonpolar solvent or mixtures thereof. In certain embodiments, suitable solvents include water, an ether, an ester, an alcohol, a halogenated solvent, a ketone, or a mixture thereof. In certain embodiments, the suitable solvent is methanol, ethanol, isopropanol, ethyl acetate, isopropyl acetate, methyl ethyl ketone, methyl isobutyl ketone or acetone. In certain embodiments, the suitable solvent is dichloromethane. In other embodiments, suitable solvents include tetrahydrofuran, dimethylformamide, dimethylsulfoxide, glyme, diglyme, methyl t-butyl ether, t-butanol, n-butanol, and acetonitrile. In some embodiments, the suitable solvent is cyclohexane.
[00140] According to another embodiment, the present invention provides a method for preparing Compound 2:
Figure imgf000025_0001
Compound 2
comprising the steps of:
combining Compound 1:
Figure imgf000025_0002
Compound 1
with a suitable solvent and optionally heating to form a solution thereof;
adding one or two equivalents of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2 -sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid to said solution; and
optionally isolating Compound 2.
[00141] As described generally above, Compound 1 is dissolved or suspended in a suitable solvent, optionally with heating. In certain embodiments Compound 1 is dissolved at about 20 to about 60 °C. In other embodiments, Compound 1 is dissolved at about 20 to about 25 °C, such as about ambient temperature. In still other embodiments, compound 1 is dissolved at the boiling temperature of the solvent. In other embodiments, compound 1 is dissolved without heating.
[00142] In certain embodiments, about 1 equivalent of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2. In other embodiments, about 2 equivalents of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2. In yet other embodiments, greater than 2 equivalents of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2 -sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2. In still other embodiments, about 0.9 to about 1.1 equivalents of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2. In another embodiment, about 0.99 to about 1.01 equivalents of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2 -sulfonic acid, 1,5- naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2. In further embodiments, about 1.8 to about 2.2 equivalents, such as about 1.98 to 2.02 equivalents, of benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid is added to Compound 1 to afford Compound 2.
[00143] It will be appreciated that the acid may be added to the mixture of Compound 1 and a suitable solvent in any suitable form. For example, the acid may be added in solid form or as a solution or a suspension in a suitable solvent. The suitable solvent may be the same suitable solvent as that which is combined with Compound 1 or may be a different solvent. According to one embodiment, the acid is added in solid form. In certain embodiments, the acid is combined with a suitable solvent prior to adding to Compound 1. According to another embodiment, the acid is added as a solution in a suitable solvent. In certain embodiments, suitable solvents include water, an ether, an ester, an alcohol, a halogenated solvent, a ketone, or a mixture thereof. In certain embodiments, the suitable solvent is methanol, ethanol, isopropanol, ethyl acetate, isopropyl acetate, methyl ethyl ketone, methyl isobutyl ketone or acetone. In certain embodiments, the suitable solvent is dichloromethane. In other embodiments, suitable solvents include tetrahydrofuran, dimethylformamide, dimethylsulfoxide, glyme, diglyme, methyl t-butyl ether, t-butanol, n-butanol, and acetonitrile. In some embodiments, the suitable solvent is cyclohexane. In certain embodiments the suitable solvent is selected from those above and is anhydrous.
[00144] In certain embodiments, the resulting mixture containing Compound 2 is cooled. In other embodiments, the mixture containing Compound 2 is cooled below 20 °C, such as below 10 °C.
[00145] In certain embodiments, Compound 2 precipitates from the mixture. In another embodiment, Compound 2 crystallizes from the mixture. In other embodiments, Compound 2 crystallizes from solution following seeding of the solution (i.e., adding crystals of Compound 2 to the solution).
[00146] Crystalline Compound 2 can precipitate out of the reaction mixture, or be generated by removal of part or all of the solvent through methods such as evaporation, distillation, filtration (e.g., nanofiltration, ultrafiltration), reverse osmosis, absorption and reaction, by adding an anti-solvent such as water, MTBE or heptane, by cooling or by different combinations of these methods. [00147] As described generally above, Compound 2 is optionally isolated. It will be appreciated that Compound 2 may be isolated by any suitable physical means known to one of ordinary skill in the art. In certain embodiments, precipitated solid compound 2 is separated from the supernatant by filtration. In other embodiments, precipitated solid Compound 2 is separated from the supernatant by decanting the supernatant.
[00148] In certain embodiments, precipitated solid Compound 2 is separated from the supernatant by filtration.
[00149] In certain embodiments, isolated Compound 2 is dried in air. In other embodiments isolated Compound 2 is dried under reduced pressure, optionally at elevated temperature.
Uses, Formulation and Administration
Pharmaceutically Acceptable Compositions
[00150] According to another embodiment, the invention provides a composition comprising Compound 2 and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of Compound 2 in compositions of this invention it is such that is effective to measurably inhibit a protein kinase, particularly an EGFR kinase, or a mutant thereof, in a biological sample or in a patient. In certain embodiments, a composition of this invention is formulated for administration to a patient in need of such composition. In some embodiments, a composition of this invention is formulated for oral administration to a patient.
[00151] The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.
[00152] The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a nontoxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, Vitamin E polyethylene glycol succinate (d-alpha tocopheryl polyethylene glycol 1000 succinate), sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, gelatine, polyvinyl pyrrolidone vinyl acetate, hydroxypropyl methyl cellulose, madnesium stearate, steric acid, citric acid, mannitol, and wool fat.
[00153] Compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be an aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
[00154] For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
[00155] Pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous and non-aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is typically combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added. [00156] Alternatively, pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
[00157] Pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
[00158] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
[00159] For topical applications, provided pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of Compound 2 include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[00160] For ophthalmic use, provided pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
[00161] Pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well- known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents. [00162] In some embodiments, pharmaceutically acceptable compositions of this invention are formulated for oral administration.
[00163] The amount of Compound 2 that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. In certain embodiments, provided compositions are formulated so that a dosage of between 0.01 - 100 mg kg body weight/day of Compound 2 can be administered to a patient receiving these compositions.
[00164] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
Uses of Compounds and Pharmaceutically Acceptable Compositions
[00165] Compound 2 and compositions described herein are generally useful for the inhibition of protein kinase activity of one or more enzymes. Examples of kinases that are inhibited by Compound 2 and compositions described herein and against which the methods described herein are useful include EGFR kinase or a mutant thereof. It has been found that Compound 2 is a selective inhibitor of at least one mutation of EGFR, as compared to wild-type ("WT") EGFR. In certain embodiments, an at least one mutation of EGFR is T790M. In certain embodiments, the at least one mutation of EGFR is a deletion mutation. In some embodiments, the at least one mutation of EGFR is an activating mutation. In certain embodiments, Compound 2 selectively inhibits at least one resistant mutation and at least one activating mutation as compared to WT EGFR. In some embodiments, Compound 2 selectively inhibits at least one deletion mutation and/or at least one point mutation, and is sparing as to WT EGFR inhibition.
[00166] A mutation of EGFR can be selected from T790M (resistant or oncogenic), L858R (activating), delE746-A750 (activating), G719S (activating), or a combination thereof.
[00167] As used herein, the term "selectively inhibits," as used in comparison to inhibition of WT EGFR, means that Compound 2 inhibits at least one mutation of EGFR (i.e., at least one deletion mutation, at least one activating mutation, at least one restistant mutation, or a combination of at least one deletion mutation and at least one point mutation) in at least one assay described herein (e.g., biochemical or cellular). In some embodiments, the term "selectively inhibits," as used in comparison to WT EGFR inhibition means that Compound 2 is at least 50 times more potent, at least 45 times, at least 40, at least 35, at least 30, at least 25, or at least 20 times more potent as an inhibitor of at least one mutation of EGFR, as defined and described herein, as compared to WT EGFR.
[00168] As used herein, the term "sparing as to WT EGFR" means that a selective inhibitor of at least one mutation of EGFR, as defined and described above and herein, inhibits EGFR at the upper limit of detection of at least one assay, such as those described in the '061 application (e.g., biochemical or cellular as described in detail in Examples 56-58). In vitro assays include assays that determine inhibition of the phosphorylation activity and/or the subsequent functional consequences, or ATPase activity of activated EGFR (WT or mutant). Alternate in vitro assays quantitate the ability of the inhibitor to bind to EGFR (WT or mutant). Inhibitor binding may be measured by radiolabeling the inhibitor prior to binding, isolating the inhibitor/EGFR (WT or mutant) complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with EGFR (WT or mutant) bound to known radioligands. In some embodiments, the term "sparing as to WT EGFR" means that Compound 2 inhibits WT EGFR with an IC50 of at least 10 μΜ, at least 9 μΜ, at least 8 μΜ, at least 7 μΜ, at least 6 μΜ, at least 5 μΜ, at least 3 μΜ, at least 2 μΜ, or at least 1 μΜ.
[00169] In certain embodiments, Compound 2 selectively inhibits (a) at least one activating mutation; and (b) T790M; and (c) is sparing as to WT. In some embodiments, an at least one activating mutation is a deletion mutation. In some embodiments, an at least one activating mutation is a point mutation. In some embodiments, an activating mutation is delE746-A750. In some embodiments, an activating mutation is L858R. In some embodiments, an activating mutation is G719S.
[00170] In some embodiments, the at least one mutation of EGFR is L858R and/or T790M.
[00171] Without wishing to be bound by any particular theory, it is believed that administration of Compound 2 to a patient having at least one activating mutation may preempt formation of the T790M resistance mutation. Thus, in certain embodiments, the present invention provides a method for inhibiting an activating mutation in a patient comprising administering to the patient Compound 2 or composition thereof, as described herein.
[00172] One of ordinary skill in the art will appreciate that certain patients have an oncogenic form of the T790M mutation, i.e., the T790M mutation is present prior to administrating any EGFR kinase inhibitor to a patient and is therefore oncogenic. Accordingly, in some embodiments, the present invention provides a method for inhibiting oncogenic T790M in a patient comprising administering to the patient a provided compound or composition thereof, as described herein.
[00173] In certain embodiments, the amount of Compound 2 in a composition is effective to measurably inhibit at least one mutant of EGFR selectively as compared to WT EGFR and other protein kinases (e.g., ErbB2, ErbB4, a TEC-kinase, and/or JAK3), in a biological sample or in a patient.
[00174] As used herein, the terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
[00175] Compound 2 is an inhibitor of at least one mutant of EGFR and is therefore useful for treating one or more disorders associated with activity of one of more EGFR mutants (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof). Thus, in certain embodiments, the present invention provides a method for treating a mutant EGFR- mediated disorder comprising the step of administering to a patient in need thereof Compound 2 or pharmaceutically acceptable composition thereof.
[00176] As used herein, the term "mutant EGFR-mediated" disorders or conditions as used herein means any disease or other deleterious condition in which at least one mutant of EGFR is known to play a role. In certain embodiments, an at least one mutant of EGFR is T790M. In some embodiments, the at least one mutant of EGFR is a deletion mutation. In certain embodiments, the at least one mutant of EGFR is an activating mutation. In some embodiments, the at least one mutant of EGFR is L858R and/or T790M. In certain embodiments, a provided compound selectively inhibits (a) at least one activating mutation, (b) T790M, and (c) is sparing as to WT. In some embodiments, an at least one activating mutation is a deletion mutation. In some embodiments, an at least one activating mutation is a point mutation. In some embodiments, an activating mutation is delE746-A750. In some embodiments, an activating mutation is L858R. In some embodiments, an activating mutation is G719S.
[00177] Accordingly, another embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which at least one mutant of EGFR is known to play a role. Specifically, the present invention relates to a method of treating or lessening the severity of a disease or condition selected from a proliferative disorder, wherein said method comprises administering to a patient in need thereof a compound or composition according to the present invention.
[00178] In some embodiments, the present invention provides a method for treating or lessening the severity of one or more disorders selected from a cancer. In some embodiments, the cancer is associated with a solid tumor. In certain embodiments, the cancer is breast cancer, glioblastoma, lung cancer, cancer of the head and neck, colorectal cancer, bladder cancer, or non-small cell lung cancer. In some embodiments, the present invention provides a method for treating or lessening the severity of one or more disorders selected from squamous cell carcinoma, salivary gland carcinoma, ovarian carcinoma, or pancreatic cancer.
[00179] In certain embodiments, the present invention provides a method for treating or lessening the severity of neurofibromatosis type I (NF1), neurofibromatosis type II (NF2) Schwann cell neoplasms (e.g. MPNST's), or Schwannomas.
[00180] Compound 2 and compositions thereof, according to the method of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of a cancer. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. Compound 2 is preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.
[00181] Pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, Compound 2 may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 60 mg/kg, or about 0.1 mg/kg to about 50 mg/kg, or about 0.25 mg/kg to about 45 mg/kg and preferably from about 0.5 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
[00182] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to Compound 2, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, polyethylene glycol (e.g., PEG 200, PEG 400, PEG 1000, PEG 2000), propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, Vitamin E polyethylene glycol succinate (d-alpha tocopheryl polyethylene glycol 1000 succinate), polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. The liquid forms above can also be filled into a soft or hard capsule to form a solid dosage form. Suitable capsules can be formed from, for example, gelatin, strach and cellulose derivatives (e.g., hydroxycellulose, hydropropylmethylcellulose).
[00183] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[00184] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[00185] In order to prolong the effect of Compound 2 of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide- polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[00186] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing Compound 2 of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[00187] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, Compound 2 is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate, Avicel, hydroxypropyl cellulose or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, PVP vinyl acetate, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar— agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium croscarmellose and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, j) solubilising agents such as Vitamin E polyethylene glycol succinate (d-alpha tocopheryl polyethylene glycol 1000 succinate), steric acid, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[00188] Solid compositions of a similar type may also be employed as fillers in soft and hard- filled capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[00189] Compound 2 can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as cosmetic coatings, enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as a polymer, sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[00190] Dosage forms for topical or transdermal administration of Compound 2 include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
[00191] According to one embodiment, the invention relates to a method of inhibiting protein kinase activity in a biological sample comprising the step of contacting said biological sample with Compound 2 or a composition comprising said compound.
[00192] According to another embodiment, the invention relates to a method of inhibiting at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutations, or combination thereof) activity in a biological sample comprising the step of contacting said biological sample with Compound 2, or a composition comprising the compound. In certain embodiments, the invention relates to a method of irreversibly inhibiting at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) activity in a biological sample comprising the step of contacting the biological sample with Compound 2, or a composition comprising the compound.
[00193] In certain embodiments, Compound 2 selectively inhibits in a biological sample (a) at least one activating mutation, (b) T790M, and (c) is sparing as to WT. In some embodiments, an at least one activating mutation is a deletion mutation. In some embodiments, an at least one activating mutation is a point mutation. In some embodiments, an activating mutation is delE746-A750. In some embodiments, an activating mutation is L858R. In some embodiments, an activating mutation is G719S.
[00194] The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
[00195] Inhibition of at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ transplantation, biological specimen storage, and biological assays.
[00196] Another embodiment of the present invention relates to a method of inhibiting at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) activity in a patient comprising the step of administering to the patient Compound 2 or a composition comprising the compound. In certain embodiments, the present invention provides a method for inhibiting (a) at least one activating mutation, and (b) T790M in a patient, and (c) is sparing as to WT, wherein the method comprises administering to the patient Compound 2 or composition thereof. In some embodiments, an at least one activating mutation is a deletion mutation. In some embodiments, an at least one activating mutation is a point mutation. In some embodiments, the present invention provides a method for inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is delE746-A750. In some embodiments, the present invention provides a method for inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is L858R. In some embodiments, the present invention provides a method for inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is G719S.
[00197] According to another embodiment, the invention relates to a method of inhibiting at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) activity in a patient comprising the step of administering to the patient Compound 2 or a composition comprising the compound. According to certain embodiments, the invention relates to a method of irreversibly inhibiting at least one mutant of EGFR activity (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) in a patient comprising the step of administering to said patient Compound 2 or a composition comprising the compound. In certain embodiments, the present invention provides a method for irreversibly inhibiting (a) at least one activating mutation, and (b) T790M in a patient, and (c) is sparing as to WT, wherein said method comprises administering to the patient Compound 2 or composition thereof. In some embodiments, an irreversibly inhibited at least one activating mutation is a deletion mutation. In some embodiments, an irreversibly inhibited at least one activating mutation is a point mutation. In some embodiments, the present invention provides a method for irreversibly inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is delE746-A750. In some embodiments, the present invention provides a method for irreversibly inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is L858R. In some embodiments, the present invention provides a method for irreversibly inhibiting at least one mutant of EGFR in a patient, wherein an activating mutation is G719S.
[00198] In other embodiments, the present invention provides a method for treating a disorder mediated by one or more of at least one mutant of EGFR (e.g., a deletion mutation, an activating mutation, a resistant mutation, or combination thereof) in a patient in need thereof, comprising the step of administering to said patient Compound 2 or pharmaceutically acceptable composition thereof. Such disorders are described in detail herein.
[00199] Depending upon the particular condition, or disease, to be treated, additional therapeutic agents, which are normally administered to treat that condition, may also be present in the compositions of this invention or as part of a treatment regimen including Compound 2. As used herein, additional therapeutic agents that are normally administered to treat a particular disease, or condition, are known as "appropriate for the disease or condition being treated."
[00200] For example, Compound 2 or a pharmaceutically acceptable composition thereof is administered in combination with chemotherapeutic agents to treat proliferative diseases and cancer. Examples of known chemotherapeutic agents include, but are not limited to, Adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, platinum derivatives, taxane (e.g., paclitaxel), vinca alkaloids (e.g., vinblastine), anthracyclines (e.g., doxorubicin), epipodophyllotoxins (e.g., etoposide), cisplatin, an mTOR inhibitor (e.g., a rapamycin), methotrexate, actinomycin D, dolastatin 10, colchicine, emetine, trimetrexate, metoprine, cyclosporine, daunorubicin, teniposide, amphotericin, alkylating agents (e.g., chlorambucil), 5-fluorouracil, campthothecin, cisplatin, metronidazole, and Gleevec™, among others. In other embodiments, Compound 2 is administered in combination with a biologic agent, such as Avastin or VECTIBIX.
[00201] In certain embodiments, Compound 2 or a pharmaceutically acceptable composition thereof is administered in combination with an antiproliferative or chemotherapeutic agent selected from any one or more of abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anastrozole, arsenic trioxide, asparaginase, azacitidine, BCG Live, bevacuzimab, fluorouracil, bexarotene, bleomycin, bortezomib, busulfan, calusterone, capecitabine, camptothecin, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cladribine, clofarabine, cyclophosphamide, cytarabine, dactinomycin, darbepoetin alfa, daunorubicin, denileukin, dexrazoxane, docetaxel, doxorubicin (neutral), doxorubicin hydrochloride, dromostanolone propionate, epirubicin, epoetin alfa, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, filgrastim, floxuridine fludarabine, fulvestrant, gefitinib, gemcitabine, gemtuzumab, goserelin acetate, histrelin acetate, hydroxyurea, ibritumomab, idarubicin, ifosfamide, imatinib mesylate, interferon alfa-2a, interferon alfa-2b, irinotecan, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, megestrol acetate, melphalan, mercaptopurine, 6- MP, mesna, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone, nelarabine, nofetumomab, oprelvekin, oxaliplatin, paclitaxel, palifermin, pamidronate, pegademase, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, porfimer sodium, procarbazine, quinacrine, rasburicase, rituximab, sargramostim, sorafenib, streptozocin, sunitinib maleate, talc, tamoxifen, temozolomide, teniposide, VM-26, testolactone, thioguanine, 6-TG, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, ATRA, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, zoledronate, or zoledronic acid.
[00202] Other examples of agents the inhibitors of this invention may also be combined with include, without limitation: treatments for Alzheimer's Disease such as donepezil hydrochloride (Aricept®) and rivastigmine (Exelon®); treatments for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex® and Rebif®), glatiramer acetate (Copaxone®), and mitoxantrone; treatments for asthma such as albuterol and montelukast (Singulair®); agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, antileukemic agents, and growth factors; and agents for treating immunodeficiency disorders such as gamma globulin.
[00203] In certain embodiments, Compound 2 or a pharmaceutically acceptable composition thereof is administered in combination with a monoclonal antibody or an siRNA therapeutic.
[00204] The additional agents may be administered separately from a Compound 2- containing composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with Compound 2 in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another (e.g., one hour, two hours, six hours, twelve hours, one day, one week, two weeks, one month).
[00205] As used herein, the terms "combination," "combined," and related terms refer to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, Compound 2 may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising Compound 2, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
[00206] The amount of Compound 2 and additional therapeutic agent (in those compositions which comprise an additional therapeutic agent as described above) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Preferably, compositions of this invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of Compound 2 can be administered.
[00207] In those compositions that include an additional therapeutic agent, that additional therapeutic agent and Compound 2 may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions may be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions, a dosage of between 0.01 - 1,000 μg/kg body weight/day of the additional therapeutic agent can be administered.
[00208] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
[00209] Compound 2 or pharmaceutical compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Vascular stents, for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury). However, patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor. Implantable devices coated with Compound 2 are another embodiment of the present invention.
[00210] All features of each of the aspects of the invention apply to all other aspects mutatis mutandis.
[00211] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
EXEMPLIFICATION
[00212] As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein.
Preparation of Compound 1
[00213] The synthesis of Compound 1 is described in detail at Example 3 of the '061 application.
Figure imgf000043_0001
Step 1 :
[00214] In a 25 mL 3 -neck round-bottom flask previously equipped with a magnetic stirrer, Thermo pocket and CaC . guard tube, N-Boc-l,3-diaminobenzene (0.96 g) and n-butanol (9.00 mL) were charged. The reaction mixture was cooled to 0 °C. 2,4-Dichloro-5- trifluoromethylpyrimidine (1.0 g) was added dropwise to the above reaction mixture at 0 °C. Diisopropylethylamine (DIPEA) (0.96 mL) was dropwise added to the above reaction mixture at 0 °C and the reaction mixture was stirred for 1 hr at 0 °C to 5 °C. Finally, the reaction mixture was allowed to warm to room temperature. The reaction mixture was stirred for another 4 hrs at room temperature. Completion of reaction was monitored by TLC using hexane: ethyl acetate (7: 3). The solid precipitated out was filtered off and washed with 1- butanol (2 mL). The solid was dried under reduced pressure at 40 °C for 1 hr. XH-NMR (DMSO-d6, 400 MHz) δ 1.48 (S, 9 H), 7.02 (m, 1 H), 7.26 (m, 2 H), 7.58 (S, 1 H), 8.57 (S, 1 H), 9.48 (S, 1 H), 9.55 (S, 1 H).
Step 2:
[00215] To the above crude (3.1 g) in dichloromethane (DCM) (25 mL) was added trifluoroacetic acid (TFA) (12.4 mL) slowly at 0 °C. The reaction mixture was allowed to warm to room temperature. The reaction mixture was stirred for another 10 min at room temperature. The crude was concentrated under reduced pressure.
Step 3 :
[00216] The concentrated crude was dissolved in DIPEA (2.0 mL) and dichloromethane (25 mL), and then cooled to -30 °C. To the reaction mixture was slowly added acryloyl chloride (0.76 g) at -30 °C. The reaction mass was warmed to room temperature stirred at room temperature for 1.0 hr. The reaction was monitored on TLC using hexane: ethyl acetate (7:3) as mobile phase. The reaction was completed after 1 hr. Step 3 yielded intermediate 1. Step 4:
[00217] To obtain a salt of compound 1, a mixture of intermediate 1 (16 mg) and 2- methoxy-4-(4-acetylpiperazinyl)aniline in dioxane (1.0 mL) with catalytic trifluoroacetic acid was stirred overnight at 50 °C. The crude was concentrated under reduced pressure and purified using HPLC (TFA modifier) to give compound 1 as a TFA salt. 1H-NMR (DMSO- d6, 400 MHz) δ 10.2 (S, 1 H), 8.2 (br, 1 H), 8.30 (S, 1 H), 7.73 (br, 1 H), 7.52 (d, J = 7.8 Hz, 1 H), 7.45 (d, J = 7.8 Hz, 1 H), 7.26 (J = 8.2 Hz, 1 H), 7.14 (be, 1 H), 6.60 (S, 1 H), 6.42 (dd, J = 11.4, 16.9 Hz, 1 H), 6.24 (d, J = 16.9 Hz, 1 H), 5.75 (d, J = 11.4 Hz, 1 H), 3.76 (S, 3 H), 3.04 (br, 4 H), 2.04 (S, 3 H); calculated mass for
Figure imgf000044_0001
555.2, found: 556.2 (M+H+). Step 5:
[00218] To obtain the free base form of Compound 1 from the TFA salt, the salt was added to DCM and cooled to 0°C. Na2C03 solution (9.6% w/w) was added at 0°C. The mixture was warmed to 20°C and stirred for 35 min. The pH of the aqueous layer was > 8. The layers were separated. Extraction of the aqueous layer was performed using DCM. The organic layers were combined and washed with brine. The organic layer was collected and evaporated to yield a solid of Compound 1. General Preparation of Compound 2
[00219] For each counterion and solvent system, ca. 25 or 50 mg of the free base of Compound 1 was slurried in 200-300 μΐ of the allocated solvent. The solvents included acetone, dichloromethane, cyclohexane, ethyl acetate, methanol (methyl ethyl ketone for sulfonic acid-containing counterions), methyl isobutyl ketone, 2-propanol (isopropyl acetate for sulfonic acid-containing counterions), tetrahydrofuran and acetonitrile:water (90: 10). The respective counterion was also dissolved / slurried in 200-300 μΐ of the allocated solvent. The counterions included benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2- sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid and 2,4,6- trihydroxybenzoic acid. One equivalent of each counterion was used and additional experiments with two equivalents of benzenesulfonic acid, hydrochloric acid, sulphuric acid and p-toluenesulfonic acid were performed. The acid solution / slurry was then added to the slurry of Compound 1 in small aliquots in order to minimize the risk of degradation. The pH of the reaction was then checked using universal indicator paper.
[00220] The mixtures of Compound 1/counterion/solvent created using the procedure above were temperature cycled between ca. 0°C and ambient (ca. 22°C) whilst stirring in 1 hour cycles for a period of 1-2 days. Overnight, samples were kept at ca. 2-5°C. The mixtures were visually checked for any obvious signs of degradation (i.e. color changes) and then, if not visually degraded, any solids present were isolated and allowed to dry at ambient conditions prior to analysis. The solids represent isolated Compound 2.
General Procedures
[00221] The solubility of the potential salts was tested using a shake flask method whereby a slurry of each salt was prepared in deionized water and the pH of the reaction was reduced to below pH 2 by adding a small amount of the counterion used for salt formation. The pH was tested using universal indicator paper. After ca. 24 hours of shaking, the slurries were filtered for the solubility determination using HPLC analysis.
[00222] X-Ray Powder Diffraction. X-ray powder diffraction (XRPD) analysis was carried out on a Siemens D5000, scanning the samples between 3 and 30, 35 or 50 °2Θ. For samples <100 mg, ca. 5-10 mg of sample was gently compressed onto a glass slide which fitted into the sample holder. For samples >100 mg, ca. 100 mg of sample was gently compressed into a plastic sample holder, so that the sample surface was smooth and just above the level of the sample holder, Measurements were made using the following experimental conditions :
start position 3.00 °2Θ
end position 30, 35 or 50 °2Θ
step size 0.02 °2Θ
scan step time 1 s
scan type continuous
offset 0 °2Θ
divergence slit type fixed
divergence slit size 2.0000 °
receiving slit size 0.2 mm
temperature 20 °C
anode material copper (Cu)
K- Alpha 1 1.54060 Angstroms
K-Alpha2 1.54443 Angstroms
K-Beta 1.39225 Angstroms
K-A2/K-A1 Ratio 0.50000
Generator settings 40 niA, 40 kV
goniometer radius 217.50
[00223] Polarized Light Microscopy. In polarized light microscopy (PLM), the presence of crystallinity (birefringence) was determined using an Olympus BX50 polarising microscope, equipped with a Motic camera and image capture software (Motic Images Plus 2.0). All images were recorded using the 20x objective, unless otherwise stated.
[00224] Thermogravimetric Analysis. For thermogravimetric analysis (TGA), approximately 5-10 mg of material was accurately weighed into an open aluminium pan and loaded into a simultaneous thermogravimetric/differential thermal analyser (TG/DTA) and held at room temperature. The sample was then heated at a rate of 10°C/min from 25°C to 300°C during which time the change in sample weight was recorded along with any differential thermal events (DTA). Nitrogen was used as the purge gas, at a flow rate of 100 cmVmin. [00225] Differential Scanning Calorimetry. For differential scanning calorimetry (DSC), approximately 5-10 mg of material was weighed into an aluminium DSC pan and sealed non- hermetically with a pierced aluminium lid. The sample pan was then loaded into a Seiko DSC6200 (equipped with a cooler) cooled and held at 25°C. Once a stable heat-flow response was obtained, the sample and reference were heated to ca. 260 °C-280 °C at scan rate of 10°C/min and the resulting heat flow response monitored.
[00226] Nuclear Magnetic Resonance Spectroscopy. XH-NMR experiments were performed on a Bruker AV400 (XH frequency: 400 MHz). lH experiments of each sample were performed in deuterated DMSO and each sample was prepared to ca. lmg/mL concentration.
[00227] Dynamic Vapour Sorption. For dynamic vapour sorption (DVS), approximately 10-20 mg of sample was placed into a wire mesh vapour sorption balance pan and loaded into a DVS-1 dynamic vapour sorption balance by Surface Measurement Systems. The sample was subjected to a ramping profile from 20 - 90 % relative humidity (RH) at 10 % increments, maintaining the sample at each step until a stable weight had been achieved (99.5 % step completion). After completion of the sorption cycle, the sample was dried using the same procedure, but all the way down to 0 % RH and finally taken back to the starting point of 20 % RH. The weight change during the sorption/desorption cycles were plotted, allowing for the hygroscopic nature of the sample to be determined.
[00228] Infrared Spectroscopy. Infrared spectroscopy (IR) was carried out on a Bruker
ALPHA P spectrometer. Sufficient material was placed onto the centre of the plate of the spectrometer and the spectra were obtained using the following parameters:
resolution 4 cm"1
background scan time 16 scans
sample scan time 16 scans
data collection 4000 to 400 cm"1
result spectrum transmittance
software OPUS version 6
[00229] For Karl Fischer (KF) Coulometric titration, 10-15 mg of solid material was accurately weighed into a vial. The solid was then manually introduced into the titration cell of a Mettler Toledo C30 Compact Titrator. The vial was back-weighed after the addition of the solid and the weight of the added solid entered on the instrument. Titration was initiated once the sample had fully dissolved in the cell. The water content was calculated automatically by the instrument as a percentage and the data printed.
[00230] Reverse-phase gradient high performance liquid chromatography (HPLC) was performed on an Agilent 1100 instrument fitted with a C18, 3.0 x 100 mm x 3.5 μιη column. The detection wavelength was 240 nm.
[00231] A Sotax AT7 dissolution bath (USP 2, EP 2 apparatus) was used for the dissolution study in which paddles were used to stir the media. All tests were carried out at 37°C and a paddle speed of 100 rpm.
Example 1
Primary Salt Screen
[00232] The results of the primary salt screen, based on the general preparation of Compound 2, are shown in Table 1. Table 1 indicates the counterion, the solvent and the solid form(s) obtained.
Table 1. Results of Primary Salt Screen
Figure imgf000049_0001
51 = salt, polymorphic form 1
52 = salt, polymorphic form 2
53 = salt, polymorphic form 3 S4 = salt, polymorphic form 4
SP = salt, partially crystalline
FA = free acid
FC = free Compound 1
XR = different XRPD pattern, but only a few peaks in the diffractogram (possibly indicating degradation)
AM = amorphous
GM = solid that rapidly converts to gum upon isolation
Example 2
Primary Salt Screen
[00233] For the potential salts obtained during the primary salt screen in Example 1, the samples were set-up for 1 week stability studies at 40°C/75% RH (open vials) and 80°C (open vials). TGA was carried out after the stability studies for samples containing sufficient material. The solubility of the samples was also tested in an aqueous medium (pH < 2). The results for the stability and solubility studies are indicated in Table 2.
Table 2. Stability and solubility results from potential salts obtained in the primary salt screen
Figure imgf000050_0001
Figure imgf000051_0001
14.4% associated with
Figure imgf000052_0001
egra aton.
Figure imgf000053_0001
Figure imgf000054_0001
Camphor- 10-sulfonic Form I 0.89 Amorphous Amorphous
Figure imgf000055_0001
[00234] From these results the bis-besylate salt was selected to be scaled up, using acetone as the solvent. In addition, the hydrobromide salt was selected to be scaled up, using acetonitrile:water (90: 10) as the solvent. The mono-maleate and bis-hydrochloride salts were also selected for scale-up experiments to assess whether these are solvated/hydrated.
Example 3
Secondary Screen of Bis-Besylate Salt
[00235] Approximately 5 mL of acetone was added to approximately 800 mg of Compound 1 to form a slurry. In a separate vial, approximately 3 mL acetone was added to 2 equivalents of benzenesulfonic acid to dissolve the acid. The acid solution was then added in small aliquots to the free base slurry while stirring. After the complete addition of the acid, a gum/oil-like material initially formed, however, this converted to a solid after ca. 30 minutes of stirring. The reaction was stirred for ca. 1.5 days before being isolated and dried. The material was initially dried at ambient under vacuum (ca. 22°C) for 3 days, however, approximately 6.7% acetone was still present at this stage. A portion was then dried for a further 2 days at 40°C under vacuum after which ca. 2.7% acetone remained. The material was then dried for a further 2 days at 60°C under vacuum. The yield was 1.1 g of material (86%).
[00236] To examine whether the citric acid in the buffers was having an effect on the solubility values obtained for pH 3, 4.5 and 6.6, the thermodynamic solubility experiments were repeated at these pH values using KHP/HC1 for pH 3, KHP/ NaOH for pH 4.5 and phosphate/NaOH for pH 6.6. The remaining solids were also analysed by XRPD analysis to establish if any changes in the solid form occurred.
[00237] XRPD analysis (Figure 1) showed the material to be crystalline. The diffractogram is consistent with the small scale bis-besylate Form I diffractograms obtained during the primary salt screen.
[00238] TGA/DTA was carried after 3 days of drying at ambient under vacuum as well as after further drying for 2 days at 40 °C under vacuum and 2 days at 60 °C under vacuum. After the ambient drying process, the TGA showed a 6.7% weight loss between ca. 50-150 °C (Figure 2) (for an acetone solvate, 1 mole equivalent of acetone would be ca. 6.3 wt%). After further drying, the TGA showed a 0.47% weight loss from the outset, likely due to unbound moisture or solvent. A further small 0.16% weight loss corresponded with the endotherm at onset ca. 142 °C (Figure 3).
[00239] DSC analysis (Figure 4) indicated a broad endotherm from the outset likely due to unbound solvent. A second endotherm was present at onset ca. 139.4 °C (peak 146.1°C).
[00240] Polarised Light Microscopy (not shown) showed birefringent particles with no clearly defined morphology present.
[00241] IR spectroscopy (Figure 5) showed a number of differences and shifts in comparison with the freebase and benzenesulfonic acid.
[00242] lH NMR spectroscopy (Figure 6) indicated that a number of the Compound 1 and benzenesulfonic acid peaks appear to be overlapping, however, the stoichiometry is approximately 2: 1 benzenesulfonic acid: Compound 1. The acetone present does not appear to be a stoichiometric amount.
[00243] DVS analysis (Figure 7) showed a water uptake of ca. 2.2% between 20 and 70% RH. The difference between the mass of the first sorption cycle and the desorption and second sorption cycle at 20% RH is likely due to the loss of excess acetone in the first cycle. The material also appears to hydrate during DVS analysis as indicated by the change in polymorphic form seen by post DVS XRPD analysis (not shown). The XRPD diffractogram also showed some loss in crystallinity.
[00244] Karl Fischer Coulometry indicated a ca. 0.77% water content (Note: due to the manual introduction of the solid material into the titration cell, measured values below 1% are generally slightly higher than the actual water content).
[00245] The HPLC purity evaluation (not shown) indicated a purity of ca. 97.6% for the bis- besylate salt with the main peak eluting at a retention time of ca. 13.05 minutes.
[00246] Slurries of the bis-besylate salt were created in acetone: water mixtures (3%, 5% and 10%) and stirred at ambient for ca. 4 days. The resulting solids were then analyzed by XRPD to determine if any changes had occurred on slurrying. The hydration study results from XRPD analysis (Figure 8) are summarised in Table 3. Table 3. Hydration Study Results
Figure imgf000057_0001
[00247] The bis-besylate salt was slurried in deionized water at ambient temperature (ca. 22°C). A sample of solid was taken at 24 & 48 hours and analysed by XRPD. The pH of the supernatant was also monitored. The Salt Disproportionation study results from XRPD analysis (Figure 9) are summarised in Table 4.
Table 4. Disproportionation Study Results
Figure imgf000057_0002
[00248] The bis-besylate salt was exposed to environments of 40°C/75%RH (relative humidity, open and closed vial) and 80°C (open vial) for 1 week to determine stability. Resulting solids were analysed by XRPD and HPLC to establish if any changes had occurred. The 1 Week stability study results from XRPD (Figure 10) and HPLC analysis (not shown) at 40°C/ 75% RH using an open and closed vial and 80°C using an open vial are indicated Table 5. Table 5. 1 Week Stability Study Results
Figure imgf000058_0001
[00249] Slurries of the bis-besylate salt were created in media of various pH (pH 1 ; pH 3; pH 4.5 and pH 6.6) and shaken for ca. 24 hours. After 24 hours, the slurries were filtered and the solution analysed by HPLC in order to determine the solubility at the various pH levels. The remaining solids were also analysed by XRPD analysis to establish if any changes in the solid form occurred. For the buffer solutions, KC1/HC1 was used for pH 1 and citrate/phosphate combinations for pH 3, 4.5 and 6.6. Thermodynamic solubility studies indicated the results shown in Table 6.
Table 6. Thermodynamic Solubility Results
Figure imgf000058_0002
Compound 1. Does not correspond with the
solids used in the buffers.
pH 4.5 KHP/ NaOH O. lO mg/ml Change in diffractogram - does not correspond with any known forms of the bis-besylate or Compound 1. Does not correspond with the solids used in the buffers.
pH 6.6 Phosphate/NaOH 0.17 mg/ml Change in diffractogram - does not correspond with any known forms of the bis-besylate or Compound 1. Does not correspond with the solids used in the buffers.
[00250] When initially setting up the slurries for thermodynamic solubility determinations, gums were obtained in all of the pH media used, however, upon shaking, the gums converted to solids after ca. 2 hours. The XRPD analysis of the excess solid from the slurries after the solubility experiments, indicate that for pH 1, the bis-besylate salt hydrates while slurrying. Hence, the solubility value obtained is likely an indication of the solubility of the hydrated material. The diffractograms for the remaining samples appear different from the input material as well as all identified forms of the bis-besylate and Compound 1 free base. The diffractograms also appear different from the diffractograms of the solids used to make up the buffers. The solubility values obtained using these pH buffers are likely not representative of the bis-besylate salt which was initially placed into the solutions.
[00251] Approximately 100 -120 mg of each form was compressed into discs by placing the material into a die (diameter: 13 mm) and compressing the die under 5 tons of pressure in a hydraulic press for ca. 2 minutes. A Sotax AT7 (conformed to EP2 and USP2) dissolution instrument was used containing paddles to stir the media at 100 rpm. Dissolution media of pH 3 (1% SDS) and pH 4.5 (1% SDS) were prepared using citrate / phosphate buffer. All materials were tested in 750 ml of the buffer medium. Discs were added at time = 0 seconds and allowed to sink to the bottom of the dissolution vessel before stirring began, ca. 1 ml aliquots of media were extracted from the dissolution vessels at times 1, 5, 10, 15, 30, 60, 120, 240 minutes and 24 hours, and tested for dissolved salt concentration by HPLC-UV. The dissolution tests were carried out in duplicate. For both dissolution media, the peak areas for the initial time points (up to 15 minutes), fell below the limit of quantification, however, when plotting Dissolution rate vs. time, the steepest part of the curve occurs during these early time points. [00252] For pH 4.5, when plotting the curve of Dissolution rate vs. Time (Figure 12), the intrinsic dissolution values obtained from the early time points on the curve (steepest part of the curve) were approximately 0.61 mg/cm2/min for both tablets 1 and 2. At the later time points, intrinsic dissolution values of 0.09 mg/cm2/min and 0.08 mg/cm2/min were obtained for tablets 1 and 2, respectively.
[00253] For pH 3.0, when plotting the curve of Dissolution rate vs. Time (Figure 13), the intrinsic dissolution values obtained from the early time points on the curve (steepest part of the curve) were approximately 0.36 mg/cm2/min for tablet 1 and 0.38 mg/cm2/min for tablet 2. At the later time points, intrinsic dissolution values of 0.08 mg/cm2/min and 0.07 mg/cm2/min were obtained for tablets 1 and 2, respectively.
Example 4
Secondary Screen of Bis-Besylate Hydrate Salt
[00254] Approximately 3 mL of acetone was added to ca. 500 mg of Compound 1 to form a slurry. In a separate vial, ca. 1 mL of acetone was added to 2 equivalents of benzenesulfonic acid in order to dissolve the acid. The acid solution was then added in small aliquots to the freebase slurry while stirring. The reaction was stirred for ca. 1 day while temperature cycling between 0 and ambient temperature (ca. 22 °C). After 1 day, deionized water was added to the reaction mixture and the slurry was allowed to stir for ca. 3 hours before being isolated and dried at ambient under vacuum.
[00255] XRPD analysis (Figure 14) showed the material to be crystalline. The diffractogram is consistent with the bis-besylate hydrate obtained from the hydration studies of the bis-besylate salt.
[00256] TGA/DTA indicated a weight loss of ca. 2.1% between ca. 70 - 100 °C (Figure 15). This corresponds approximately with the 2.03 wt% water required for a monohydrate. A ca. 2.2% weight loss was present from the outset to ca. 70 °C, likely due to unbound water. Although the total ca. 4.2% weight loss corresponds approximately with a dihydrate, the first weight loss occurs from the outset followed by a second clear weight loss corresponding with mono amounts of water. As the first weight loss occurs from ca. 25 °C, this would likely be due to unbound water.
[00257] DSC analysis indicated a broad endotherm between ca. 40-115 °C. Two further endotherms were then present at onset 119.7 °C (peak 134.3 °C) and onset 153.8 °C (peak 165.1 °C) (Figure 16). [00258] PLM analysis showed some birefringence, however the particle size is very small and no clear morphology could be seen (not shown). Hot-stage microscopy was carried out on a sample of the bis-besylate hydrate. No visual changes could be observed prior to the material melting and degrading (turned brown) at ca. 160 °C.
[00259] IR analysis (Figure 17) showed differences from both the free base and benzenesulfonic acid spectra as well as some differences when comparing the spectra of the input bis-besylate salt with that of the hydrated material.
[00260] XH NMR spectroscopy (Figure 18) indicated that a number of the Compound 1 and benzenesulfonic acid peaks appear to be overlapping, however, the stoichiometry appears to be approximately 2: 1 benzenesulfonic acid: Compound 1. A small non-stoichiometric amount of acetone was present in the spectrum.
[00261] DVS analysis (Figure 19) showed a water uptake of ca. 1.3% between 20 and 70% RH. No hysteresis was seen between the sorption and desorption cycles. The XRPD diffractogram of the material post DVS analysis was consistent with the diffractogram of the input bis-besylate hydrate material (not shown).
[00262] The 1 week stability data at 40 °C/75% RH (open container) indicated that by XRPD, the material remained consistent with the input material with no changes in polymorphic form (Figure 20).
[00263] HPLC purity determinations indicated an initial purity of ca. 98.4% and a purity of ca. 98.3% after 1 week storage at 40 °C/75% RH.
[00264] Thermodynamic solubility studies of the bis-besylate hydrate indicated the results shown in Table 7.
Table 7. Thermodynamic Solubility Results
Figure imgf000061_0001
pH 4.5 Citrate/Phosphate Below Very little solid present for XRPD, however,
LOQ a change in the diffractogram is seen where it does not correspond with any identified forms of the bis-besylate salt or Compound 1. It also does not correspond with the solids used in the buffers.
H 6.6 Citrate/Phosphate Not Very little solid present for XRPD, however, detected by a change in the diffractogram is seen where HPLC it does not correspond with any identified forms of the bis-besylate salt or Compound 1. It also does not correspond with the solids used in the buffers.
[00265] Intrinsic dissolution tests were carried out using pH 4.5 (1% SDS) and pH 3.0 (1% SDS). For both dissolution media, the peak areas for the initial time points (up to 15 minutes), fell below the limit of quantification, however when plotting Dissolution rate vs. time, the steepest part of the curve occurs during these early time points. For pH 4.5, when plotting the curve of Dissolution rate vs. Time (Figure 22), the intrinsic dissolution values obtained from the early time points on the curve (steepest part of the curve) were approximately 0.43 mg/cm2/min for tablet 1 and 0.44 mg/cm2/min for tablet 2. At the later time points (toward the end of the dissolution study), intrinsic dissolution values of 0.012 mg/cm2/min and 0.006 mg/cm2/min were obtained for tablets 1 and 2, respectively.
[00266] For pH 3.0, when plotting the curve of Dissolution rate vs. Time (Figure 23), the intrinsic dissolution values obtained from the early time points on the curve (steepest part of the curve) were approximately 0.38 mg/cm2/min for tablet 1 and 0.39 mg/cm2/min for tablet 2. At the later time points, intrinsic dissolution values of 0.01 mg/cm2/min for both tablets 1 and 2 were obtained.
[00267] A larger batch of the bis-besylate hydrate salt was prepared using the following procedure. Approximately 20 mL of acetone was added to ca. 14 g of Compound 1 in a round bottomed flask to form a slurry. In a separate flask, ca. 10 mL of acetone was added to 2 equivalents of benzenesulfonic acid in order to dissolve the acid. The acid solution was then added in small aliquots to the freebase slurry whilst stirring at ca. 0 °C. The resulting slurry was then allowed to stir at ambient for ca. 2 hours. It was then placed at ca. 5 °C for 2 days before stirring for a further 3 hours at ambient temperature. The acetone was then removed and ca. 20 mL of water was added to the material. The slurry was temperature cycled (0 °C - ambient temperature (ca. 22 °C)) in 2 hour cycles for ca. 1 day. The solid was then isolated by filtration and allowed to dry at ambient conditions under vacuum before analysis. The drying was continued for ca. 10 days.
[00268] The properties of the material from this larger batch were similar to those described above. In addition to those properties, it was noted that when the bis-besylate hydrate was left on the bench for 2 hours and TGA was again carried out, the sample seemed to pick up the water to have a total ca. 4.5% weight loss in the final TGA. It does not appear to be possible to remove the remaining 2% of unbound water by drying as this is regained when exposed to ambient conditions. Also, KF titration determined the water content of the material to be ca. 3.97%. While the ca. 4 wt% water would correspond theoretically with a dihydrate, the weight loss in the TGA appears to start from the outset followed by a more clear second weight loss which corresponds approximately with 1 equivalent of water. The material likely shows some hygroscopicity resulting in the initial TGA weight loss.
Example 5
Secondary Screen of Mono-maleate Salt
[00269] Approximately 3 mL of dichloromethane was added to ca. 200 mg of Compound 1 to form a slurry. In a separate vial, ca. 1 mL of dichloromethane was added to 1 equivalent of maleic acid in order to dissolve the acid. The acid solution was then added in small aliquots to the freebase slurry while stirring. The slurry obtained was yellow in color. The reaction was stirred for ca. 1.5 days between 0 °C and ambient temperature (ca. 22 °C) and remained at ca. 4 °C for a further 2 days before being isolated and dried at ambient. The material was dried at ambient temperature under vacuum (ca. 22 °C) for ca. 2 days.
[00270] XRPD analysis (Figure 24) showed the material to be crystalline. The diffractogram is consistent with the small scale mono-maleate Form I diffractogram obtained during the primary salt screen.
[00271] TGA/DTA was carried after 2 days of drying at ambient under vacuum. The TGA showed a 0.4% weight loss from the outset, likely due to unbound moisture or solvent. A large 10.9% weight loss is associated with endothermic/exothermic events in the DTA between ca. 145-185 °C, followed by further weight losses due to likely degradation (Figure
25) .
[00272] DSC analysis indicated an endotherm at onset 160.4 °C (peak 163.8 °C), directly followed by an exotherm, likely due to recrystallisation and then final degradation (Figure
26) . [00273] ΧΗ NMR spectroscopy (Figure 27) indicated approximately 1 : 1 stoichiometry of Compound 1 : maleic acid. Dichloromethane was not present in the spectrum. Therefore, the mono-maleate salt does not appear to be solvated.
Example 6
Secondary Screening of Bis-hydrochloride Salt (Form I)
[00274] Approximately 1.5 mL of acetonitrileiH^O (90: 10) was added to ca. 200 mg of Compound 1 to form a slurry. In a separate vial, ca. 1 mL of acetonitrileiFLO (90: 10) was added to 2 equivalents of hydrochloric acid. The acid solution was then added in small aliquots to the freebase slurry while stirring. The reaction was stirred for ca. 1.5 days between 0°C and ambient temperature (ca. 22 °C) and remained at ca. 4 °C for a further 2 days before being isolated and dried at ambient temperature. The material was dried at ambient temperature under vacuum (ca. 22 °C) for ca. 2 days.
[00275] XRPD analysis (Figure 28) showed the material to be crystalline. The diffractogram is consistent with the small scale bis-hydrochloride Form I diffractogram obtained during the primary salt screen.
[00276] TGA/DTA was carried after 2 days of drying at ambient under vacuum. The TGA showed a 2.7% gradual weight loss from the outset to ca. 180 °C. A further 4.3% weight loss is seen between ca. 180-210 °C, which corresponds with an endotherm in the DTA trace (Figure 29).
[00277] DSC analysis indicated a broad endotherm between ca. 30-160 °C. A further endotherm is then present at onset 206.4°C (peak 226.5°C), directly followed by a smaller endotherm at peak 238.2°C (Figure 30).
[00278] Karl Fischer analysis showed ca. 3.3% water content (ca. 2.8% water required for a monohydrate).
[00279] XH NMR spectroscopy (Figure 31) indicated that the spectrum had shifted in comparison with Compound 1, indicating likely salt formation. No signs of degradation could be seen. The free base peak appears to be partially overlapping with the region for acetonitrile, however, no significant amounts of acetonitrile appear to be present. Example 7
Secondary Screening of Hydrobromide Salt (1 equiv.)
[00280] Approximately ca. 5 mL of acetonitrile: water (10%) was added to ca. 1 g of Compound 1 free base to form a slurry. In a separate vial, ca. 3 mL of acetonitrile : water (10%) was added to 1 equivalent of hydrobromic acid (48%). The acid solution was then added dropwise over a 1 hour period to the free base slurry whilst stirring and maintaining a temperature between 0-5 °C. After the complete addition of the acid, a further 3 mL of acetonitrile : water (10%) was added. The reaction was stirred for ca. 1 day before being isolated and dried under vacuum at ambient (ca. 22 °C). A yield of ca. 79% was obtained.
[00281] XRPD analysis (Figure 32) was carried out on the wet sample and after drying. The analysis indicated that the material undergoes a form change upon drying. The diffractogram of the scaled up material, both before and after drying, was different from the diffractogram of the primary screen hydrobromide sample.
[00282] TGA/DTA showed a 1.01% weight loss from the outset, likely due to unbound moisture or solvent. No further weight losses were seen prior to degradation at onset ca. 230°C (Figure 33).
[00283] DSC analysis (Figure 34) indicated a broad endotherm from the outset likely due to unbound solvent/water. A second endotherm was then seen at onset ca. 230 °C (peak 238 °C), followed by likely degradation.
[00284] Polarised Light Microscopy showed very small particles with no clearly defined morphology present (not shown).
[00285] IPv spectroscopy (Figure 35) showed a number of differences and shifts in comparison with the freebase.
[00286] XH NMPv spectroscopy (Figure 36) indicated a number of peak shifts in comparison with the freebase.
[00287] DVS analysis (Figure 37) showed a water uptake of 0.97% between 20 and 70%
RH. The water uptake between 0-90% RH is reversible showing very little hysteresis. Post
DVS XRPD analysis indicated that the polymorphic form appears to remain consistent after exposure to varying RH % conditions (not shown).
[00288] Karl Fischer Coulometry indicated a ca. 1.65% water content.
[00289] The HPLC purity evaluation indicated a purity of ca. 97.5% for the hydrobromide salt with the main peak eluting at a retention time of ca. 13 minutes. [00290] Slurries of the hydrobromide salt were created in acetone: water mixtures (3%, 5% and 10%) and stirred at ambient for ca. 3 days. The resulting solids were then analysed by XRPD to determine if any changes had occurred on slurrying. The hydration study results from XRPD analysis (Figure 38) are summarised in Table 8.
Table 8. Hydration Study Results
Figure imgf000066_0001
[00291] The hydrobromide salt was slurried in deionised water at ambient temperature (ca. 22°C). A sample of solid was taken at 1, 24 & 48 hours and analysed by XRPD. The pH of the supernatant was also monitored. The Salt Disproportionation study results from XRPD analysis (Figure 39) are summarised in Table 9.
Table 9. Dis ro ortionation Stud Results
Figure imgf000066_0002
[00292] The hydrobromide salt was exposed to environments of 40 °C/75%RH (open and closed vial) and 80 °C (open vial) for 1 week to determine stability. Resulting solids were analysed by XRPD and HPLC to establish if any changes had occurred. The 1 Week stability study results from XRPD (Figure 40) and HPLC analysis at 40 °C/ 75% RH using an open and closed vial and 80 °C using an open vial are indicated Table 10.
Table 10. 1 Week Stability Study Results
Figure imgf000067_0001
[00293] Slurries of the hydrobromide salt were created in media of various pH (pH 1 ; pH 3; pH 4.5 and pH 6.2) and shaken for ca. 24 hours. After 24 hours, the slurries were filtered and the solution analyzed by HPLC in order to determine the solubility at the various pH levels. The remaining solids were also analysed by XRPD analysis to establish if any changes in the solid form occurred. For the buffer solutions, KCl/HCl was used for pH 1 and citric acid / sodium citrate combinations for pH 3, 4.5 and 6.2. The thermodynamic solubility studies indicated the results shown in Table 1 1.
Table 11. Thermodynamic Solubility Results
Figure imgf000067_0002
correspond with the diffractograms obtained for the
thermodynamic solubility experiments carried out on the bis-besylate salt.
The diffractogram appears different from the input hydrobromide material, all known forms of the
Citric
Compound 1 free base and the citric acid used in buffer H acid/
0.03 preparation. The diffractogram also appears to
6.2 Sodium
correspond with the diffractograms obtained for the
Citrate
thermodynamic solubility experiments carried out on the bis-besylate salt.
[00294] The diffractograms for the pH 3.0, 4.5 and 6.2 experiments appeared different from the input material as well as all identified forms of the hydrobromide salt and Compound 1 free base. The diffractograms also appeared different from the diffractograms of the solids used to make up the buffers. The solubility values obtained using these pH buffers are therefore likely not representative of the hydrobromide salt which was initially placed into the solutions.
[00295] Approximately 100 -120 mg of material was compressed into discs by placing the material into a die (diameter: 13 mm) and compressing the die under 5 tons of pressure in a hydraulic press for ca. 2 minutes. A Sotax AT7 (conformed to EP2 and USP2) dissolution instrument was used containing paddles to stir the media at 100 rpm. Dissolution media of pH 3 (1% SDS) and pH 4.5 (1% SDS) were prepared using citrate / phosphate buffer. All materials were tested in 750 ml of the buffer medium. Discs were added at time = 0 seconds and allowed to sink to the bottom of the dissolution vessel before stirring began, ca. 1 ml aliquots of media were extracted from the dissolution vessels at times 1, 5, 10, 15, 30, 60, 120, 240 minutes and 24 hours, and tested for API concentration by HPLC-UV. The dissolution tests were carried out in duplicate. For both dissolution media, the peak areas for the initial time points (up to 15 minutes), fell below the limit of quantification, however, when plotting Dissolution rate vs. time, the steepest part of the curve occurs during these early time points.
[00296] For pH 4.5, when plotting the curve of Dissolution rate vs. Time (Figure 42), the intrinsic dissolution values obtained from the early time points on the curve (steepest part of the curve) were approximately 0.27 mg/cm2/min for tablet 1 and 0.28 mg/cm2/min for tablet 2. [00297] For pH 3.0, when plotting the curve of Dissolution rate vs. Time (Figure 43), the intrinsic dissolution values obtained from the early time points on the curve (steepest part of the curve) were approximately 0.35 mg/cm2/min for both tablets 1 and 2.
Example 8
Secondary Screening of Hydrobromide Salt (2 equiv.)
[00298] Approximately 1ml of methanol was added to ca. 200 mg of Compound 1 to form a slurry. In a separate vial, ca. 1 mL of methanol was added to 2 equivalents of hydrobromic acid (48%). The acid solution was then added dropwise over a 1 hour period to the free base slurry whilst stirring and maintaining a temperature between 0-5 °C. After the complete addition of the acid, a further 1 mL of methanol was added. The reaction was stirred for ca. 3 hours before being isolated and dried. A yield of approximately 68% was obtained.
[00299] XRPD analysis (Figure 44) was carried out after filtration and the diffractogram obtained was consistent with the Form I material obtained using both 1 and 2 equivalents of HBr in the primary salt screen.
[00300] TGA/DTA (Figure 45) showed a 1.2% weight loss from the outset to ca. 100°C, likely due to unbound moisture or solvent. No further weight losses were seen prior to degradation at onset ca. 230°C. The TGA/DTA is similar to the trace obtained for the 1 equivalent scaled-up form of Example 6.
[00301] IR spectroscopy (Figure 46) showed a number of differences and shifts in comparison with the free base and the hydrobromide (1 equiv.) scaled-up salt.
Example 9
Secondary Screening of Hydrobromide Salt (Unknown Form)
[00302] The thermodynamic solubility experiments carried out on the hydrobromide salt resulted in the formation of an unknown solid form. In attempts to characterize this form, as well as establish the rate of conversion to this form while slurrying the material, the following experiments were carried out. Initially, approximately 100 mg of the hydrobromide (1 equiv.) material was slurried in a pH 6.2 aqueous solution at ambient and XRPD analysis was carried out at time points 5 min., 1 hr, 2 hrs, 4 hrs and 8 hrs. Further analysis was then also carried out on the converted material. [00303] The XRPD analysis (Figure 47) carried out on the hydrobromide (1 equiv.) salt sample after slurrying the solid in an aqueous pH 6.2 medium for 5 min, 1 hr, 2 hrs, 4 hrs and 8 hrs indicated that conversion to the unknown solid form occurs between 2-4 hours.
[00304] PLM analysis carried out on a slurry of the material indicated a very small particle size. Some birefringence was observed (not shown). Upon drying the material became glasslike.
[00305] 1H NMR analysis was carried out on this material which showed a spectrum which was different in terms of peak positions from both the free base spectrum and the hydrobromide spectrum (Figure 48).
[00306] DSC analysis was also attempted on the glass-like material, however, a large broad endotherm is seen from the outset to ca. 1 10 °C, followed by a pattern characteristic of amorphous material (Figure 49).
[00307] The slurry experiment of Compound 1 free base and the bis-besylate hydrate (carried out in attempts to produce more of this form for analysis) were unsuccessful in producing this unknown solid form. For the free base slurry, the material remained as the free base Form I and for the bis-besylate hydrate slurry, the material lost some crystallinity, but remained as the bis-besylate hydrate (Figure 50).
[00308] The further scale-up of the hydrobromide (1 equiv.) salt and subsequent slurrying in a pH 6.2 aqueous medium resulted in this unknown solid form being obtained (Figure 51), however, all attempts at filtering the material were unsuccessful with the solid going through a sintered filter and multiple sheets of filter paper, due to the small particle size. Again, attempts at evaporating off the solvent resulted in a glass-like material being obtained. This appears to indicate that the unknown form is unstable when isolated.
Example 10
Tertiary Screening of Hydrobromide Salt (1 equiv.)
[00309] Approximately 85 mL of acetonitrile:water (90: 10) was added to ca. 20 g of Compound 1 in a round bottomed flask to form a slurry. In a separate flask, 1 equivalent of hydrogen bromide (ca. 4.073 mL) was added to ca. 70 mL of acetonitrile:water (90: 10). The acid solution was then added in small aliquots to the free base slurry while stirring at ca. 4 °C. The resulting slurry was then allowed to stir at ambient temperature for ca. 2 hours. It was then placed at ca. 5 °C for 1 day before stirring for a further 4 hours at ambient temperature. The reaction was then filtered and the solid dried under vacuum at ambient temperature (ca. 22°C). The drying was continued for ca. 2 days. Due to the partially crystalline nature of the material after drying, the material was then slurried in ca. 50 mL of an acetone:water (90: 10) mixture. The reaction was temperature cycled between ca. 4-22 °C in 1 hour cycles while stirring for ca. 2 days. The reaction was then filtered and dried at ambient for ca. 4 days before being analyzed. The yield after the further slurrying was 16.4 g (63%).
[00310] XRPD analysis (Figure 52) carried out on the initial scale-up material while wet, showed the sample to be highly crystalline. After drying, the solid converted to a different polymorphic form and also lost some crystallinity. XRPD analysis (Figure 53) on the material after further slurrying in acetone:water(10%) and subsequent drying indicated a crystalline material. The diffractogram corresponded with the smaller scale hydrobromide sample obtained after drying during Example 1.
[00311] IR Spectroscopy (Figure 54) showed differences when compared with the free base spectrum. The spectrum also appeared consistent with the spectrum obtained for the hydrobromide salt in Example 1.
[00312] PLM (not shown) showed small particles with no defined morphology and little birefringence.
[00313] XH NMR (Fi gure 55) indicated a number of peak shifts in comparison with the free base. A small non-stoichiometric amount of acetone was present in the spectrum.
[00314] TGA/DTA (Figure 56) showed a weight loss from the outset of ca. 0.4%, likely due to unbound moisture or solvent. No further significant weight losses were seen prior to degradation at onset ca. 230 °C.
[00315] DSC analysis (Figure 57) indicated a shallow, broad endotherm from the outset likely due to unbound solvent/water. A second endotherm was then present at onset ca. 240 °C (peak 244 °C), followed by likely degradation.
[00316] KF analysis determined the water content of the material to be ca. 0.76%.
[00317] HPLC purity determination indicated a purity of ca. 98.1%.
[00318] The content of carbon, hydrogen and nitrogen in the material was determined by placing the samples into a tin capsule, placed inside an autosampler drum of an elemental analysis system. The sample environment was purged by a continuous flow of helium and the samples dropped at pre-set intervals into a vertical quartz tube maintained at 900 °C. The mixture of combustion gases was separated and detected by a thermal conductivity detector giving a signal proportional to the concentration of the individual components of the mixture. The content of bromine in the material was determined by oxygen flask combustion of the sample. Once the combustion and absorption into solution had occurred, the samples were titrated using a calibrated Mercuric Nitrate solution. Elemental analysis (CHN and bromide) indicated the following percentages:
Figure imgf000072_0001
[00319] Ion chromatography was carried out using a Metrohm 761 Compact Ion Chromatograph for the analysis of ions in aqueous solutions. Calibration standards were prepared from certified 1000 ppm stock solutions. Ion chromatography showed the presence of 12.38% bromide.
[00320] In order to examine the effect of removing the water which is retained by the material, (despite extended periods of drying) a small sample was heated to 100 °C in a TGA pan and XRPD analysis was then carried out (Figure 58). The analysis indicates some loss in crystallinity, however, the polymorphic form remains consistent after removing the ca. 0.5% water by heating. Nevertheless, the material appears to be slightly hygroscopic.
Example 11
Large-Scale Preparation of Hydrobromide Salt (1 equiv.)
[00321] Approximately 1 L of acetone:water (90: 10) was added to ca. 319 g of Compound 1 in a 5 L reaction vessel with the reactor temperature set to 4 °C. A suspension was obtained. The suspension was stirred at 450 rpm. In a separate flask, 1 equivalent of hydrogen bromide (48%)(ca. 65 mL) was added to ca. 750 mL of acetone:water (90: 10). The acid solution was then added to the 5 L reactor over a 1 hour period, while maintaining a temperature of ca. 4 °C. After 30 minutes, a further 700 mL of acetone:water (90: 10) was added to the reactor. After the complete addition of the HBr solution, the reactor temperature was raised to 20 °C for 2 hours. The reaction was then again cooled to ca. 4 °C and maintained at this temperature for a further 3 hours. The reaction mixture was then filtered and dried under vacuum at ambient temperature (ca. 22 °C) for 3 days. The solid was stirred periodically during the drying process. The yield after drying was 258.1 g (71%).
[00322] XRPD analysis (Figure 59) carried out on the initial scale-up material while wet, showed the sample to be highly crystalline. After drying, the solid converted to a different polymorphic form (Figure 60). The dried material is the same form as that obtained from the primary salt screen.
[00323] IR Spectroscopy (Figure 61) showed differences when compared with the freebase spectrum. The spectrum also appeared consistent with the spectra obtained for the hydrobromide salt prepared in Examples 1 and 7.
[00324] PLM analysis showed a needle-like, fibrous morphology when wet (not shown). Upon drying and hence polymorph conversion, the needle-like morphology was lost with small particles resulting.
[00325] XH NMR (Fi gure 62) indicated a number of peak shifts in comparison with the free base. Trace amounts of acetone were present in the spectrum.
[00326] TGA/DTA (Figure 63) showed a weight loss from the outset of ca. 0.4%, likely due to unbound moisture or solvent. No further significant weight losses were seen prior to degradation at onset ca. 230 °C. Thus, the material appears to retain ca. 0.5% water at ambient conditions despite extended periods of drying and therefore appears to be slightly hygroscopic.
[00327] DSC analysis (Figure 64) indicated a shallow, broad endotherm from the outset likely due to unbound solvent/water. A second endotherm was then present at onset ca. 241 °C (peak 245 °C), followed by likely degradation.
[00328] KF analysis determined the water content of the material to be ca. 0.74%.
[00329] HPLC purity determination indicated a purity of ca. 99.1%.
[00330] Slurries of the hydrobromide salt were prepared in buffered aqueous media at pH 1.0 (HC1/KC1 buffer), pH 3.0 (citrate buffer), pH 4.5 (citrate buffer) and pH 6.2 (citrate buffer) as well as in an aqueous solution with pH reduced to below 2 using HBr (48%). The respective slurries were shaken for a period of 24 hours at 22 °C. The solids were then removed by filtration and tested by XRPD analysis. The mother liquors were analyzed by HPLC to determine API solubility. HPLC solubility determination in various pH media showed the following results: H condition Cone. (mg/niL)
Aqueous solution with pH
3.52
reduced to below 2 using HBr.
pH 1.0 (HC1/KC1 buffer) 4.09
pH 3.0 (citrate buffer) 0.20
pH 4.5 (citrate buffer) 0.17
pH 6.2 (citrate buffer) 0.04
[00331] XRPD analysis of the solids recovered after the solubility experiments (Figure 65) showed all samples to correspond predominantly with the input hydrobromide salt material, with the samples in the pH 3.0, 4.5 and 6.2 buffers showing traces of a form previously identified from disproportionation studies and previous slurring of the hydrobromide salt in pH buffers > pH 3.
[00332] Elemental analysis (CHN and bromide) indicated the following percentages:
Figure imgf000074_0001
[00333] A small slurry of the scale-up material was stored for ca. 1.5 months at ca. 4°C. Upon re-analyzing the material by PLM analysis, the crystals appeared as very flat, rod- shaped particles in comparison to the fibrous, needle-like particles previously observed (not shown). The material converted to the same form as the one obtained upon drying with a change in crystal morphology from fibrous needle-like crystals to flat, rod-like crystals. XRPD analysis (Figure 66) indicated a diffractogram which corresponded with the dry hydrobromide salt material (peaks at 7.59, 15.28, 21.10, 23.21, 30.88, 35.54, 43.58 and 47.13 °2-theta). The peaks appear very sharp with some preferred orientation in the diffractogram.
Example 12
Primary Polymorph Screening of Hydrobromide Salt
[00334] Preparation of Amorphous Material. Hydrobromide salt material was ground using a Retsch Ball Mill for ca. 25 minutes, with a 5 minute break midway to prevent the sample from overheating. The sample was then analysed by XRPD to determine form and by HPLC to check for degradation. Post grinding XRPD analysis showed the hydrobromide salt material to be amorphous with an HPLC purity of ca.99.5%. (Figure 79). Amorphous material was desired in order to both increase the solubility and not to bias the screening study towards one particular form.
[00335] Solvent Solubility Screen. Approximately 10 mg of amorphous hydrobromide salt was placed in each of 24 vials and 5 volume aliquots of the appropriate solvent system was added to the vial. Between each addition, the mixture was checked for dissolution. This procedure was continued until dissolution was observed or until 100 volumes of solvent had been added. Amorphous hydrobromide salt material was found to be highly soluble in 3 of the 24 solvent systems but exhibited low solubility in the remaining solvents. The approximate solubility values of the amorphous hydrobromide salt in the 24 solvent systems are presented in Table 12:
Table 12. Approximate Solubility in Selected Solvents
Figure imgf000075_0001
[00336] Temperature Cycling Experiments. The results obtained from the solubility approximation experiments were used to prepare slurries for temperature cycling. The slurries were temperature cycled between 4 °C and 25 °C in 4 hour cycles for a period of 72 hours (slurries were held at 4 °C for 4 hours followed by a hold at ambient for 4 hours, the cooling/heating rates after the 4 hour hold periods was ca. 1 °C/min). Solid material was then recovered for analysis.
[00337] Crash Cooling Experiments. Crash cooling experiments were performed by placing saturated solutions of the material, in each of the 24 selected solvent systems, in environments of 2 °C and -18 °C for a minimum of 48 hours. Any solid material was then recovered for analysis.
[00338] Rapid Evaporation Experiments. Rapid evaporation experiments were conducted by evaporating the solvents from saturated, filtered solutions of the material, in each of the 24 solvent systems, under vacuum. Any solid material was then recovered and analysed after the solvent had evaporated to dryness.
[00339] Anti-solvent Addition Experiments. Anti-solvent addition experiments were conducted at ambient temperature by adding the selected anti-solvent to saturated, filtered solutions of the material, in each of the 24 selected solvent systems. The anti-solvent selected was heptane, with tert-butylmethyl ether and water being used for solvents immiscible with heptane. Addition of anti-solvent was continued until there was no further precipitation or until no more anti-solvent could be added. Any solid material was recovered and analysed quickly in order to prevent form changes.
[00340] Slow Evaporation Experiments. Slow evaporation experiments were conducted by evaporating the solvents from saturated, filtered solutions of the material, in each of the 24 solvent systems at ambient conditions. Any solid material was then recovered and analysed after the solvent had evaporated to dryness.
[00341] Desolvation of Solvated Forms. Potential solvated forms were subjected to heating on a TGA instrument to a temperature slightly beyond the initial weight loss. It could then be determined by subsequent XRPD analysis whether the form had changed as a result of the loss of solvent molecules. After heating to 180 °C using TGA instrumentation, Form V solvate was found to have reverted to Form I by XRPD analysis. The resultant diffractogram is shown in Figure 80. The attempted desolvation of Form VII resulted in a gum following heating. [00342] Investigation into Wet and Dry Samples of Form I. Initially, wet samples of Form 1 showed some differences in the XRPD diffractograms to those of the dry samples. Further investigation, including drying studies followed by XRPD analysis, TGA, and XRPD analysis with spinning were carried out. For Form I, the wet material showed significant preferred orientation and shifting was observed in the diffractograms when compared to the dry material. Figure 81 shows input material Form I compared with a wet sample, and after stages of drying.
[00343] The results from the experiments conducted during the primary polymorph screen are shown in Table 13. Results were obtained from PLM and XRPD analysis. Overall it can be seen that multiple potential polymorphic forms were identified during the screening experiments.
• Form I was obtained from multiple temperature cycling experiments.
• Form III, an anhydrous form, was obtained from rapid evaporation of DMSO, crash cooling to 2 °C in ethanol, and anti-solvent addition from acetone, acetonitrile, and ethanol.
• Form rv, a 1,4-dioxane solvate, was obtained from temperature cycling in 1,4- dioxane.
• Form V, a DMF solvate, was obtained from temperature cycling and rapid evaporation from DMF.
• Form VI, a DMSO solvate, was obtained from temperature cycling in DMSO.
• Form VII, a DMSO solvate, was obtained from slow evaporation from DMSO.
Table 13. Results of Primary Hydrobromide Salt Screen
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
NS - no solid observed
AM/PLM - amorphous bv XRPD, birefringence observed by PLM
FB - Compound 1 free base
PLM - birefringence by PLM
WD - weak data
- poorly crystalline
+ - no clear morphology
Λ - only 2 peaks present; needle-like morphology
* - plate-like morphology
† - similar to Form VI
* - rod-like morphology
§ - missing peaks
Example 13
Secondary Polymorph Screening of Hydrobromide Salt and Developability Assessment
[00344] Form III hydrobromide salt of Compound 1 (1 equiv.) was obtained during the primary polymorph screen from multiple experiments. This form was therefore progressed for scale-up and further analysis.
[00345] Form III Hydrobromide Salt Preparation. Approximately 500 mg of amorphous Compound 2 HBr salt material was slurried in ca. 6 mL of acetonitrile. The suspension was then temperature cycled between 4 and 25 °C in four hour cycles for ca. 2 days. The secondary screen analysis was carried out on the material when it was damp, due to the instability of Form III.
[00346] During the scale-up of the Form III hydrobromide salt, the material remained yellow in colour. XRPD analysis showed the material produced from scale-up to be crystalline and consistent with the small scale Form III hydrobromide salt diffractogram. PLM analysis indicated birefringent, needle-like crystals when wet. Hot stage microscopy indicated that as the solvent dried off between 40 and 50°C, the crystal morphology changed to more rod-like crystals. By ca. 250 °C, the material was observed to melt. For TGA/DTA analysis, a damp sample of Form III was placed into the TGA pan. An initial 10.3% weight loss was observed due to the unbound solvent. The form change which occurs between 40 and 50 °C by hotstage microscopy was masked by the solvent loss. A further endotherm corresponding with Form I hydrobromide salt was observed at onset ca. 239 °C (peak ca. 245 °C). DSC analysis indicated an initial endotherm from the outset up to approximately 100 °C. A final endotherm was observed at onset ca. 233 °C (peak ca. 247 °C), which appears consistent with the Form I melt. IR spectroscopy indicated very small differences between the IR spectrums of Forms I and III.
[00347] DVS analysis showed the following observations:
o Cycle 1 - Sorption 20-90%RH
■ Sample gradually takes up ca. 1.045% mass,
o Cycle 2 - Desorption 90-0%RH
■ Between 90-0%RH, sample mass decreases gradually by ca. 1.983%. o Cycle 3 - Sorption 0-20%RH
■ Moisture uptake of ca. 0.535% between 0-20%RH.
[00348] The material was observed to be slightly hygroscopic. Post DVS XRPD indicated that the material converted to Form I hydrobromide salt during DVS analysis. lH NMR spectroscopy carried out in deuterated DMSO showed a spectrum which corresponded with the Form I hydrobromide salt. KF analysis indicated the presence of 1.4% water. HPLC purity analysis indicated a purity of ca. 99.43%. Ion chromatography indicated the presence of 12.17% bromide (ca. 12.57% required for 1 equivalent).
[00349] XRPD analysis carried out on the thermodynamic solubility experiment solids remaining after 24 hours, indicated that for the pH 6.6 and 4.5 experiments, the Form III hydrobromide salt converted to a freebase hydrate form, the solid from the pH 3.0 experiment became amorphous and the solid from the pH 1 experiment remained predominantly consistent with the Form III hydrobromide, with some loss in crystallinity.
[00350] 7 day Stability Studies at 25 °C, 80 °C, 40 °C/75%RH (open and closed conditions). Approximately 15 mg of Form III was placed into vials and then exposed to 25 °C, 80 °C and 40 °C/75%RH environments (open and closed vials) for 1 week to determine stability. The resulting solids were analysed by XRPD and HPLC to establish if any changes had occurred. The 1 week stability studies carried out in open and closed vials at 25°C, 80°C and 40°C/75% RH indicated the following results: Table 14. 7 day stability studies (open container)
Figure imgf000081_0001
Table 15. 7 day stability studies (closed container)
Figure imgf000081_0002
[00351] From the characterisation carried out on Form III, this form was determined to be a metastable, likely anhydrous form of the hydrobromide salt. Form III was observed to be very unstable with conversion to Form I occurring upon isolation and drying of the material.
[00352] Thermodynamic Solubility Studies. Slurries of Form III were created in media of various pH (pH 1; pH 3; pH 4.5 and pH 6.6) and shaken for ca. 24 hours. After 24 hours, the slurries were filtered and the solution analysed by HPLC in order to determine the solubility at the various pH levels. For the buffer solutions, KC1 /HC1 was used for pH 1 and citrate / phosphate combinations for pH 3, 4.5 and 6.6 (10 mM). The pH of the solutions was also measured prior to HPLC analysis. XRPD analysis was carried out on the remaining solids after 24 hours of shaking.
[00353] Thermodynamic solubility experiments carried out in buffers pH 1, 3.0, 4.5 and 6.6 indicated the following result:
Table 16. Thermodynamic Solubility Studies
Figure imgf000082_0001
[00354] Competitive Slurry Experiments. Competitive slurry experiments were set up in acetone, isopropanol, acetone:water (80:20) and isopropyl acetate at both room temperature (ca. 22 °C) and 60 °C. Approximately 200 mg of each of Forms I and III material was placed into a vial and 4 mL of the appropriate solvent system was added to produce a slurry. For each experiment, the slurries were allowed to stir for ca. 3 days. Analysis by XRPD was then conducted to determine the form of the resultant solid. Competitive slurry experiments of Form I vs. Form III were carried out in 4 solvent systems and resulting solids were analysed by XRPD analysis (Figure 82 and Figure 83). Results are summarised in Table 17.
Table 17. Summary of results from competitive slurry experiments
Figure imgf000082_0002
[00355] From the competitive slurry experiments, Form I was found to be the thermodynamically most stable form in acetone, isopropanol and isopropyl acetate at both ambient and 60 °C. In acetone: water (80:20), conversion to an unidentified form resulted (labelled as Form VIII). [00356] Characterization of Form VIII. An initial assessment of Form VIII, obtained from competitive slurry experiments of Forms I and III in acetone:water (80:20), was made in order to determine the nature of the form and evaluate whether it is consistent with freebase material or the HBr salt. The material resulting from the competitive slurry experiments appeared light yellow in colour. PLM analysis indicated birefringent material with no clearly defined morphology. After drying under vacuum for ca. 24 hours, the TGA/DTA indicated a weight loss of 5.2% from the outset followed by a second weight loss of 1.2%, with endotherms in the DTA trace at ca. 40 °C and ca. 96 °C. A final endotherm was observed in the DTA trace at onset ca. 184 °C (peak ca. 194 °C). Very little change was observed by hotstage microscopy prior to the melt at ca. 197 °C. DSC analysis indicated a broad endotherm starting from the outset (peak ca. 93 °C ) followed by a second endotherm at peak ca. 140 °C and a third endotherm at onset ca. 178 °C (peak ca. 193 °C). Ion chromatography indicated a bromide content of 12.8% (approximately 1 equivalent).
[00357] In order to examine the effect of desolvating/dehydrating Form VIII, the material was heated to 150 °C in a TGA pan and XRPD analysis was then carried out. The polymorphic form appeared to remain the same. After heating to 150 °C and carrying out XRPD analysis, TGA analysis was again carried out on the same material and showed a weight loss of 6.0% from the outset followed by a second weight loss of 0.9%, with endotherms in the DTA trace at ca. 42 °C and 96 °C. A final endotherm was observed in the DTA trace at onset ca. 186 °C (peak ca. 194 °C). The sample appeared to re-hydrate when exposed to atmospheric conditions. This would likely explain the consistency between the XRPD diffractograms before and after desolvation/dehydration.
[00358] Hydration Studies at 55 °C. Slurries were created using ca. 200 mg of Form I salt material in 2 mL of the appropriate solvent system. These were stirred at ca. 55 °C for 6 hours. The solvent systems used are listed in Table 18.
Table 18. Solvent Systems for Hydration Studies at 55 °C
Solvent System
Ethanol:Water (l%)
EthanohWater (2%)
EthanohWater (5%)
EthanohWater (10%)
IP A/Acetone (9: l):Water (1%)
IP A/Acetone (9: 1): Water (2%)
IP A/Acetone (9: 1): Water (5%)
IP A/Acetone (9: 1): Water (10%)
[00359] Following the hydration studies, material was analysed by XRPD to determine whether hydration or disproportionation had occurred at the various water activity levels. XRPD analysis of EtOH: Water samples revealed that, at 1, 2, and 5% water, the resultant diffractograms corresponded with the Form I input HBr salt material. At 10% water, the HBr hydrate was formed. The same pattern emerged for samples slurried in IP A/Acetone(9: l): Water mixtures, where at 1, 2, and 5% water the resultant diffractograms corresponded with the input Form I HBr salt, however, at 10% water, the HBr hydrate was obtained. The diffractograms can be seen in Figure 84 and Figure 85.
[00360] Hydration Studies at 15 °C and 35 °C. Slurries were created using ca. 200 mg of Form I salt material in 2 mL of the appropriate solvent system. These were stirred at ca. 15 °C and ca. 35 °C for 24 hours. The solvent systems used are listed in Table 19.
Table 19. Solvent Systems for Hydration Studies at 15 °C and 35 °C
Figure imgf000084_0001
[00361] Following the hydration studies, XRPD analysis of samples revealed that the resultant diffractograms corresponded with the Form I HBr salt and hydration did not occur at the 2% water level. The diffractograms can be seen in Figure 86. [00362] The results of the polymorph screen for the hydrobromide salt of compound 1 (compound 2 hydrobromide) is depicted in Figure 87. Compound 2 hydrobromide exists in eight (8) different solid forms, including amorphous, anhydrous, solvated and hydrated forms. Figure 87 illustrates the interconversion between several of the identified forms, with Form I exhibiting particular stability under a variety of conditions.
Example 14
Dog PK Study 1
[00363] Compound 1 free base and compound 2, as the Form I monohydrobromide (HBr) salt, were evaluated in a cross-over dog PK study. Compound 1 free base capsule consisted of compound 1 free base in Vitamin E TPGS and PEG 400 filled into a capsule. The Form I hydrobromide salt capsule consisted of Form I HBr alone filled into a capsule.
[00364] Compound 1 free base capsule and Form I HBr capsule were dosed orally at 28.5 and 24.5 mg/kg (as active) QD, respectively, to three fasted male non-nai've beagle dogs (body weight range: 10.1 - 10.8 kg) with a 5-day washout period. Approximately 5 mL of tap water was orally administered to encourage swallowing and ensure delivery of capsules into the stomach. Plasma samples were collected at pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose. The plasma concentrations of compound 1 were determined by a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method. The results are provided in Table 20.
[00365] When compound 1 is administered orally to fasted dogs at 24.5 - 28.5 mg/kg QD, compound 1 exposure (based on AUC and Cmax) is significantly higher when drug is administered as the Form I HBr salt compared to the free base form.
Table 20. Mean pharmacokinetic parameters (%CV) of compound 1 in fasted dogs (n=3) receiving compound 1 (free base) capsule and compound 2 (Form I hydrobromide) capsule orally
Figure imgf000085_0001
Dog #3 had emesis at 30 min post dose. At the 1 h time point, a partial capsule was found under its cage. Thus, data from dog #3 was not included in the calculation of PK parameters. Example 15
Dog PK Study 2
[00366] Compound 1 free base and compound 2, as the Form I monohydrobromide (HBr) salt, were evaluated in a cross-over dog PK study in which male dogs were pre-treated with either pentagastrin (to decrease gastric pH) or famotidine (to increase gastric pH) prior to oral dosing to control gastric pH. In addition, the effect of food on the systemic exposure to compound 1 was also evaluated in dogs receiving Form I HBr with pentagastrin pre- treatment. Compound 1 free base capsule consisted of compound 1 free base in Vitamin E TPGS and PEG 400 filled into a capsule. The Form I hydrobromide salt capsule consisted of Form I HBr alone filled into a capsule.
[00367] Compound 1 free base and Form I HBr capsules were dosed orally at 30 mg/kg (as active) QD to three non-nai've male beagle dogs (body weight range: 9.6 - 10.5 kg) that were treated prior to dosing with 1) pentagastrin and fasted, 2) famotidine and fasted, or 3) pentagastrin and fed. There was a minimum 6-day washout between dosing. On the day of dosing under fed condition, dogs were given 60 gram of a high fat diet (Harlan Teklad 2027C) and allowed to consume all of the food within 15-20 minutes. The animals were given a 10-minute rest period and then the capsule doses were administered. Plasma samples were collected at pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose. The results are provided in Table 21.
[00368] When compound 1 was administered orally to dogs at 30 mg/kg QD, compound 1 exposure was significantly higher when drug is administered as the HBr salt compared to the free base form under both low and high gastric pH conditions. In dogs receiving the free base capsules under high gastric pH condition, a 32- to 48-fold reduction in compound 1 exposure was observed compared to that under low pH condition. The effect of varying gastric pH on the systemic exposure to compound 1, measured as Cmax and AUC, was greatly minimized when Form I HBr was administered. Administering Form I HBr with food resulted in an increase in Cmax and AUC of compound 1 in dogs. Table 21. Mean pharmacokinetic parameters (%CV) of compound 1 in dogs (n=3) receiving compound 1 (free base) capsule and compound 2 (Form I hydrobromide) capsule orally following gastric pH adjustment treatment
Figure imgf000087_0001
Example 16
Administration to Healthy Volunteers
[00369] The primary objective of the study is to compare the compound 1 pharmacokinetic (PK) profiles of single doses of Form I monohydrobromide formulations with that of the compound 1 free base in healthy adult males.
[00370] This is a single centre non-randomised, open-label, single dose study in healthy male subjects. Subjects will be screened for eligibility to participate in the study up to 28 days before dosing. The subjects will be admitted to the clinical unit at approximately 09:00 in the morning on the day prior to dosing (Day-1) and will remain on site until 24 h after each dose. Each subject will attend a follow-up visit 4 to 6 days after the final dose.
[00371] One group of 12 subjects will be dosed in an effort to obtain the data described above. Each subject will receive the following formulations in a crossover investigation. Dosing will be separated by at least 7 days.
• Regimen A: 150 mg compound 1 (free base) capsule
• Regimen B: 50 mg as active compound 2 (Form I HBr)tablet formulation
• Regimen C: <150 mg as active compound 2 (Form I HBr) tablet formulation
[00372] All formulations will be dosed in the morning, following an overnight fast. Subjects will be allowed water up to 2 h before the scheduled dosing time and will be provided with 240 mL of water at 2 h post-dose. Decaffeinated fluids will be allowed ad libitum from lunch time on the day of dosing. [00373] If, for technical reasons, dosing is delayed for more than 2 h beyond the expected dosing time, subjects will receive 200 mL of Lucozade Sport at the originally scheduled dosing time, or earlier if possible.
[00374] Subjects will be provided with a light snack and then fast from all food and drink (except water) for a minimum of 8 h on the day prior to dosing until approximately 4 h post- dose at which time lunch will be provided. An evening meal will be provided at approximately 9 h post-dose and an evening snack at approximately 14 h post-dose. On subsequent days, meals will be provided at appropriate times.
[00375] Venous blood samples will be withdrawn via an indwelling cannula or by venepuncture at the following times after dosing (hours): 0.5, 1, 1.5, 2, 4, 8, and 12.
[00376] The primary endpoint of the study is to compare the PK profiles of a formulation of Form I HBr with that of compound 1 as a free base by measuring the following parameters: Tlag, Cmax, Tmax, AUC(0-iast), AUC(0-inf), AUC%extraP, Frei, lambda-z, Ti/2el. The secondary endpoint of the study is to collect information about the safety and tolerability of compound 1 (free base) and compound 2 (Form I HBr salt) by assessing: physical examinations, safety laboratory tests, vital signs, electrocardiograms (ECGs), body temperature and AEs.
[00377] Plasma concentration data will be tabulated and plotted for each subject for whom concentrations are quantifiable. PK analysis of the concentration time data obtained will be performed using appropriate non-compartmental techniques to obtain estimates of the following PK parameters (where relevant).
Tlag the sampling time before the first quantifiable concentration of compound 1 in a concentration vs time profile
c ^max the maximum observed plasma concentration
T 1 max the time from dosing at which Cmax occurs
AUC(O-last) the area under the concentration vs time curve from time zero to the last measured time point
AUC(O-inf) the area under the concentration vs time curve from time zero extrapolated to infinity
AUC%extrap the percentage of AUC(o-inf) accounted for by extrapolation AUC(o -tau) the area under the concentration vs time curve within the
dosing interval, estimated using the [linear or linear/log down] trapezoidal rule
AUC(0-24) the area under the concentration vs time curve from time zero to 24 hour post morning dose
RA relative accumulation Frei relative bioavailability of the test formulations compared with the reference formulation eg Regimens B, or C (test) compared with Regimen A (reference)
lambda-z slope of the regression line passing through the apparent
elimination phase in a concentration vs time plot
Ti/2el the apparent elimination half-life
Assessment of dose proportionality, as appropriate eg Cmax/D; AUC/D
[00378] The initial 50 mg HBr dose selected for Regimen B (determined by AUC) is anticipated to be that which is expected to give a similar exposure to the 150 mg free base. This dose is also expected to provide less patient-to-patient variability.
[00379] There will be an interim analysis after completion of Regimens A and B during which the safety, tolerability and PK data will be reviewed. These data will be used to assess whether dose adjustment is needed. For dose selection to proceed, safety data from a minimum of 8 evaluable subjects (defined as subjects who have received study drug and have completed all safety assessments up to 24 h) in a group must be available for review. The dose selected for Regimen C will be that which is expected to give a similar exposure to the 150 mg free base. However, if the 50 mg HBr dose used in Regimen B exceeds the exposure of the 150 mg free base, and is well tolerated and within the limits defined within the protocol, Regimen C will not occur.
[00380] If the dose is changed, the Form I HBr formulation will be dosed again at the revised dose (Regimen C). There will then follow a further period of interim analysis to confirm that the Regimen C dose provides either, 1) a lower active dose as compared to Regimen A that provides an equivalent or higher exposure and/or provide less patient-to- patient variability, or 2) an active dose similar to that of Regimen A with a higher exposure and/or provide less patient-to-patient variability.

Claims

CLAIMS We claim:
1. Compound 2:
Figure imgf000090_0001
wherein:
n is 1 or 2; and
X is hydrobromic acid, benzenesulfonic acid, camphor sulfonic acid, 1,2- ethane disulfonic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5 -naphthalene disulfonic acid, oxalic acid, 4- toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid.
2. The compound of claim 1, wherein X is hydrobromic acid.
3. The compound of claim 2, wherein the compound is a Form I hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta.
4. The compound of claim 3, wherein the compound is a Form I hydrobromic acid salt characterized by two or more peaks in a powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta.
5. The compound of claim 4, wherein the compound is a Form I hydrobromic acid salt characterized by three or more peaks in a powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta.
6. The compound of claim 5, wherein the compound is a Form I hydrobromic acid salt characterized by substantially all of the peaks in a X-ray powder diffraction pattern selected from those at about 9.84, 15.62, 17.39, 19.45, 20.69, 21.41, 22.38, 23.56, 25.08 and 27.45 degrees 2-theta.
7. The compound of claim 6, wherein the compound is a Form I hydrobromic acid salt characterized by substantially all of the peaks in a X-ray powder diffraction pattern selected from those at about
Figure imgf000091_0001
The compound of claim 2, wherein the compound is a Form III hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta.
The compound of claim 2, wherein the compound is a Form IV hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta.
10. The compound of claim 2, wherein the compound is a Form V hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta.
1 1. The compound of claim 2, wherein the compound is a Form VI hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2-theta.
12. The compound of claim 2, wherein the compound is a Form VII hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta.
13. The compound of claim 2, wherein the compound is a Form VIII hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 8.79, about 11.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta.
14. The compound of claim 1, wherein X is benzenesulfonic acid.
15. The compound of claim 14, wherein the compound is a hydrate.
16. The compound of claim 15, having one or more peaks in a powder X-ray diffraction pattern selected from those at about 10.68, about 16.10, about 18.44 and about 22.36 degrees 2-theta.
17. The compound of claim 1, wherein X is camphor sulfonic acid.
18. The compound of claim 1, wherein X is 1,2-ethane disulfonic acid.
19. The compound of claim 1, wherein X is hydrochloric acid.
20. The compound of claim 1, wherein X is maleic acid.
21. The compound of claim 1 , wherein X is methanesulfonic acid.
22. The compound of claim 1, wherein X is naphthalene-2-sulfonic acid.
23. The compound of claim 1, wherein X is 1,5 -naphthalene disulfonic acid.
24. The compound of claim 1, wherein X is oxalic acid.
25. The compound of claim 1, wherein X is p-toluenesulfonic acid.
26. The compound of claim 1, wherein X is 2,4,6-trihydroxybenzoic acid.
27. A composition comprising the compound of claim 1 and a pharmaceutically
acceptable carrier or excipient.
28. A method for inhibiting at least one mutant of EGFR selectively as compared to wild type (WT) EGFR, in a biological sample or in a patient, comprising contacting the biological sample with, or administering to the patient, a compound according to claim 1, or a composition thereof.
29. The method according to claim 28, wherein said method is sparing for WT EGFR.
30. The method according to claim 28, wherein the at least one mutant is an activating mutant, a deletion mutant, a point mutation, or a mutant selected from T790M, delE746-A750, L858R, G719S.
31. A method for treating a mutant EGFR-mediated disorder or condition in a patient, comprising administering to the patient a composition according to claim 27. The method of claim 31, wherein the disorder or condition is a cancer.
PCT/US2013/030996 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor WO2013138502A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
ES13761487T ES2698298T3 (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor
PL13761487T PL2825042T3 (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor
SG11201405692UA SG11201405692UA (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor
EP13761487.1A EP2825042B1 (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor
MX2014010848A MX356179B (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor.
CA2866857A CA2866857C (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor
SI201331233T SI2825042T1 (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor
BR112014022790-0A BR112014022790B1 (en) 2012-03-15 2013-03-13 SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF
RU2014136893A RU2711077C9 (en) 2012-03-15 2013-03-13 Salts of epidermal growth factor receptor kinase
LTEP13761487.1T LT2825042T (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor
RS20181300A RS57901B1 (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor
JP2015500567A JP6317320B2 (en) 2012-03-15 2013-03-13 Salt of epidermal growth factor receptor kinase inhibitor
CN201811096266.5A CN109053595B (en) 2012-03-15 2013-03-13 Salts of epidermal growth factor receptor kinase inhibitors
KR1020147028832A KR102090453B1 (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor
MYPI2014002630A MY185243A (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor
CN201380025160.5A CN104284584B (en) 2012-03-15 2013-03-13 The salt of epidermal growth factor receptor kinase inhibitor
DK13761487.1T DK2825042T3 (en) 2012-03-15 2013-03-13 SALTS OF THE CHINASE INHIBITOR OF THE EPIDERMAL GROWTH FACTOR RECEPTOR
IL234426A IL234426B (en) 2012-03-15 2014-09-02 Salts of an epidermal growth factor receptor kinase inhibitor
PH12014502037A PH12014502037A1 (en) 2012-03-15 2014-09-12 Salts of an epidermal growth factor receptor kinase inhibitor
HK15106102.5A HK1205430A1 (en) 2012-03-15 2015-06-26 Salts of an epidermal growth factor receptor kinase inhibitor
HRP20181784TT HRP20181784T1 (en) 2012-03-15 2018-10-30 Salts of an epidermal growth factor receptor kinase inhibitor
CY20181101143T CY1122176T1 (en) 2012-03-15 2018-11-01 SALTS OF AN INHIBITOR OF DETERMINAL GROWTH FACTOR RECEPTOR KINASE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611400P 2012-03-15 2012-03-15
US61/611,400 2012-03-15

Publications (1)

Publication Number Publication Date
WO2013138502A1 true WO2013138502A1 (en) 2013-09-19

Family

ID=49161781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/030996 WO2013138502A1 (en) 2012-03-15 2013-03-13 Salts of an epidermal growth factor receptor kinase inhibitor

Country Status (28)

Country Link
US (5) US9108927B2 (en)
EP (1) EP2825042B1 (en)
JP (2) JP6317320B2 (en)
KR (1) KR102090453B1 (en)
CN (2) CN104284584B (en)
AR (1) AR090357A1 (en)
AU (3) AU2013201519C1 (en)
BR (1) BR112014022790B1 (en)
CA (1) CA2866857C (en)
CY (1) CY1122176T1 (en)
DK (1) DK2825042T3 (en)
ES (1) ES2698298T3 (en)
HK (1) HK1205430A1 (en)
HR (1) HRP20181784T1 (en)
IL (1) IL234426B (en)
LT (1) LT2825042T (en)
MX (1) MX356179B (en)
MY (1) MY185243A (en)
PH (1) PH12014502037A1 (en)
PL (1) PL2825042T3 (en)
PT (1) PT2825042T (en)
RS (1) RS57901B1 (en)
RU (1) RU2711077C9 (en)
SG (2) SG11201405692UA (en)
SI (1) SI2825042T1 (en)
TR (1) TR201816244T4 (en)
TW (1) TWI591060B (en)
WO (1) WO2013138502A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
WO2015117547A1 (en) * 2014-02-04 2015-08-13 Jiangsu Medolution Limited Substituted pyrimidines useful as egfr-t790m kinase inhibitors
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
CN104961688A (en) * 2014-12-25 2015-10-07 苏州晶云药物科技有限公司 Phosphate of epidermal growth factor receptor kinase inhibitor and preparation method thereof
WO2016101912A1 (en) * 2014-12-25 2016-06-30 苏州晶云药物科技有限公司 Crystal form of salt of epidermal growth factor receptor kinase inhibitor and preparation method thereof
EP2994456A4 (en) * 2013-05-06 2017-01-04 Clovis Oncology, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
EP3640246A4 (en) * 2017-06-13 2020-08-05 Korea Research Institute of Chemical Technology N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
JP2021512087A (en) * 2018-01-31 2021-05-13 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド ERBB / BTK inhibitor
WO2023011358A1 (en) * 2021-08-02 2023-02-09 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ609957A (en) * 2010-11-01 2015-08-28 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
EP3327014A4 (en) * 2015-07-24 2019-01-02 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
CN105461640B (en) * 2015-12-02 2017-11-21 芷威（上海）化学科技有限公司 A kind of preparation method of tyrosine kinase inhibitor
CN105481779B (en) * 2015-12-24 2019-01-25 南京华威医药科技集团有限公司 Anticancer drug Rociletinib and its intermediate preparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908906B2 (en) * 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2012021444A1 (en) * 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
US20120149687A1 (en) 2010-11-01 2012-06-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4032637A (en) 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4337341A (en) 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5453510A (en) 1990-07-13 1995-09-26 Burroughs Wellcome Co. Neuromuscular blocking agents
JPH0741461A (en) 1993-05-27 1995-02-10 Eisai Co Ltd Sulfonic acid ester derivative
WO1996028427A1 (en) 1995-03-10 1996-09-19 Berlex Laboratories, Inc. Benzamidine derivatives their preparation and their use as anti-coagulants
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
WO1999031073A1 (en) 1997-12-15 1999-06-24 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
KR100658489B1 (en) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. HIV replication inhibiting pyrimidines
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
US6127376A (en) 1998-12-04 2000-10-03 Berlex Laboratories, Inc. Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
AU2871900A (en) 1999-02-04 2000-08-25 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
JP2003503404A (en) 1999-06-29 2003-01-28 エギシュ ヂョヂセルヂャール エルテー Piperazinylalkylthiopyrimidine derivative, pharmaceutical composition containing this derivative and process for producing this derivative
WO2001047921A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2001085699A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US7427689B2 (en) 2000-07-28 2008-09-23 Georgetown University ErbB-2 selective small molecule kinase inhibitors
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
JO3429B1 (en) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidines derivatives
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
HUP0402106A3 (en) 2001-11-01 2009-07-28 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003209077A1 (en) 2002-02-08 2003-09-02 Smithkline Beecham Corporation Pyrimidine compounds
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003228345B2 (en) 2002-03-21 2009-02-05 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
US20040002395A1 (en) 2002-06-27 2004-01-01 Poynor Raymond L. Bridge weight for metal wood golf club
DE60330466D1 (en) 2002-07-29 2010-01-21 Rigel Pharmaceuticals Inc METHOD FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINE-IAMINE COMPOUNDS
CA2439440A1 (en) 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
AU2002951853A0 (en) 2002-10-04 2002-10-24 Commonwealth Scientific And Industrial Research Organisation Crystal structure of erbb2 and uses thereof
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP5602333B2 (en) 2003-02-07 2014-10-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pyrimidine derivatives for prevention of HIV infection
WO2004074244A2 (en) 2003-02-20 2004-09-02 Smithkline Beecham Corporation Pyrimidine compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
NZ545270A (en) 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
EP1663242B1 (en) 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
EP2287156B1 (en) 2003-08-15 2013-05-29 Novartis AG 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
US20070105839A1 (en) 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP1694652A1 (en) 2003-12-19 2006-08-30 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
PT1704145E (en) 2004-01-12 2012-09-04 Ym Biosciences Australia Pty Selective kinase inhibitors
GT200500008A (en) 2004-01-16 2005-08-16 QUINOLINE INTERMEDIARIES AS INHIBITORS OF THIROSINE KINASE RECEPTORS AND THE SYNTHESIS OF THE SAME
WO2005092836A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
WO2005105988A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Crystal structure of human jak3 kinase domain complex and binding pockets thereof
JP4812763B2 (en) 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド Cycloalkyl-substituted pyrimidinediamine compounds and uses thereof
EP1598343A1 (en) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine derivatives as PLK inhibitors
EP2592155B2 (en) 2004-06-04 2019-09-11 Genentech, Inc. EGFR mutations
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419161D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US7622486B2 (en) 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
CN101031550B (en) 2004-09-30 2015-05-27 泰博特克药品有限公司 HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines
BRPI0516597A (en) 2004-10-13 2008-09-16 Wyeth Corp compound of the formula
US20060088471A1 (en) 2004-10-20 2006-04-27 Proteolix, Inc. Compounds for enzyme inhibition
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
ES2380550T3 (en) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Spiro-2,4-pyrimidinediamine compounds and their uses
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
JP5208516B2 (en) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド Pyrimidine derivatives as kinase modulators and methods of use
JP2008527007A (en) 2005-01-14 2008-07-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Cinnamide and hydrocinnamide derivatives having Raf-kinase inhibitory activity
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2006086777A2 (en) 2005-02-11 2006-08-17 Memorial Sloan Kettering Cancer Center Methods and compositions for detecting a drug resistant egfr mutant
CN101155799A (en) 2005-03-16 2008-04-02 塔格根公司 Pyrimidine inhibitors of kinases
DE102005016634A1 (en) 2005-04-12 2006-10-19 Merck Patent Gmbh Novel aza heterocycles as kinase inhibitors
US20060270694A1 (en) 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
KR101312225B1 (en) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Compositions and methods for inhibition of the jak pathway
WO2007048064A2 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Amino-pyrimidines as casein kinase ii (ck2) modulators
BR122021011787B1 (en) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Biaryl metapyrimidine kinase inhibitors, pharmaceutical composition and process for preparing a pharmaceutical composition
JP2009514876A (en) 2005-11-03 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions for protein kinases
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
EP1968950A4 (en) 2005-12-19 2010-04-28 Genentech Inc Pyrimidine kinase inhibitors
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
BRPI0706747A2 (en) 2006-01-30 2011-04-05 Exelixis Inc 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
JP4653842B2 (en) 2006-02-17 2011-03-16 ライジェル ファーマシューティカルズ， インコーポレイテッド 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2645958C (en) 2006-03-30 2014-11-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
WO2007113256A1 (en) 2006-03-30 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
CA2861601A1 (en) 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
DE102006027156A1 (en) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag New sulfimide compounds are protein kinase inhibitors useful to treat e.g. cancer, Hodgkin's lymphoma, Kaposi's sarcoma, cardiovascular disease, Crohn's disease, endometriosis and hemangioma
CA2656290A1 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
MX2009000769A (en) 2006-07-21 2009-01-28 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors.
DE102006041382A1 (en) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl sulfoximides as protein kinase inhibitors
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
ATE497496T1 (en) 2006-10-19 2011-02-15 Rigel Pharmaceuticals Inc 2,4-PYRIDIMEDIAMONE DERIVATIVES AS INHIBITORS OF JAKKINASES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
ES2403546T3 (en) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Bruton tyrosine kinase activity probe and method of use
US8163902B2 (en) 2006-11-21 2012-04-24 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
AU2007333394C1 (en) 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2670645A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
EP1939185A1 (en) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer
KR20090094073A (en) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Hiv inhibiting 6-substituted pyrimidines
CN106045965A (en) 2006-12-29 2016-10-26 爱尔兰詹森科学公司 HIV inhibiting 5,6-substituted pyrimidines
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
JP5539734B2 (en) 2007-01-31 2014-07-02 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド Thiopyrimidine-based compounds and uses thereof
JP4221470B2 (en) 2007-02-01 2009-02-12 トヨタ自動車株式会社 Electric vehicle control apparatus and electric vehicle control method
DE102007010801A1 (en) 2007-03-02 2008-09-04 Bayer Cropscience Ag Use of new and known 2,4-diaminopyrimidine derivatives as fungicides, especially for controlling phytopathogenic fungi
CN101677554A (en) 2007-03-20 2010-03-24 史密丝克莱恩比彻姆公司 Chemical compounds
JP2010522188A (en) 2007-03-20 2010-07-01 スミスクライン ビーチャム コーポレーション Compound
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
WO2008151183A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
CN101903357A (en) 2007-07-17 2010-12-01 里格尔药品股份有限公司 Cyclic amine substituted pyrimidinediamines as PKC inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
US20090088371A1 (en) 2007-08-28 2009-04-02 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
AU2008296545B2 (en) 2007-08-28 2011-09-29 Irm Llc 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
TWI552752B (en) 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2234986A2 (en) 2007-12-20 2010-10-06 Cellzome Limited Sulfamides as zap-70 inhibitors
CA2715962C (en) 2008-02-22 2017-03-07 Rigel Pharmaceuticals, Inc. Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis
EP2276747A1 (en) 2008-03-11 2011-01-26 Cellzome Limited Sulfonamides as zap-70 inhibitors
US8205348B2 (en) 2008-03-19 2012-06-26 Zashiki-Warashi Manufacturing Inc. Tile spacer and holder therefor
CL2009000600A1 (en) 2008-03-20 2010-05-07 Bayer Cropscience Ag Use of diaminopyrimidine compounds as phytosanitary agents; diaminopyrimidine compounds; its preparation procedure; agent that contains them; procedure for the preparation of said agent; and method for combating pests of animals and / or harmful plant pathogenic fungi.
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2300013B1 (en) 2008-05-21 2017-09-06 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2011526299A (en) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド Heteroaryl compounds and their use
MX2011000661A (en) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors.
US20110245284A1 (en) 2008-09-03 2011-10-06 Bayer Cropscience Ag Alkoxy- and Alkylthio-Substituted Anilinopyrimidines
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
CA3018087C (en) 2009-01-15 2019-09-24 F. Hoffmann-La Roche Ag Antibodies against phosphorylated tyrosines on erythropoietin receptor (epor)
EP2414337B1 (en) 2009-04-03 2013-05-01 Cellzome GmbH Methods for the identification of kinase interacting molecules and for the purification of kinase proteins
RS54552B1 (en) 2009-05-08 2016-06-30 Astellas Pharma Inc. Diamino heterocyclic carboxamide compound
US20120165332A1 (en) 2009-06-18 2012-06-28 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20130317029A1 (en) 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
JP5999177B2 (en) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Compound for inhibiting cell proliferation of EGFR-activated cancer
MX355728B (en) 2011-05-17 2018-04-27 Univ California Kinase inhibitors.
BR112014022789B1 (en) 2012-03-15 2022-04-19 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor, pharmaceutical composition and uses thereof
SG11201405692UA (en) 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Salts of an epidermal growth factor receptor kinase inhibitor
PE20151604A1 (en) 2012-11-02 2015-11-04 Pharmacyclics Llc ADJUVANT THERAPY WITH KINASE INHIBITORS FROM THE TEC FAMILY
JP2016518408A (en) 2013-05-06 2016-06-23 クロヴィス・オンコロジー，インコーポレーテッド Salt of epidermal growth factor receptor kinase inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908906B2 (en) * 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2012021444A1 (en) * 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
US20120149687A1 (en) 2010-11-01 2012-06-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIN, N. U.; WINER, E. P., BREAST CANCER RES, vol. 6, 2004, pages 204 - 210
OGISO ET AL., CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN EPIDERMAL GROWTH FACTOR AND RECEPTOR EXTRACELLULAR DOMAINS IN CELL, vol. 110, 2002, pages 775 - 787, XP002961395 *
See also references of EP2825042A4

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540335B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US11292772B2 (en) 2012-03-15 2022-04-05 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US10946016B2 (en) 2012-03-15 2021-03-16 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US10570099B2 (en) 2012-03-15 2020-02-25 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US10004741B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US10005738B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9539255B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9980964B2 (en) 2013-02-08 2018-05-29 Celgene Car Llc ERK inhibitors and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9796700B2 (en) 2013-02-08 2017-10-24 Celgene Car Llc ERK inhibitors and uses thereof
US9504686B2 (en) 2013-02-08 2016-11-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
EP2994456A4 (en) * 2013-05-06 2017-01-04 Clovis Oncology, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
WO2015117547A1 (en) * 2014-02-04 2015-08-13 Jiangsu Medolution Limited Substituted pyrimidines useful as egfr-t790m kinase inhibitors
JP2017505319A (en) * 2014-02-04 2017-02-16 チャンスー メドリューション リミテッド Pyrimidinium compounds substituted as EGFR-T790M kinase inhibitors
CN105980377A (en) * 2014-02-04 2016-09-28 江苏迈度药物研发有限公司 Substituted pyrimidines useful as EGFR-T790M kinase inhibitors
US10167264B2 (en) 2014-02-04 2019-01-01 Jiangsu Medolution Ltd Substituted pyrimidines useful as EGFR-T790M kinase inhibitors
US10202364B2 (en) 2014-08-13 2019-02-12 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
CN104961688A (en) * 2014-12-25 2015-10-07 苏州晶云药物科技有限公司 Phosphate of epidermal growth factor receptor kinase inhibitor and preparation method thereof
WO2016101912A1 (en) * 2014-12-25 2016-06-30 苏州晶云药物科技有限公司 Crystal form of salt of epidermal growth factor receptor kinase inhibitor and preparation method thereof
EP3640246A4 (en) * 2017-06-13 2020-08-05 Korea Research Institute of Chemical Technology N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
JP2021512087A (en) * 2018-01-31 2021-05-13 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド ERBB / BTK inhibitor
EP3746424A4 (en) * 2018-01-31 2021-08-25 Dizal (Jiangsu) Pharmaceutical Co., Ltd Erbb/btk inhibitors
US11504375B2 (en) 2018-01-31 2022-11-22 Dizal (Jiangsu) Pharmaceutical Co., Ltd. ErbB/BTK inhibitors
JP7427597B2 (en) 2018-01-31 2024-02-05 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド ERBB/BTK inhibitor
EP4356975A3 (en) * 2018-01-31 2024-07-24 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Erbb/btk inhibitors
WO2023011358A1 (en) * 2021-08-02 2023-02-09 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor

Also Published As

Publication number Publication date
BR112014022790B1 (en) 2022-04-19
PL2825042T3 (en) 2019-02-28
AU2013201519A1 (en) 2013-10-03
CN104284584A (en) 2015-01-14
SG10201700799WA (en) 2017-02-27
MX2014010848A (en) 2014-12-10
AU2013201519B2 (en) 2016-02-25
EP2825042A4 (en) 2015-09-23
AU2018201896A1 (en) 2018-04-12
ES2698298T3 (en) 2019-02-04
CN104284584B (en) 2019-06-04
PT2825042T (en) 2018-11-16
DK2825042T3 (en) 2018-11-26
SG11201405692UA (en) 2014-10-30
US20130267531A1 (en) 2013-10-10
KR102090453B1 (en) 2020-03-19
SI2825042T1 (en) 2019-01-31
CN109053595A (en) 2018-12-21
EP2825042B1 (en) 2018-08-01
CN109053595B (en) 2022-04-01
AU2013201519C1 (en) 2016-06-23
HRP20181784T1 (en) 2018-12-28
RU2014136893A (en) 2016-05-10
PH12014502037B1 (en) 2014-11-24
TR201816244T4 (en) 2018-11-21
RS57901B1 (en) 2019-01-31
AU2016203343A1 (en) 2016-06-16
US20190152925A1 (en) 2019-05-23
RU2711077C9 (en) 2020-08-11
TWI591060B (en) 2017-07-11
US10570099B2 (en) 2020-02-25
IL234426B (en) 2018-07-31
EP2825042A1 (en) 2015-01-21
TW201341372A (en) 2013-10-16
US9108927B2 (en) 2015-08-18
US9540335B2 (en) 2017-01-10
LT2825042T (en) 2018-12-10
CY1122176T1 (en) 2020-07-31
JP6317320B2 (en) 2018-04-25
US20210017137A1 (en) 2021-01-21
BR112014022790A2 (en) 2017-06-20
MY185243A (en) 2021-04-30
US11292772B2 (en) 2022-04-05
US20170217904A1 (en) 2017-08-03
HK1205430A1 (en) 2015-12-18
KR20140138941A (en) 2014-12-04
US20150344441A1 (en) 2015-12-03
JP2018024708A (en) 2018-02-15
RU2711077C2 (en) 2020-01-15
CA2866857C (en) 2021-03-09
JP6676602B2 (en) 2020-04-08
AR090357A1 (en) 2014-11-05
JP2015510890A (en) 2015-04-13
PH12014502037A1 (en) 2014-11-24
AU2018201896B2 (en) 2019-10-31
MX356179B (en) 2018-05-17
CA2866857A1 (en) 2013-09-19
US10005738B2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
US11292772B2 (en) Salts of an epidermal growth factor receptor kinase inhibitor
US10946016B2 (en) Solid forms of an epidermal growth factor receptor kinase inhibitor
US20160074399A1 (en) Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13761487

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2866857

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/010848

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2015500567

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013761487

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20147028832

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDP00201406214

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2014136893

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014022790

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014022790

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140915